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Background: Rates of participation in centre (hospital)-cardiac rehabilitation by patients with heart
failure are suboptimal. Heart failure has two main phenotypes differing in underlying pathophysiology:
heart failure with reduced ejection fraction is characterised by depressed left ventricular systolic
function (‘reduced ejection fraction’), whereas heart failure with preserved ejection fraction is
diagnosed after excluding other causes of dyspnoea with normal ejection fraction. This programme
aimed to develop and evaluate a facilitated home-based cardiac rehabilitation intervention that could
increase the uptake of cardiac rehabilitation while delivering the clinical benefits of centre-based
cardiac rehabilitation.
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Objectives: To develop an evidence-informed, home-based, self-care cardiac rehabilitation programme
for patients with heart failure and their caregivers [the REACH-HF (Rehabilitation Enablement in
Chronic Heart Failure) intervention]. To conduct a pilot randomised controlled trial to assess the
feasibility of a full trial of the clinical effectiveness and cost-effectiveness of the REACH-HF intervention
in addition to usual care in patients with heart failure with preserved ejection fraction. To assess the
short- and long-term clinical effectiveness and cost-effectiveness of the REACH-HF intervention in
addition to usual care in patients with heart failure with reduced ejection fraction and their caregivers.
Design: Intervention mapping to develop the REACH-HF intervention; uncontrolled feasibility study;
pilot randomised controlled trial in those with heart failure with preserved ejection fraction; randomised
controlled trial with a trial-based cost-effectiveness analysis in those with heart failure with reduced
ejection fraction; qualitative studies including process evaluation; systematic review of cardiac
rehabilitation in heart failure; and modelling to assess long-term cost-effectiveness (in those with heart
failure with reduced ejection fraction).
Setting: Four centres in England and Wales (Birmingham, Cornwall, Gwent and York); one centre in
Scotland (Dundee) for a pilot randomised controlled trial.
Participants: Adults aged ≥ 18 years with heart failure with reduced ejection fraction (left ventricular
ejection fraction < 45%) for the main randomised controlled trial (n = 216), and those with heart failure
with preserved ejection fraction (left ventricular ejection fraction ≥ 45%) for the pilot randomised
controlled trial (n = 50).
Intervention: A self-care, facilitated cardiac rehabilitation manual was offered to patients (and
participating caregivers) at home over 12 weeks by trained health-care professionals in addition to
usual care or usual care alone.
Main outcome measures: The primary outcome was disease-specific health-related quality of life
measured using the Minnesota Living with Heart Failure Questionnaire at 12 months. Secondary
outcomes included deaths and hospitalisations.
Results: The main randomised controlled trial recruited 216 participants with heart failure with reduced
ejection fraction and 97 caregivers. A significant and clinically meaningful between-group difference in the
Minnesota Living with Heart Failure Questionnaire score (primary outcome) at 12 months (–5.7 points,
95% confidence interval –10.6 to –0.7 points) favoured the REACH-HF intervention (p = 0.025). Eight
(4%) patients (four in each group) had died at 12 months. There was no significant difference in hospital
admissions, at 12 months, with 19 participants in the REACH-HF intervention group having at least one
hospital admission, compared with 24 participants in the control group (odds ratio 0.72, 95% confidence
interval 0.35 to 1.51; p = 0.386). The mean cost of the intervention was £418 per participant with heart
failure with reduced ejection fraction. The costs at 12 months were, on average, £401 higher in the
intervention group than in the usual care alone group. Model-based economic evaluation, extrapolating
from the main randomised controlled trial in those with heart failure with reduced ejection fraction over
4 years, found that adding the REACH-HF intervention to usual care had an estimated mean cost per
participant of £15,452 (95% confidence interval £14,240 to £16,780) and a mean quality-adjusted life-
year gain of 4.47 (95% confidence interval 3.83 to 4.91) years, compared with £15,051 (95% confidence
interval £13,844 to £16,289) and 4.24 (95% confidence interval 4.05 to 4.43) years, respectively, for
usual care alone. This gave an incremental cost per quality-adjusted life-year of £1721. The probabilistic
sensitivity analysis indicated 78% probability that the intervention plus usual care versus usual care
alone has a cost-effectiveness below the willingness-to-pay threshold of £20,000 per quality-adjusted
life-year gained. The intervention was well received by participants with heart failure with reduced
ejection fraction and those with heart failure with preserved ejection fraction, as well as their caregivers.
Both randomised controlled trials recruited to target, with > 85% retention at follow-up.
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Limitations: Key limitations included (1) lack of blinding – given the nature of the intervention and the
control we could not mask participants to treatments, so our results may reflect participant expectation
bias; (2) that we were not able to capture consistent participant-level data on level of intervention
adherence; (3) that there may be an impact on the generalisability of findings due to the demographics
of the trial patients, as most were male (78%) and we recruited only seven people from ethnic minorities.
Conclusions: Evaluation of the comprehensive, facilitated, home-based REACH-HF intervention
for participants with heart failure with reduced ejection fraction and caregivers indicated clinical
effectiveness in terms of health-related quality of life and patient self-care but no other secondary
outcomes. Although the economic analysis conducted alongside the full randomised controlled trial
did not produce significant differences on the EuroQol-5 Dimensions or in quality-adjusted life-years,
economic modelling suggested greater cost-effectiveness of the intervention than usual care. Our
REACH-HF intervention offers a new evidence-based cardiac rehabilitation option that could increase
uptake of cardiac rehabilitation in patients with heart failure not attracted to or able to access
hospital-based programmes.
Future work: Systematic collection of real-world data would track future changes in uptake of and
adherence to alternative cardiac rehabilitation interventions in heart failure with reduced ejection
fraction and increase understanding of how changes in service delivery might affect clinical and health
economic outcomes. The findings of our pilot randomised controlled trial in patients with heart failure
with preserved ejection fraction support progression to a full multicentre randomised controlled trial.
Trial registration: Current Controlled Trials ISRCTN86234930 and ISRCTN78539530.
Funding details: This project was funded by the National Institute for Health Research (NIHR) Programme
Grants for Applied Research programme and will be published in full in Programme Grants for Applied
Research; Vol. 9, No. 1. See the NIHR Journals Library website for further project information.
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Heart failure can be classified by the percentage of blood pushed out of the left ventricle when theheart beats – the ‘ejection fraction’. Half of all people with heart failure have heart failure with
reduced ejection fraction (ejection fraction of < 45%) and the rest have heart failure with preserved
ejection fraction (ejection fraction of ≥ 45%).
Rehabilitation for people with heart failure improves their quality of life and reduces hospital admissions.
Most rehabilitation has taken place in groups in hospital settings, but poor levels of participation mean
that alternative ways of accessing rehabilitation, such as home-based programmes, are recommended.
The Rehabilitation Enablement in Chronic Heart Failure (REACH-HF) intervention comprises three
printed components: (1) an ‘HF Manual’ with information for patients and an exercise programme,
(2) a ‘Family and Friends Resource’ for caregivers and (3) a ‘Progress Tracker’ booklet for patients to
chart their progress. The programme is delivered by trained nurses or physiotherapists.
We carried out two studies of the REACH-HF intervention. In our main trial, we allocated at random
216 people with heart failure with reduced ejection fraction from four UK centres to receive the
REACH-HF intervention or usual medical care alone. The results of this study suggest that those who
received the REACH-HF intervention had a better quality of life. Economic modelling demonstrated
that the intervention is well within the willingness-to-pay limits recommended by the National Institute
for Health and Care Excellence. However, the economics analysis from the full trial did not show
significant differences between the two groups in hospital admissions. The cost of the intervention was
£418 per patient.
We also undertook a pilot trial of the same design in a single centre in 50 patients with heart failure
with preserved ejection fraction. The findings of this pilot study showed that the intervention and
study design were well accepted and these results support a future full trial of REACH-HF in patients
with heart failure with preserved ejection fraction.
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In the UK, nearly 1 million people live with heart failure, costing the NHS over £2.3B per year.
Heart failure has two main phenotypes: heart failure with reduced ejection fraction is characterised
by depressed left ventricular systolic function (‘reduced ejection fraction’), whereas heart failure with
preserved ejection fraction is diagnosed after excluding other causes of dyspnoea with normal ejection
fraction. Although evidence-based therapies for heart failure with reduced ejection fraction result
in improved life expectancy and quality of life, evidence-based treatments for heart failure with
preserved ejection fraction are lacking.
A 2014 Cochrane review found improvements in quality of life and reduced hospital admissions in
people with heart failure with reduced ejection fraction who participated in exercise-based cardiac
rehabilitation compared with those who received usual care alone. Cardiac rehabilitation comprises
three key elements: exercise to rebuild physical capacity, psychological support and support for key
self-care behaviours. In 2010, the National Institute for Health and Care Excellence recommended
centre/group exercise-based cardiac rehabilitation for those with heart failure with reduced ejection
fraction and heart failure with preserved ejection fraction. However, referral to and uptake of cardiac
rehabilitation for people with heart failure remain suboptimal. Uptake improves when patients have a
choice of centre- or home-based cardiac rehabilitation after myocardial infarction or revascularisation,
and updated National Institute for Health and Care Excellence guidance in 2018 recommended
offering home-based cardiac rehabilitation for patients with heart failure. The Rehabilitation Enablement
in Chronic Heart Failure (REACH-HF) investigators therefore evaluated a facilitated, home-delivered,
self-care cardiac rehabilitation intervention for patients with heart failure and their caregivers.
Aims and intended outputs
The overarching aim of the REACH-HF programme was to increase the evidence that cardiac
rehabilitation for heart failure can enhance current low uptake and inform future service commissioning.
We aimed to answer the following research questions:
1. What are the necessary intervention components of a home-based, self-care manual for patients
with heart failure (1A) and for their caregivers (1B)?
2. How feasible is the REACH-HF intervention in patients with heart failure with preserved
ejection fraction?
3. What is the clinical effectiveness and cost-effectiveness of the REACH-HF intervention compared
with usual care in patients with heart failure with reduced ejection fraction? What is the impact for
caregivers of using the intervention compared with usual care?
4. What is the long-term cost-effectiveness of the REACH-HF intervention, other home-based cardiac
rehabilitation and centre-based cardiac rehabilitation compared with usual care and home-based
cardiac rehabilitation in patients with heart failure with reduced ejection fraction?
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To answer these questions, we:
1. developed a novel, evidence-informed, facilitated, self-care home-based cardiac rehabilitation
intervention (the REACH-HF intervention) for people with heart failure and their caregivers and
undertook an uncontrolled feasibility study in patients in heart failure with reduced ejection fraction
(work package 1)
2. conducted a single-centre pilot, randomised controlled trial of the intervention to determine the
feasibility of a full trial of its clinical effectiveness and cost-effectiveness in addition to usual care in
patients with heart failure with preserved ejection fraction (work package 2)
3. undertook a multicentre randomised controlled trial and process evaluation to determine the
clinical effectiveness and cost-effectiveness of the intervention in addition to usual care in patients
with heart failure with reduced ejection fraction and their caregivers (work package 3)
4. used evidence synthesis and modelling methods to collate evidence on home- and centre-based
cardiac rehabilitation and assess the longer-term cost-effectiveness of the REACH-HF intervention,
other home-based cardiac rehabilitation and centre-based cardiac rehabilitation versus usual care in
patients with heart failure with reduced ejection fraction (work package 4).
Results
Work package 1: development of an evidence-informed, home-based, self-care cardiac
rehabilitation programme for people with heart failure and their caregivers (REACH-HF)
Methods
We used the intervention mapping framework to develop a home-based, self-care manual for patients
with heart failure with reduced ejection fraction (‘the REACH-HF intervention’) and their caregivers.
We used formal and informal literature reviewing, individual qualitative interviews, focus groups and
workshops with various stakeholders (patients, caregivers, service providers and experts in the field) to
develop a model of targets for change and intended processes of change (a logic model). We identified
and ‘mapped’ change techniques to each intended process of change and strategically organised the
intervention components.
Key findings
We created the REACH-HF intervention: a comprehensive, theory-based, user-centred, home-based,
self-care support programme for people with heart failure and their caregivers, which includes three core
printed components – the REACH-HF Manual, a participant ‘Progress Tracker’ booklet and a ‘Family and
Friends Resource’ for caregivers – as well as a facilitators’ training course. The intervention was tested in
a feasibility study in patients with heart failure with reduced ejection fraction. Attendance was high: all
patients attended three or more face-to-face sessions and typically received four telephone contacts.
Once the identified modifications to the manual and facilitator training were incorporated, the revised
intervention was used in both randomised controlled trials, in which it was well accepted by patients,
caregivers and health-care professional facilitators.
Work package 2: single-centre, pilot randomised controlled trial to assess the feasibility of
a definitive trial of the clinical effectiveness of the REACH-HF intervention in addition to
usual care in patients with heart failure with preserved ejection fraction
Methods
We undertook a pilot randomised controlled trial and process evaluation in a centre in Dundee with
a specialist interest in caring for patients with heart failure with preserved ejection fraction. The trial
recruited 50 participants and their caregivers from outpatient clinics and a Scottish register/database;
25 participants were randomly allocated to receive a modified form of the REACH-HF intervention
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that included information relevant for patients with heart failure with preserved ejection fraction in
addition to usual medical management for heart failure, and 25 were randomly allocated to usual care
alone. Patient outcomes, including health-related quality of life (primary) and psychological well-being,
exercise capacity, physical activity, heart failure-related hospitalisation and costs (secondary), were
collected by blinded assessors at baseline and 3 and 6 months post randomisation. Outcomes were
also collected for caregivers. A mixed-methods process evaluation was undertaken in parallel with
quantitative assessment of intervention fidelity and qualitative exploration of heart failure with
preserved ejection fraction patients’ and caregivers’ experiences. Data included audio-recorded
intervention sessions, demographic information, intervention fidelity scores and qualitative interviews
following completion of the intervention in a purposeful sample of 15 patients with heart failure with
preserved ejection fraction and seven caregivers.
Key findings
The study recruited 50 participants with symptomatic heart failure with preserved ejection fraction
(left ventricular ejection fraction ≥ 45%) (mean age 73.9 years, 54% female) and 21 caregivers.
Study retention and intervention uptake were excellent (90% and 92%, respectively).
At 6 months, data from 45 patients showed a mean between-group difference in favour of the
intervention for the primary outcome – Minnesota Living with Heart Failure Questionnaire score –
although the confidence interval was wide and included 0 (between-group mean difference −11.5,
95% confidence interval −22.8 to 0.3). Eleven participants (four intervention, seven control) were admitted
to hospital over the 6 months of follow-up; four of these admissions (all in the control group) were
related to heart failure. The estimated average cost of the REACH-HF intervention per patient with
heart failure with preserved ejection fraction was £362.61.
Intervention fidelity analysis indicated adequate delivery of most REACH-HF components.
In the context of this single-centre pilot not fully powered to demonstrate between-group differences
in patients or caregivers, these findings should be considered indicative.
Interpretation
These findings supported the feasibility of and rationale for delivering the facilitated home-based
REACH-HF intervention for patients with heart failure with preserved ejection fraction and their
caregivers and progression to a full multicentre randomised controlled trial of its clinical effectiveness
and cost-effectiveness.
Work package 3: multicentre randomised controlled trial and process evaluation of the
clinical effectiveness and cost-effectiveness of the REACH-HF intervention in addition to
usual care in people with heart failure with reduced ejection fraction and their caregivers
Methods
The trial recruited people with heart failure with reduced ejection fraction from four centres
(i.e. Birmingham, Cornwall, Gwent and York). Participants were randomly allocated to the REACH-HF
intervention plus usual care or usual care alone. Those randomised to the intervention usually had
a home-based consultation with a cardiac rehabilitation or heart failure nurse or physiotherapist
trained to facilitate it. The facilitator assessed participants’ individual needs and provided instruction
in use of appropriate sections of the Heart Failure Manual. During the 12 weeks after randomisation,
the facilitator answered questions from participants or caregivers during home visits or by e-mail or
telephone. The primary outcome was disease-specific health-related quality of life measured using the
Minnesota Living with Heart Failure Questionnaire at 12 months. Secondary outcomes included death
or admissions with decompensated heart failure or acute coronary syndrome, N-terminal pro-B-type
natriuretic peptide levels, Incremental Shuttle Walk Test, psychological well-being, physical activity level,
generic health-related quality of life, caregiver outcome, health-care utilisation, adverse events and costs.
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Key findings
The study recruited 216 participants, predominantly men (78%), with an average age of 70 years and
mean left ventricular ejection fraction of 34%. Overall, 185 (86%) participants provided data for the
primary outcome.
Adding the REACH-HF intervention to usual care resulted in clinically superior disease-specific
health-related quality of life at 12 months compared with usual care alone. At 12 months, there was
a significant and clinically meaningful between-group difference in the Minnesota Living with Heart
Failure Questionnaire score of –5.7 points (95% confidence interval –10.6 to –0.7 points) favouring
the intervention (p = 0.025). The Minnesota Living with Heart Failure Questionnaire physical score also
significantly favoured the intervention (mean difference at 12 months –3.2, 95% confidence interval
–5.7 to –0.6; p = 0.016) but the emotional score did not (mean difference at 12 months –0.8, 95%
confidence interval –2.2 to 0.6; p = 0.273). Post hoc analysis showed that 48 (52%) participants in the
REACH-HF group and 31 (33%) in the control group achieved a reduction of 5 Minnesota Living with
Heart Failure Questionnaire points.
Other than patient self-care (p < 0.001), no significant difference was seen in other secondary outcomes,
including clinical events (p > 0.05) at follow-up, compared with usual care. Eight (4%) patients died (four
in each group). Nineteen participants in the REACH-HF group and 24 in the control group had one or
more hospital admissions, totalling 33 hospital admissions (four heart failure related) in the REACH-HF
group and 35 (10 heart failure related) in the control group. The Self-Care of Heart Failure Index
maintenance score at 12 months favoured the intervention (p < 0.001). Within-group improvements
from baseline were seen with REACH-HF for the Hospital Anxiety and Depression Scale anxiety and
depression, Incremental Shuttle Walk Test and Self-Care of Heart Failure Index (management and
confidence), but these were not statistically significant compared with the control group at 12 months.
No differences were seen in the other secondary outcomes (EuroQol-5 Dimensions, HeartQoL and
physical activity). Patterns of primary and secondary results were similar at 4 and 6 months. We found
no significant interaction effect on the Minnesota Living with Heart Failure Questionnaire at 12 months
between treatment and N-terminal pro-B-type natriuretic peptide level, presence of caregiver,
recruitment site or duration of heart failure.
The mean cost of the REACH-HF intervention was £418 per participant. The costs at 12 months were,
on average, £401 higher in the intervention group than in the usual care alone group.
Limitations
Lack of blinding because of the complex nature of the intervention and control was a key limitation,
introducing possible patient expectation bias. Our findings should be interpreted with caution, as the
sex balance among patients with heart failure in the UK is almost equal, whereas 78% of recruits were
male and we recruited only seven people from ethnic minorities.
Interpretation
The REACH-HF home-based facilitated intervention for heart failure with reduced ejection fraction was
clinically superior in disease-specific health-related quality of life at 12 months, offering an affordable
alternative to traditional centre-based programmes to address current low uptake of cardiac rehabilitation
for heart failure.
Work package 4: longer-term cost-effectiveness of REACH-HF, home-based cardiac
rehabilitation and centre-based cardiac rehabilitation versus usual care in people with
heart failure with reduced ejection fraction
Methods
We used model-based analyses to capture disease progression using health states representing
important event-related activities of heart failure. A Cochrane systematic review of exercise-based
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cardiac rehabilitation (home and centre based) undertaken as part of our programme informed
data inputs to the evidence synthesis. A Markov model developed using a patient lifetime horizon
integrated evidence from the REACH-HF main trial, a systematic review/meta-analysis of randomised
trials, estimates of mortality and hospital admissions, and UK costs (2015–16 prices). Taking a UK
National Health and Personal Social Services perspective, we estimated the incremental cost per
quality-adjusted life-year gained, assessing uncertainty using probabilistic and deterministic sensitivity
analyses. We estimated the cost-effectiveness of home-based cardiac rehabilitation versus usual care,
REACH-HF intervention versus usual care, and centre-based cardiac rehabilitation versus usual care.
Using the common comparator of usual care, we indirectly compared trial-based evidence for centre-
based cardiac rehabilitation and the REACH-HF intervention in our multicentre randomised controlled
trial to derive the relative effect of centre-based cardiac rehabilitation versus our intervention.
The cost-effectiveness of centre-based cardiac rehabilitation versus usual care was considered, for
consistency, using a common decision-analysis framework that we developed.
Key findings
In base-case analysis, the REACH-HF intervention was associated with a per-patient mean quality-
adjusted life-year gain of 0.23, an increased mean cost of £400 compared with usual care, and a cost
per quality-adjusted life-year of £1720. Probabilistic sensitivity analysis indicated a 78% probability
that the intervention plus usual care versus usual care alone has cost-effectiveness below the
willingness-to-pay threshold of £20,000 per quality-adjusted life-year gained. Results were similar for
home-based cardiac rehabilitation (based on our meta-analysis) versus usual care. Sensitivity analyses
indicate that the findings are robust to changes in model assumptions and parameters.
Interpretation
Modelling predicts a reduction in hospital admissions consistent with published trials of home-based
cardiac rehabilitation. Adding the REACH-HF intervention and home-based cardiac rehabilitation
programmes is likely to be cost-effective compared with usual care alone in patients with heart failure
with reduced ejection fraction.
Future steps
We are disseminating our findings to the NHS Systematic collection of real-world data would track
future changes in uptake and adherence of cardiac rehabilitation in patients with heart failure.
Monitoring implementation of a home-delivered, evidence-based intervention can increase
understanding of how changes in service delivery might affect patient and caregiver outcomes.
The positive findings of our single-centre pilot randomised controlled trial in patients with heart failure
with preserved ejection fraction suggest that a full multicentre randomised controlled trial of the
REACH-HF intervention in people with heart failure with preserved ejection fraction is a logical,
achievable next step.
Conclusion
We developed and evaluated a comprehensive, facilitated, home-based cardiac rehabilitation intervention
for patients with heart failure and their caregivers. Overall, 185 (86%) participants provided data for the
primary outcome. The improvement in the Minnesota Living with Heart Failure Questionnaire score with
the REACH-HF intervention at 12 months was significant and clinically meaningful. The maintenance
score on the Self-Care of Heart Failure Index, a measure of self-care, was also significantly in favour
of the REACH-HF intervention group at 12 months. Within-group improvements from baseline in the
REACH-HF group for the Hospital Anxiety and Depression Scale anxiety and depression, Incremental
Shuttle Walk Test and Self-Care of Heart Failure Index (management and confidence) did not reach
statistical significance compared with the control group at 12 months. Four deaths occurred in each group.
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In the REACH-HF group, 19 participants had one or more hospital admissions, compared with
24 in the control group. Overall, there was no statistically significant difference in hospital admissions:
33 in the REACH-HF group (four heart failure-related) and 35 in the control group (10 heart failure
related). The mean cost of the intervention was £418 per participant. The EuroQol-5 Dimensions
scores at 12 months showed no difference in quality-adjusted life-year gain between groups, with usual
care dominant, so the REACH-HF intervention was not cost-effective using this short-term perspective.
However, economic modelling showed that the intervention was associated with a per-patient mean
quality-adjusted life-year gain of 0.23 and a cost per quality-adjusted life-year gain of £1720 – below
the threshold of £20,000 per quality-adjusted life-year gained recommended by the National Institute
for Health and Care Excellence.
With the caveats above, these findings suggest clinical effectiveness and long-term cost-effectiveness
of the REACH-HF intervention for patients with heart failure with reduced ejection fraction.
The REACH-HF intervention offers a new evidence-based cardiac rehabilitation option, which, being
home based, could increase uptake of cardiac rehabilitation in patients with heart failure not attracted
to hospital-based group programmes.
Our pilot randomised controlled trial in heart failure with preserved ejection fraction supports
the rationale for a full multicentre randomised controlled trial of its clinical effectiveness and
cost-effectiveness. Health economic modelling shows long-term potential cost savings for the
NHS from introducing home-based cardiac rehabilitation intervention for patients with heart failure
with reduced ejection fraction. This could address the low uptake of cardiac rehabilitation in people
with heart failure by offering patients, clinicians and commissioners an alternative to hospital-based
cardiac rehabilitation.
Trial registration
This trial is registered as ISRCTN86234930 and ISRCTN78539530.
Funding
This project was funded by the National Institute for Health Research (NIHR) Programme Grants for
Applied Research programme and will be published in full in Programme Grants for Applied Research;
Vol. 9, No. 1. See the NIHR Journals Library website for further project information.
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Our original proposal stated that the Rehabilitation Enablement in Chronic Heart Failure (REACH-HF)
programme of research would include four linked work packages (WPs) that aim to:
1. develop an evidence-informed, home-based, self-care cardiac rehabilitation (CR) programme for
people with heart failure (HF) and their caregivers (‘the REACH-HF intervention’)
2. conduct a pilot trial to assess the feasibility of a definitive trial of the REACH-HF intervention in
heart failure with preserved ejection fraction (HFpEF)
3. conduct a randomised controlled trial (RCT) to assess the clinical effectiveness and cost-effectiveness
of the REACH-HF intervention versus usual care in people with heart failure with reduced ejection
fraction (HFrEF) and their carers
4. undertake evidence synthesis/modelling to assess the clinical effectiveness and cost-effectiveness of
the REACH-HF intervention versus centre-based CR in people with HFrEF.
Our original research questions were:
l WP1 –
¢ What are the necessary intervention components of a home-based, self-care manual for patients
with HF?
¢ What are the necessary intervention components of a home-based, self-care manual for
caregivers of patients with HF?
l WP2 –
¢ How feasible is the REACH-HF intervention in patients with HFpEF?
l WP3 –
¢ What are the clinical effectiveness and cost-effectiveness of the REACH-HF intervention
compared with usual care in patients with HFrEF?
¢ What is the impact for caregivers of using the intervention versus usual care?
l WP4 –
¢ What are the clinical effectiveness and cost-effectiveness of the REACH-HF intervention versus
centre-based CR in patients with HFrEF?
¢ What is the expected value of information for future research, including a RCT of the REACH-HF
intervention versus centre-based CR in patients with HFrEF?
Over the 6 years of our programme of applied research, we were able to complete all four WPs as per
our original research questions, although we had to modify our economic evaluation in WP4. Given the
paucity of direct head-to-head RCTs in the HF population identified by the updated Cochrane review1
of home- versus hospital-based CR (four RCTs in a total of 295 patients, with only one single-centre
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study undertaken in a UK setting) and that the data were too limited to directly estimate the longer-
term cost-effectiveness of home- versus hospital-based CR, we decided to restrict our economic
modelling to examine the questions of the longer cost-effectiveness of:
l the REACH-HF intervention versus usual care
l home-based CR versus usual care
l centre-based CR versus usual care.
In summary, the only change that we made to our original proposal was to WP4, for which we modified
the economic modelling, as we were not able to make a direct comparison of the effectiveness of
the REACH-HF intervention versus centre-based CR in people with HFrEF. Instead, our modelling
compared home- and centre-based CR versus usual care.
Setting the scene
The burden of heart failure
Chronic HF is a burgeoning global health challenge that affects about 64 million people worldwide,2,3
including nearly 5 million people in the USA4 and about 900,000 people in the UK.5 In the Western
world, 1–2% of adults are living with the condition,6 and the prevalence is predicted to increase with
the ageing population.3,7 Low- and middle-income countries are also seeing an increase in prevalence,
as people in these countries adopt Western lifestyles, leading to higher rates of obesity, diabetes and
hypertension – morbidities that contribute to development of HF.8,9
An editorial in The Lancet highlighted the negative impact of HF, describing it as ‘a dangerous, debilitating,
and common disease, subjecting patients, carers, and doctors to a substantial burden. The need for
admission to hospital and provision of specialist care, often for extended periods, means that the costs
to health systems are correspondingly great’.3 In 2002, the annual NHS spend on HF was £716M – just
less than 2% of the total NHS expenditure of nearly £40B. Globally, the economic burden is predicted to
grow to more than US$108B [£82B, conversion as at 27 June 2018: 1 US$ =$ 0.760133 Great British
pounds (GBP)] as the population ages and nations become more industrialised. Hospital admissions are a
key driver of the rising costs related to HF in high-income countries: in people > 65 years of age, it is the
most common reason for hospital admission in the USA, where about 1 million admissions per year are
related to HF, which is comparable to annual admissions for HF in Europe.3
With the prevalence of HF predicted to increase as a result of increased life expectancy and a
corresponding increase in the elderly population,3 care needed by elderly people, especially those with
long-term conditions and multimorbidities, will also increase. Nearly 80% of patients with HF have
three or more comorbidities, with the most common preceding a diagnosis of HF being hypertension,
ischaemic heart disease, osteoarthritis and atrial fibrillation (AF).7 A recent population-based study in
the UK assessed the interval need (a measure of dependency and an assessment of demand) that was
being met by carers for generational cohorts of elderly people and identified a change in care needs
between 1991 and 2011, with an increase in elderly people being cared for in the community, creating
more responsibilities for family and friends.10
People with HF are commonly categorised on the basis of their left ventricular ejection fraction (LVEF):
patients with HF with reduced ejection fraction (HFrEF) (typically LVEF < 40–45%) have ‘systolic’
HF due to impaired left ventricular contraction, while those with normal LVEF (typically > 45–50%)
have HF with preserved ejection fraction (HFpEF).11,12 Although individuals with HFpEF are thought
to account for more than half of all patients with HF, most trials have recruited only patients with
HFrEF – probably because patients with HFpEF tend to be older and have multiple comorbidities and
historically there has been a lack of consensus on the exact definition of HFpEF. The prevalence of
HFrEF is decreasing, whereas the prevalence of HFpEF is increasing.
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Both forms of chronic HF can cause several symptoms, including shortness of breath, fatigue, fluid
retention, impaired cognitive function and appetite disturbance. People with HF consequently experience
exercise intolerance, poor health-related quality of life (HRQoL), increased hospital admissions, increased
mortality and higher health-care costs, which seem to be similar for those with HFrEF and HFpEF.4,13
Historically, 5-year survival rates for patients with HF have been worse than for the most common
cancers. With the increasing cost of hospitalisations, the focus of treatment over the past two decades
has been on pharmacological therapies and devices (biventricular pacemakers and implanted cardiac
defibrillators), which have resulted in improvements in survival and fewer hospitalisations, mainly in
patients with HFrEF.3
Poor HRQoL in people with HF13 is multifaceted and involves complex interactions across a range
of measures, including severity of HF, extent of comorbidity (e.g. pulmonary disease and chronic
kidney disease), exercise capacity, physical activity status, activities of daily living14,15 and depressive
symptoms, which alone are evident in up to 42% of patients with HF.16 As survival rates in people
with HFrEF have improved, HRQoL is becoming a key patient-reported outcome measure.3,17,18
Better management of HF can reduce uncertainty and anxiety and may improve quality of life.19
The evidence base for cardiac rehabilitation in heart failure
Cardiac rehabilitation has, in its broadest sense, been defined as the sum of activities required to:
. . . influence favourably the underlying cause of cardiovascular disease, as well as to provide the best
possible physical, mental and social conditions, so that the patients may, by their own efforts, preserve or
resume optimal functioning in their community and through improved health behaviour, slow or reverse
progression of disease.
Reproduced with permission from British Association for
Cardiovascular Prevention and Rehabilitation20
Although exercise training remains a key component of CR, current practice guidelines consistently
recommend ‘comprehensive rehabilitation’ programmes that contain the core components necessary to
optimise cardiovascular risk reduction, foster health promotion behaviour patterns and their maintenance
over time, reduce disability, and promote an active lifestyle. Guideline-based CR consists of three key
elements: exercise to rebuild physical capacity and heart health, psychological support to help manage
the emotional consequences of living with a heart condition, and support for key self-care behaviours.
In the context of HF, key self-care behaviours include taking medications, engaging in (long-term)
exercise, managing stress/anxiety and monitoring/managing fluid build-up.21 Friends and family can
have a key role in supporting patients to engage in and maintain these key self-care behaviours. CR for
HF supports patients and carers to achieve or maintain good HRQoL as part of managing HF symptoms
and HF-related self-care.
In 2004, the first Cochrane systematic review22 of exercise-based interventions for HF in 29 studies
(1126 randomised participants) with up to 12-month follow-up reported that exercise training
significantly improved exercise capacity compared with no exercise training. Only one study examined
the effect of exercise on mortality and morbidity, and only nine out of 29 RCTs measured HRQoL, with
seven of these reporting an improvement in exercise capacity. An updated Cochrane review14 published
in 2010 focused on trials with follow-up of 6 months or longer that reported on HRQoL and clinical
events – that is, mortality and hospitalisation. This review, which included data from a trial-level
aggregate of 19 RCTs involving 3647 participants, found no difference in short- or long-term all-cause
mortality between exercise and no exercise; however, exercise therapy resulted in a reduction in HF-
related hospitalisations [risk ratio 0.72, 95% confidence interval (CI) 0.52 to 0.99] and an improvement
in patient-reported HRQoL (standardised mean difference 20.63, 95% CI 20.37 to 20.80). However, most
of the trials recruited predominantly men (median 87%) and, although more recent studies have included
women, they were limited to people with mild or moderate HF – that is, class II or III of the New York
Heart Association (NYHA) classification, which is used to categorise the severity of HF based on symptoms
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and functional exercise capacity, but not severe disease.11,23 None of the trials included people with HFpEF,
and the interventions in 14 out of 19 RCTs were delivered in centre-based settings.
A further update of the Cochrane review in 2014 reassessed the effectiveness of exercise-based
rehabilitation on mortality, hospital admissions, morbidity and HRQoL in people with HF compared with
no exercise training.24 It also sought to identify additional evidence, including cost and cost-effectiveness,
for those individuals poorly represented in previous reviews (i.e. older people, women and people with
HFpEF) and the interventions specifically delivered in a home- or community-based setting. This review,
which included 33 trials involving 4740 people with HF, identified no difference in pooled mortality
between exercise-based rehabilitation and no exercise in trials with up to 12-months’ follow-up [relative
risk (RR) 0.93, 95% CI 0.69 to 1.27]. However, there was a trend towards a reduction in mortality for
exercise-based rehabilitation alone after more than 12 months of follow-up (RR 0.88, 95% CI 0.75 to
1.02). Compared with no CR, exercise training reduced the rate of overall hospitalisation (RR 0.75,
95% CI 0.62 to 0.92) and HF-specific hospitalisation (RR 0.61, 95% CI 0.46 to 0.80). A change of 5 points
in the Minnesota Living with Heart Failure Questionnaire (MLHFQ) score is considered clinically
important (higher scores indicate poorer HF-related HRQoL), and inclusion of exercise in rehabilitation
programmes resulted in a greater improvement in this disease-specific measure of HRQoL (13 trials,
1270 participants, mean difference –5.8 points, 95% CI –9.2 to –2.4 points). Univariate meta-regression
analysis showed that the benefits of exercise-based CR are independent of participants’ age, sex or
degree of left ventricular dysfunction, type of CR (exercise only versus comprehensive), mean dose of
exercise intervention, length of follow-up, overall risk of bias and trial publication date. Most of the
participants included in this review had HFrEF and were categorised as having NYHA class II or III
disease.15,24 The more recent trials included people with HFpEF and NYHA class IV disease and greater
proportions of women and older patients. Evidence from two trials supported the cost-effectiveness
of exercise-based CR in terms of gain in quality-adjusted life-years (QALYs) and life-years saved.25,26
Although Cochrane reviews of RCTs are not conclusive about the mortality benefits of CR, data from
national audits show that patients referred to CR have better survival; however, observational analyses
like these should be interpreted with caution, as they are subject to selection bias and confounding.
On the basis of evidence accumulating on the clinical benefits of CR, in 2010 the National Institute
for Health and Care Excellence (NICE) recommended supervised, group-format, exercise-based
rehabilitation for people with HF.27 Similarly, other international guidelines on the management of HF,
including those published by the American College of Cardiology/American Heart Association and
the European Society of Cardiology (ESC), recommend CR as an effective and safe intervention.11,28
The ESC recommends that CR must be integrated into the overall provision of care for patients with
HF based on class IA evidence, which shows that regular aerobic exercise improves functional capacity
and symptoms in people with HFrEF and also reduces the risk of hospitalisations in these patients.11
Current provision of cardiac rehabilitation
Historically, CR after myocardial infarction (MI) and revascularisation (percutaneous coronary
intervention or coronary artery bypass graft) has been provided for groups of patients in centre-based
settings, such as hospitals. The 2017 annual statistical report from the National Audit of Cardiac
Rehabilitation (NACR) states that, overall, 51% of eligible patients who had a MI, percutaneous
coronary intervention or coronary artery bypass graft participated in CR in England, Northern Ireland
and Wales.29 Lower rates of uptake in these groups led to innovative ways of delivering CR, such as
home-based CR using the Heart Manual.30 This step-by-step guide is supported by a trained nurse
facilitator and directs the patient through a 6-week programme of exercise, stress management
and education (www.theheartmanual.com; accessed 20 February 2020). Supervised group-based
interventions, as recommended by NICE,5,31 may be difficult for patients to access,32 and home-based
CR programmes, such as the Heart Manual, are no less clinically effective than centre-based programmes
but equally cost-effective. Patients like to have a choice of CR, and studies have shown that choice can
enhance uptake.
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The CR needs of people with HF can be more complex than for patients after uncomplicated MI or
revascularisation – the settings in which CR was first used. People with HF are prone to greater levels
of disability, as disease progression leads to increasing incapacity and deconditioning.33 Activities of
daily living are limited by symptoms such as shortness of breath and fatigue, thus affecting HRQoL.13
The 2017 National Heart Failure Audit stated that there is underprovision of CR in the UK, with
< 20% of patients with HF being referred to CR during hospitalisation.34 According to the 2016 and
2017 reports from the NACR, people with HF make up < 10% of all patients who participate in CR.35
The 2017 standards of the British Association for Cardiac Prevention (BACPR) recommend that HF
should be a priority area and that CR providers should consider offering alternatives to centre-based
CR to improve the current low uptake of CR in people with HF.20
Importance and relevance of programme
The underprovision of CR has been evident for several years, with a national survey undertaken as
part of the programme development application for the REACH-HF programme showing that only one
in seven (35/224, 16%) CR centres in England, Wales and Northern Ireland provided a dedicated HF
programme in 2009–10. A European survey conducted around the same time showed that < 20% of
patients with HF were involved in CR. A recent registry study from the USA reported that only 10%
of eligible patients with HF were referred for CR after hospital discharge, although this proportion
increased between 2005 and 2014.36
Despite good evidence (see The evidence base for cardiac rehabilitation in heart failure), the importance of
CR in HF is not acknowledged in major clinical reviews. A key potential strategy for commissioners to
improve on the current poor provision of CR in HF and address this important unmet need is to offer
individuals choice by including a home-based CR intervention that is evidence based and provides an
alternative to centre-based CR.
Involvement of caregivers
Despite recommendations that family members or caregivers should be included in discussions about
care, few evaluations of supportive interventions for individuals caring for someone with HF have
been published to date. There have, however, been calls for research to develop interventions with
caregivers to improve quality of care, reduce costs and improve patients’ HRQoL.37
Caregivers have an important role in supporting the management of chronic disease, although this
often comes at considerable personal cost, and many caregivers are uncertain about how best to
provide this support. Most caregivers have health and well-being problems of their own – either
pre-existing conditions or issues arising from the burden of their caregiving activities. Caregiver burden
is due to the tasks of caring (objective burden) and the distress associated with the role (subjective
burden). The objective burden comes from activities that include physical tasks such as washing,
dressing, feeding and assistance with mobility, which are often performed at night. Other caregiving
activities support self-care of chronic conditions such as HF, including assisting with identification of
signs and symptoms of deterioration, taking action during an emergency, and assisting with blood
pressure monitoring and medication management. Caregivers also support adherence to dietary
restrictions, support emotional needs, promote exercise and physical activity, provide transport,
maintain safety, and liaise with health-care professionals (HCPs).
Innovation
We set out to design and develop a novel HF rehabilitation intervention/approach that would
(1) provide information that is individually tailored rather than a one-size-fits-all approach; (2) include
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facilitation and careful monitoring of the development of self-care skills and strategies by a specially
trained facilitator; (3) offer near-patient care in the patient’s home rather than requiring attendance
at hospital clinics; (4) employ theoretically informed and evidence-based practice to support behaviour
change; and (5) provide an intervention strongly informed by service-user consultation at every stage
of its development. Overall, the intervention package was expected to offer a higher standard of care,
and we hypothesised that it would result in improved self-care.38
Original aims, objectives and outputs
The overarching aim of this programme was to improve the body of evidence-based knowledge of CR
for HF to enhance the current low uptake of CR in HF and to inform future service commissioning.
Our specific objectives were to:
l develop an evidence-informed, home-based, self-care CR programme for patients with HF and their
caregivers (‘the REACH-HF intervention’)
l conduct a pilot trial to assess the feasibility of a full trial to assess the clinical effectiveness and
cost-effectiveness of the REACH-HF intervention in addition to usual care in patients with HFpEF
l assess the clinical effectiveness and cost-effectiveness of the REACH-HF intervention in addition to
usual care in patients with HFrEF and their caregivers
l assess cost-effectiveness over the longer term of the REACH-HF intervention, other home-based
CR and centre-based CR versus usual care in patients with HFrEF.
To meet these objectives, we developed a series of inter-related WPs (Figure 1):
l WP1 – to develop a novel, evidence-informed, facilitated, self-care home-based rehabilitation
intervention (‘the REACH-HF intervention’) for people with HF (see WP1A) and their caregivers
(see WP1B) and undertake an uncontrolled feasibility study in patients with HfrEF.
l WP2 – to conduct a single-centre, pilot RCT of the REACH-HF intervention to determine the
feasibility of a full trial of its clinical effectiveness and cost-effectiveness in addition to usual care
in patients with HFpEF (see Work package 2: single-centre, pilot randomised controlled trial of the
REACH-HF intervention in patients with heart failure with preserved ejection fraction).
l WP3 – to assess the clinical effectiveness and cost-effectiveness of the REACH-HF intervention
in addition to usual care in patients with HFrEF and their caregivers in a multicentre RCT
(see Work package 3: multicentre randomised controlled trial of the REACH-HF intervention in patients
with heart failure with reduced ejection fraction).
l WP4 – to assess the longer-term cost-effectiveness of the REACH-HF intervention, other home-
based CR and centre-based CR versus usual care in people with HFrEF by using evidence synthesis
and modelling methods to bring together evidence on home- and centre-based CR (see Work package 4:
model-based cost-effectiveness analysis).
We were able to fully meet the programme objectives:
l We co-designed the REACH-HF intervention with stakeholders including patients, caregivers,
clinicians and commissioners.
l Both WP2 and WP3 trials recruited to target and had excellent retention.
l We successfully completed an updated evidence synthesis and economic modelling of the clinical
effectiveness and cost-effectiveness of home- and centre-based CR.
Table 1 summarises the publication outputs from this programme.
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Work package 1: intervention development and feasibility study
Some parts of these sections have been reproduced with permission from Greaves et al.39 This article
is distributed under the terms of the Creative Commons Attribution 4.0 International License
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction
in any medium, provided you give appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public
Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data
made available in this article, unless otherwise stated. The text includes minor additions and formatting
changes to the original text.
Work package 1: overview
We used a systematic intervention development framework – intervention mapping47 – to develop
a novel, evidence-informed, facilitated, home-based, self-care manual for people with HFrEF (‘the
REACH-HF intervention’) (see WP1A) and their caregivers (see WP1B) and evaluated this intervention
TABLE 1 Alignment of programme objectives, WPs and outputs as presented in the report
Programme objectives Synopsis: research development Programme outputs
WP1 – to develop an evidence-
informed, home-based, self-care CR
programme for patients with HF and
their caregivers (‘the REACH-HF
intervention’)
WP1A: systematic intervention
mapping methods to develop a
facilitated home-based, self-help
intervention for patients with HFrEF
(‘the REACH-HF intervention’)
WP1B: individual qualitative
interviews and focus group
interviews in participants’ homes to
systematically develop a theoretically
robust, home-based resource for
caregivers of people with HF
The REACH-HF intervention was
also evaluated in a feasibility study
in patients with HFrEF with parallel
process evaluation
REACH-HF intervention, comprising HF
Manual, participant Progress Tracker
booklet, Family and Friends Resource
for caregivers, and facilitation by cardiac
nurses or physiotherapists (details
available from investigator team)
Greaves et al.39 (see Appendix 1)
Wingham et al.40 (see Appendix 1)
WP2 – to conduct a pilot trial to assess
the feasibility of undertaking a full trial
to assess the clinical effectiveness and
cost-effectiveness of the REACH-HF
intervention in addition to usual care in
patients with HFpEF
WP2: pilot trial to assess the
effectiveness of the REACH-HF
intervention in patients with HFpEF
Eyre et al.41 (see Appendix 1)
Lang et al.42 (see Appendix 1)
Smith et al.43 (see Appendix 1)
WP3 – to assess the clinical
effectiveness and cost-effectiveness
of the REACH-HF intervention in
addition to usual care in patients
with HFrEF and their caregivers
WP3: RCT and process evaluation
to assess the clinical effectiveness
and cost-effectiveness of the
REACH-HF intervention in addition
to usual care vs. usual care alone in
patients with HFrEF
Taylor et al.38 (see Appendix 1)
Dalal et al.44 (see Appendix 1)
Wingham et al.10 (see Appendix 1)
Frost et al.45 (see Appendix 1)
Report on trial-based cost-effectiveness
analysis (unpublished report, see
Appendix 3)
WP4 – to assess cost-effectiveness
over the longer term of the REACH-HF
intervention, home-based CR and
centre-based CR vs. usual care
in people with HFrEF
WP4: evidence synthesis/modelling
to assess the cost-effectiveness over
the longer term of the REACH-HF
intervention, home-based CR and
centre-based CR vs. usual care
in people with HFrEF
Long et al.1 (see Appendix 1)
Taylor et al.46 (see Appendix 1)
Report on model based on cost-
effectiveness analysis (unpublished
report, see Appendix 3)
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in a feasibility study in patients with HFrEF. This included the use of formal and informal literature
reviewing, individual qualitative interviews, focus groups and workshops with a range of stakeholders
(patients, caregivers, service providers and experts in the field) to develop a model of targets for
change and intended processes of change (a logic model). Following this, we identified and ‘mapped’
change techniques to each intended process of change and strategically organised the intervention
components. This resulted in a comprehensive, theory-based, user-centred, home-based, self-care
support programme for people with HF and their caregivers. We collaborated closely with our
patient and public involvement (PPI) advisory group throughout, such that the intervention can be
considered to have been co-created with patients with HF and their caregivers. The resulting REACH-HF
intervention includes three core printed components (i.e. the Heart Failure Manual, a Family and Friends
Resource for caregivers and a Progress Tracker booklet), a choice of two exercise programmes for
patients and a training course for facilitators. The intervention was delivered by trained facilitators
(cardiac nurses or physiotherapists with experience of delivering CR programmes). We stipulated that,
in most cases, patients should receive a minimum of two face-to-face sessions and around six contacts
in total over the course of 12 weeks. The methods used to develop the novel REACH-HF intervention
and a detailed description of the intervention and its theoretical basis have been published.39 This paper
included a supplemental file with data on the feasibility and acceptability of the intervention for patients
and caregivers but with data on changes in outcome measures redacted (these data were considered
sensitive at the time, as the main trial was under way). We now include the previously unpublished
results of the feasibility study in Report Supplementary Material 2. The REACH-HF intervention was
trialled in a feasibility study in patients with HFrEF and was used successfully in both of our RCTs
(see Work package 2: single-centre, pilot randomised controlled trial of the REACH-HF intervention in patients
with heart failure with preserved ejection fraction and Work package 3: multicentre randomised controlled
trial of the REACH-HF intervention in patients with heart failure with reduced ejection fraction). In both
studies, it was well accepted by study participants and HCP facilitators.
Work package 1: introduction
To manage HF effectively, patients need to engage in a number of self-care behaviours including
exercise-based CR, which is recommended nationally and internationally.48 However, participation
in CR remains suboptimal in people with HF, which has been attributed to difficulties in patients
accessing hospital- or centre-based CR and lack of support for caregivers. Consequently, there have
been calls for alternative ways of delivering CR for patients with HF to improve the poor uptake.
Work package 1 concerned the development and feasibility testing of a novel, home-based intervention –
‘the REACH-HF intervention’ – for people with HF (WP1A) and their caregivers (WP1B). A detailed
report of the development process and content of the intervention and its theoretical basis has been
published (see Appendix 1). Report Supplementary Material 2 provides the results of a single-arm feasibility
study designed to test the acceptability of the REACH-HF intervention in patients with HFrEF and the
research methods for the main trial (see Work package 3: multicentre randomised controlled trial of the
REACH-HF intervention in patients with heart failure with reduced ejection fraction) and to identify ways to
improve/optimise the intervention ready for further evaluation. The intervention’s development and its
content are further described below.
Work package 1: research aims
Intervention development aims (work packages 1A and 1B combined)
The aims of the intervention development were to:
l establish the support needs of people with HF and their caregivers
l use a systematic intervention development framework (intervention mapping) to develop a
home-based CR intervention that is theory based and evidence informed, involving people with
HF and their caregivers
l develop a training course to support intervention delivery.
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Feasibility study aims
The aims of the feasibility study were to:
l assess the feasibility and acceptability of adding the REACH-HF intervention to usual care for
patients with HFrEF, their caregivers and intervention facilitators
l assess the fidelity (quality) of delivery of the REACH-HF intervention
l assess the feasibility of outcome data collection processes and measure completion/attrition rates
l identify any changes needed in the REACH-HF intervention or facilitator training.
Work package 1: methods
Framework for intervention development
Following the UK Medical Research Council guidance for developing complex health-care interventions,49
we used a systematic, evidence-informed approach to develop the REACH-HF intervention. Our approach
was based on intervention mapping – a six-step systematic framework for intervention development:50
Step 1 – ‘needs assessment’ to identify targets for change.
Step 2 – building matrices to ‘map’ change targets against determinants of the desired changes.
Step 3 – selection of appropriate behaviour change techniques and strategies to address each
determinant identified in step 2.
Step 4 – production of detailed intervention and training materials.
Step 5 – anticipating adoption and implementation of the intervention.
Step 6 – plans for evaluation of processes and effects.
Intervention mapping seeks to ground the intervention in the context and the population to be
targeted, as well as the existing evidence base. A key element of the intervention development process
was the inclusion of the REACH-HF PPI group, which consisted of six people from Cornwall with a
range of experiences with HF and three caregivers of people with HF. An overview of the intervention
development process is provided in Figure 2, and the following sections provide a summary of the first
five steps of the intervention mapping process. The process evaluation plans (step 6) are described







































• Define change objectives
• Identify determinants of change
• Specify techniques to modify
    determinants
• Train providers/facilitators
FIGURE 2 Development of the REACH-HF intervention. CG, caregivers; Cm, commissioners; HP, health-care providers
(e.g. general practitioners, cardio specialists, nurses); P, patients; qual, qualitative; quant, quantitative.
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Step 1: needs assessment/identifying targets for change
Identification of needs The process began by assessing the needs of patients with HF, their caregivers
and the service providers. This included gathering information on the problem, its causes and the
target population and then developing a ‘causal model’ outlining the main modifiable factors that might
contribute to an improvement in HRQoL for people with HF (see Figure 2).
Reviews of qualitative and quantitative literature provided a starting point for assessing the self-care
support needs of patients and caregivers. An ongoing literature search (updated every 2–3 months)
identified published reviews of self-care and rehabilitation interventions for people with HF from
1994 onwards. In addition, two de novo systematic reviews were undertaken by the project team:
a meta-ethnographic synthesis of qualitative literature on the attitudes, beliefs and expectations of
people with HF receiving CR51 and a systematic review and meta-analysis of the efficacy and safety
of CR in people with HFpEF.52 We also reviewed national and international clinical guidelines for HF
recommended by our project management group, including the ESC21 and NICE practice guidelines.27
The key recommendations on behaviour change, information needs or other changes needed to
improve the HRQoL of patients or caregivers were extracted, along with potential self-care strategies
and potential determinants of such changes.
A number of systematic reviews and guidelines highlighted the importance of exercise-based
rehabilitation as a central element in driving positive outcomes in HF.14,21,27,52 As a result, a specialist
working subgroup of project team members (PD, SS, KJ, JA, CG and RT) met several times (along with
extensive e-mail interaction) to develop and refine the exercise and physical activity components of
the intervention.
We conducted focus group interviews with two community-based HF support groups and attendees
at a hospital-based rehabilitation class. Each group included 12–20 patients and 6–10 caregivers. The
main topic areas were ‘coming to terms with heart failure’; benefits of and barriers to exercise/physical
activity; problems and solutions associated with taking medications; information and support needs;
advice for family members or caregivers; and how the REACH-HF intervention should be delivered.
To further elicit the views of key stakeholders, a needs assessment questionnaire was circulated to
10 people with HF and 24 other experts in the field, including two behavioural scientists, 14 specialist
nurses (HF, CR and primary care cardiac nurses), two cardiologists, two general practitioners (GPs), two
exercise physiologists with CR experience and two pharmacists. This was an opportunity sample based
on contacts known to the REACH-HF project management group and people in the focus groups who
had volunteered to complete the questionnaire. The questionnaire (which is published alongside the
intervention development paper39) included questions about what outcomes are important for people
with HF; self-care behaviours that should be targeted; information and support needs; suggested
content and delivery formats; and who might deliver the intervention. Respondents were also asked
how the manual could be adapted for a range of users, including those with HFpEF.
The REACH-HF PPI group helped to design the topic guide for the focus group interviews, completed
and commented on the needs assessment survey and commented on summaries of information from
the focus groups. The group met every 2 months throughout the 12-month needs assessment stage,
with additional e-mail and postal correspondence between meetings.
A qualitative research study involving face-to-face, semistructured interviews with a purposive sample
of 26 caregivers of people with HF with a range of sex, age and socioeconomic status was also
conducted to specifically identify caregivers’ needs.40
DOI: 10.3310/pgfar09010 Programme Grants for Applied Research 2021 Vol. 9 No. 1
Copyright © 2021 Dalal et al. This work was produced by Dalal et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social
Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution,
reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/. For attribution the
title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
11
Understanding the context or community in which an intervention is delivered is another important
aspect of needs assessment.50 A member of the research team (Wendy Armitage from the Heart Manual
Department) conducted site visits to HF treatment centres and a range of staff at four sites (Truro,
York, Birmingham and Abergavenny) and administered a questionnaire on current service provision.53
This identified existing strengths, limitations, competencies and capacities of potential providers.
Two team members (Carolyn Deighan and Michelle Clark from the Heart Manual Department)
reviewed further literature to identify evidence on the effectiveness of relaxation and mindfulness
interventions for people with HF (and other chronic illnesses) to inform the stress management
component of the Heart Failure Manual. Finally (just prior to implementation in the feasibility study),
a training needs questionnaire was sent to HCPs who had been selected to deliver the intervention
to assess their current state of knowledge/expertise with regard to key elements of the intervention.
This was used to tailor the training course in step 4.
Analysis and integration of needs assessment data A key challenge was to summarise and integrate
the data and ideas from many diverse sources. We did this using a framework for mixed-mode evidence
synthesis called triangulation protocol.54 First, a thematic synthesis of the needs assessment documents
and recordings was used to generate a ‘needs assessment’ table, which listed the key recommendations
from each evidence component. We then considered where the recommendations from each source
agreed (convergence), offered complementary information on the same issue (complementarity) or
seemed to be contradictory (dissonance). Where there was dissonance, we resolved this through
further discussion with the members of the project management and PPI groups. The focus of the
data synthesis was on identifying (1) targets for change and (2) modifiable determinants of the
changes suggested. This analytical process was conducted separately for patients and caregivers.
The themes identified by the above synthesis were organised into a logic model55 for the intervention
(Figure 3). This was developed by grouping the targets for change into broad themes (behavioural,
environmental, social and psychological) and mapping them onto a generic causal modelling framework
for intervention development (the PRECEDE model50,56). It was acknowledged that environmental and
contextual factors (e.g. home environment, social support networks) might affect HRQoL directly or
indirectly (via interaction with behavioural or psychological factors).
Prioritisation and intervention focus The targets for change (Box 1) were then prioritised through a
process that included noting the level of agreement between stakeholders from the needs assessment
table, consultation with the project PPI group and further discussion within the project team.
We took into account the strength of the evidence base and the potential for improving HRQoL.
The highest priority targets for change (shown in dark blue in Box 1) were then grouped into the
following five categories:
1. engaging in exercise training to build (and maintain) cardiovascular fitness
2. managing stress, breathlessness and anxiety
3. HF symptom monitoring (and associated help-seeking), particularly in terms of managing fluid status
4. taking prescribed medications
5. understanding HF.
Item 5 (understanding HF) was included following step 3 (see below), as it was identified as a core
determinant underpinning engagement with the first four targets for change.
The project management group and PPI group agreed that the above core priorities should receive
strong focused support from the intervention facilitator and that the intervention manual should
contain interactive elements to support change in these areas (e.g. for exercise training, we included
a choice of a walking programme or chair-based exercise programme, as well as interactive tools for
goal-setting and self-monitoring).
SYNOPSIS

















    hospital






• Manage fluid status
• Monitor signs and














• Ability for ADL
• Sleep quality


















FIGURE 3 Logic model/behavioural specification for the REACH-HF intervention. ADL, activities of daily living.
BOX 1 Developing the REACH-HF HF Manual: targets for change
Targets for change
Engage in exercise training (to improve cardiovascular fitness).
Longer-term physical activity (to maintain cardiovascular fitness).
Manage stress/anxiety.
Manage fluid status (over and under hydration).
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A second set of targets (the light blue text in Box 1) were identified as important for some but not
all patients (e.g. smoking cessation and healthy eating). It was agreed that these aspects should be
assessed and (briefer) intervention from the facilitator provided if needed.
A third set of targets, although important for some patients, were deemed to be outside the remit of
the provider (e.g. management of severe depression) or possible to address through existing services
(e.g. smoking cessation). It was agreed that these topics would be dealt with using a case-management
approach.
A fourth set of targets were categorised as peripheral or minor topics, such as vaccination. For these
topics, the patient was assessed, given some information and, if needed, signposted to further agencies
or information (e.g. websites).
Manage/live with uncertainty (about possible deterioration/decompensation events/end of life).
Sleep well.





Manage/organise the home and work environments.
Manage financial burden/organising benefits.
Manage comorbidities (other illnesses) that might affect the ability to manage HF.
Manage and respond appropriately to devices (e.g. implantable cardiac defibrillator, cardiac
resynchronisation therapy), including managing anxiety around devices.
Understand medications/treatments.
Get vaccinations.
Engage in sexual activity if desired.
Dark blue font indicates full coverage (core topic and important for all).
Light blue font indicates needs-based intervention (topic important for some but not all patients).
Orange font indicates case management approach (topic important for some but needing external input).
Light orange font indicates information only (topic peripheral or of relatively minor importance in most cases).
BOX 1 Developing the REACH-HF HF Manual: targets for change (continued)
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Caregiver targets for change and prioritisation The core priorities for the caregiver resource were to:
1. facilitate improvement in HRQoL for the person with HF by helping them to achieve the core
priorities for change for patients (see Box 1)
2. improve the quality of life for caregivers by acting to maintain their own health and well-being.
The target of ‘understanding heart failure’ was also felt to be of core importance in underpinning
engagement with the above targets. The targets for change for caregivers that emerged from the
needs assessment process are shown in Box 2. A focus group with four caregivers was conducted to
prioritise the targets in the same way as described for the patient manual (see Analysis and integration
of needs assessment data).
BOX 2 Developing the REACH-HF Caregiver Resource: targets for change
Caregiver targets for change
Support monitoring and management of signs/symptoms of HFa (e.g. when to ‘step in’).
Understand HF.a
Understand and manage medicines.a
Exercise/physical activity promotiona (facilitate the HF Manual exercise programme as well as maintenance).
Provide emotional support to help manage patient’s mood, anxiety, stress.
Manage caregiver stress and emotional consequences.
Manage own physical healtha (including physical activity/lifestyle, health problems, safe lifting).
Become a caregiver (psychological and practical adaptation, role negotiation).
Sleep well.
Deal with emergencies (including resuscitation issues).
Communication with health professionals.
Manage/organise the home and work environments – daily hassles.
Maintain own social activities/social roles.
Monitor signs/symptoms of depression of cared-for person.a
Understand and manage comorbidities.a
Provide and engage social support (e.g. offer information, encouragement and practical support; engage
friends, relatives, carer groups).
Live with uncertaintya (e.g. possible deterioration/decompensation events, end-of-life issues).
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Step 2: specifying performance objectives/identifying determinants of change
The behavioural, environmental, social and psychological targets for change resulting from needs
assessment (see Boxes 1 and 2) were broken down into more proximal ‘performance objectives’.
Performance objectives are statements of who needs to change and what behaviours or thought
processes need to be changed (and in what circumstances) to achieve each target.50 For each performance
objective, modifiable determinants of change were identified using several parallel methods:
l Existing evidence (e.g. process evaluations in rehabilitation studies).
l Theories of behaviour change and psychological adaptation.51,57–63
l Evidence identified during the needs assessment stage (e.g. qualitative data, needs
assessment questionnaire).
l A structured 1-day workshop with a panel of experts in the field (two exercise/rehabilitation
specialists, two cardiac specialist nurses, two GPs with cardiac special interest, two cardiologists and
three behavioural scientists).
l Similar structured workshops (three separate 2-hour sessions) with the PPI group. The consultation
workshops focused on the ‘core priority’ change targets.
In the workshops, the ‘core priority’ targets for change and their associated performance objectives were
presented to the expert panel and the PPI group. For each performance objective, the panel were asked:
l What will help people to achieve this target?
l What will stop people achieving this target? What will get in the way?
l How could we help people to overcome any barriers and achieve this target?
A facilitated group discussion resulted in a list of modifiable determinants (barriers and facilitators)
relating to each objective.
The performance objectives and determinants were then used to construct a set of ‘mapping matrices’ or
tables. The first two columns in Table 2 show the performance objective and determinants for performance
objective 1: ‘Engage in exercise training sessions 2–3 times per week’ as an example. Separate matrices
of performance objectives and determinants were constructed for the caregiver intervention.
The intervention design team specified a theoretical basis that (1) provided sufficient range to incorporate
all the determinants of change identified for each change target, and (2) was as parsimonious as possible.
Attend to physical needs of the cared-for person (practical tips).
Manage and respond appropriately to devices (e.g. implantable cardioverter defibrillator, cardiac
resynchronisation therapy), including managing anxiety around devices.a
Engage social services (e.g. carer needs assessment).
Manage financial burden/organising benefits for caregiver.
a These self-care issues are also dealt with in the HF Manual, and relevant sections are referenced from
the caregiver resource.
Dark blue font indicates full coverage (core topic and important for all).
Light blue font indicates brief, needs-based intervention (topic important for some but not all patients).
Orange font indicates case management approach (topic important for some but needing external input).
BOX 2 Developing the REACH-HF Caregiver Resource: targets for change (continued)
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determinants Change techniques Strategies
1. Engage in exercise
training sessions







l Provide information on
consequencesc
l Provide information on
illness identity, timeline,
causes, consequences and
control to build a functional
understanding/illness model
(how HF works and how
exercise affects HF)d
l Simultaneous self-monitoring
of behaviour and symptomsd
l Prompt intention formationc
l Motivational interviewingc
l Manual text on benefits of physical
activity/fitness in relation to HF
symptoms (M)
l Self-monitoring of symptoms
(including mood, sleep quality)
alongside progress with exercise
to help build associations between
exercise and health/learning
from experience (M). Reflections
by facilitator on these
associations (F)
l Discussion of existing knowledge
about how HF works and
how self-care actions affect
symptoms, mood/stress and quality
of life (F)




l Time l Time managementc l Assessment of barriers to activity
and tailored support (F), including




l Plan social support
(informational, emotional,
practical)c
l Assessment of barriers to activity
and tailored support (F), including
exploration of social support
l Engage caregiver in a supporting
role, with encouragement, planning
and practical help (F)
l Provide caregiver with Friends and
Family Resource (CGM)
l Physical capacity l Individual tailoring of
exercise level to current
fitnessd
l Set starting level to match existing
capacity (based on ISWT) (F)
l Confidence
(self-efficacy)
l Set graded tasks (graded
efficacy and capacity building)c
l Prompt specific goal settingc
l Prompt barrier identification
(and problem-solving)c
l Prompt review of
behavioural goalsc
l Motivational interviewingc
l Multilevel DVD of graded exercises
to demonstrate suitable
exercises (M)
l Walking programme as an alternative
to the DVD
l Facilitation of use of action-planning
and problem-solving tools in the
HF Manual and Progress Tracker
(F, M)
l Regular review of progress and
increasing goals for level/duration
of exercise, when existing level
becomes easy (F)
l Exploring and addressing barriers
through use of motivational
interviewing techniques (F)
continued
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Step 3: specification of change techniques and strategies
Step 3 of the intervention mapping process involved the selection of change techniques (e.g. behaviour
change and psychological intervention techniques) targeting each of the determinants of change
identified in step 2. In addition to expert opinion and experience, this work drew on an existing
taxonomy of behaviour change techniques64 and the expertise of the REACH-HF collaborators in
developing disease management programmes and CR programmes to identify potentially successful
strategies for patients with HF and their caregivers. The PPI group were asked about the strategies
that they had found to be successful and reviewed the selected change strategies (and the final programme
materials) to ensure that they were likely to be feasible and acceptable for patients and caregivers.
Step 4: production of detailed intervention and training materials
The outputs from the first three stages of the intervention mapping process were used to generate
detailed intervention materials and a training course for facilitators. These are described in Work
package 1: results. The PPI group commented on the materials in terms of both format and content.
Step 5: anticipating adoption and implementation issues – the REACH-HF feasibility study
We conducted a single-arm feasibility study (ISRCTN25032672) with a parallel process evaluation
across four sites (Birmingham, Cornwall, Gwent and York) to (1) assess the feasibility and acceptability
of adding the REACH-HF intervention to usual care for patients with HFrEF, their caregivers and
intervention facilitators, (2) help refine the intervention in advance of the main trial and (3) assess
the quality of intervention delivery.39
The REACH-HF intervention was delivered to 23 patients (and 12 caregivers) by seven trained
intervention facilitators at four sites (Cornwall, Abergavenny, Birmingham and York) over a period of




determinants Change techniques Strategies




of behaviour and moodd
l Patient to choose between DVD
programme or walking programme
(or a mixture)
l Self-monitoring of mood (and sleep
quality) alongside progress with
exercise to help build associations
between exercise and positive mood/
learning from experience (M)
l Reflections by facilitator on these
associations (F)
CGM, caregiver manual; DVD, digital versatile disc; F, facilitator task; ISWT, Incremental Shuttle Walk Test;
M, manual content.
a This is only a selection from the full intervention map for the wider change target ‘engaging in exercise training
and physical activity to build (and maintain) cardiovascular fitness)’. The other performance objectives (not shown)
were 2. Safely build up intensity/type of exercise as fitness improves to achieve a ‘basic level of fitness’; 3. Engage in
a maintenance exercise regimen at least twice weekly once a basic level of fitness has been achieved; 4. Monitor
activity levels and maintain at a level that maintains fitness and quality of life but does not lead to frequent bouts
of exhaustion; 5. Restart the activity regimen at an appropriate point following setbacks (e.g. a period of illness);
6. Learn how to assess level of exertion to exercise at the right level; and 7. Learn how to assess level of
breathlessness and take appropriate action before it gets out of control’.
b Exercises designed to improve cardiovascular fitness, improve efficiency of movement and enhance the ability to
perform functional activities associated with daily living (by building and maintaining muscle strength and prevention
of muscle shortening).
c Techniques listed in the Abraham and Michie64 taxonomy.
d Techniques not listed in the Abraham and Michie64 taxonomy.
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12 weeks in addition to usual care. Process data to help assess feasibility, acceptability and quality of
intervention delivery (intervention fidelity) were collected from multiple sources:
1. Qualitative methods were used to explore the stakeholder experiences of using and delivering the
intervention. Brief semistructured interviews with 13 patients and seven caregivers about their
experiences of receiving the REACH-HF intervention were conducted by telephone or face to face.
These were undertaken at 6 weeks (halfway through the intervention period) and at around 15 weeks
(at the end of the intervention period). The seven intervention facilitators completed feedback forms
at the end of each session. They documented what went well or not well and also participated in
up to three (audio-recorded) debriefing/feedback sessions during intervention delivery and a focus
group at the end of the intervention period. Topic guides (see Report Supplementary Material 1) were
developed in consultation with the intervention development team, the REACH-HF investigators and
our PPI Advisory Group.
2. A 13-item intervention fidelity checklist was applied to audio-recordings of all intervention sessions
for 18 participants to assess the quality of intervention delivery (see Appendix 1). This produced a
score of 0–6 for each (predefined) key component of the intervention process. Two members of the
intervention design team (from a pool of three team members) independently rated intervention
fidelity for each recording. To improve inter-rater reliability, prior to rating all the recordings,
the three coders (Anna Sansom, Colin J Greaves and Jennifer Wingham) coded the same four audio-
recordings and had debrief meetings to compare scores and agree principles to identify examples
of adequate, excellent or poor delivery for scoring going forwards. A detailed instruction set was
developed and is available in Appendix 1.39
3. Patient and caregiver outcome measures planned for the main RCT were collected before and after
the intervention (3 months after baseline) to assess their feasibility and acceptability. Serious
adverse events (SAEs) and adverse events that were potentially related to the intervention were
recorded for patients (not for caregivers).
Work package 1: analysis
The recorded interview data, facilitator feedback forms and other qualitative data were subjected to
simple thematic analysis.65 Data were transcribed verbatim and analysed to extract concepts, which
were then grouped into higher-level themes using a constant comparison approach. Data were organised
using NVivo version 11.0 (QSR International, Warrington, UK). Two researchers independently analysed a
sample of interviews and then conferred to develop an initial coding framework (see Report Supplementary
Material 3). Quantitative outcome measures were summarised using basic descriptive statistics, with mean
pre–post change scores for outcomes presented alongside CIs, as well as completion rates. Fidelity scores
were summarised across participants for each checklist item and also broken down by facilitator.
Work package 1: results
Feasibility study results
A summary of the findings is available in Appendix 1. The feasibility study recruited 23 patients and
12 caregivers, and seven intervention facilitators provided the intervention.
l Patients and caregivers were highly satisfied with the REACH-HF intervention and attendance at
sessions was high (all patients attended at least three face-to-face sessions and typically received
four telephone contacts).
l A number of potential modifications to the content of the manual and facilitator training were identified.
l Intervention fidelity scoring of all of the delivered consultations for 18 cases indicated adequate
delivery for most aspects of the intervention by all facilitators [mean scores ranged from 2.6 (item 11,
caregiver health and well-being) to 5.0 (item 1, person-centred delivery)] and are presented in in the
feasibility study report (see Report Supplementary Material 1, Table A).
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l Two items [addressing emotional consequences of being a caregiver (item 10) and caregiver health
and well-being (item 11)] had suboptimal delivery–fidelity scores.
l We also computed fidelity scores collated per facilitator, and these are presented in Table 5. These
represent delivery for only three patients per facilitator and so should be treated with caution.
Despite this, we observed reasonable consistency between facilitators on most items.
l Levels of outcome completion were generally excellent, and patients/caregivers perceived relatively
low measurement burden.
l A number of patient and caregiver outcomes following the REACH-HF intervention showed
evidence of improvement (with all of the caveats of a small population of selected participants and
uncontrolled comparisons).
l No patient or caregiver safety concerns were identified.
l Physical fitness [measured through the Incremental Shuttle Walk Test (ISWT)] was successfully
carried out by the majority of patients. As per previous studies, older patients with multiple
comorbidities showed some improvement, but this did not achieve statistical significance over time.
A number of ideas for improving the text of the HF Manual and the training were identified, such as
changing the name of the original ‘Caregiver Resource’ to ‘Family and Friends Resource’ to promote
engagement with the intervention, as many cohabitees did not identify themselves as a ‘caregiver’.
Following processing of the above data, the HF Manual (including the Family and Friends Resource
and Progress Tracker) and training course were substantially revised. This final version was then
evaluated in Work package 3: multicentre randomised controlled trial of the REACH-HF intervention in
patients with heart failure with reduced ejection fraction.
The REACH-HF intervention
The REACH-HF intervention is a comprehensive self-care support programme comprising the ‘HFManual’,
including a choice of two exercise programmes for patients, a Family and Friends Resource for caregivers,
a Progress Tracker booklet and a facilitator training course. For patients, the main self-care targets are
engaging in exercise training, monitoring for symptom deterioration, managing stress and anxiety,
managing medications and understanding HF (see Box 1 for an expanded list). Secondary targets include
managing low mood and smoking cessation (where relevant). For caregivers, the main intervention targets
are supporting self-care for the patient and looking after their own physical and mental health (see Box 2).
The intervention is facilitated by trained HCPs with specialist cardiac experience (e.g. a HF nurse or
physiotherapist) over 12 weeks via home and telephone contacts. The four main REACH-HF intervention
elements as described in Figure 4.
Heart Failure Manual
This is a self-help resource for use by patients and their caregivers. The HF Manual includes patient-
focused/plain English explanations of what HF is and how people can learn to live with the condition
to maximise their quality of life. The text aims to improve understanding of HF in terms of the identity
of the illness, as well as causes, consequences, control/treatment and timeline, in line with Leventhal’s
common sense model of illness.61 It includes sections on taking medications, fluid management (including
a traffic-light guide on recognising when to seek help), managing stress, managing changes in symptoms
and a choice of two structured exercise programmes (see REACH-HF exercise programme). The manual
also includes a compact disc (CD) with relaxation and breathing control exercises from the existing
Heart Manual30 and appendices offering self-care advice on other self-care behaviours, such as smoking
cessation, implanted devices, managing low mood and healthy eating.
Progress Tracker
This is an interactive booklet designed to facilitate learning from experience/over time and build
understanding about the impact self-care activities have on symptoms, emotional well-being and
quality of life through practice, self-monitoring of progress and (facilitated) problem-solving.
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Family and Friends Resource
This is a manual for use by caregivers. It aims to increase caregiver understanding and skills both to
help the person with HF and to look after their own physical and mental well-being. The resource is
divided into three main sections: (1) supporting the patient’s self-management of HF (‘Providing
support’), (2) caring for the caregiver (‘Being a caregiver’) and (3) practical advice, including mobilising
social support, accessing benefits and other formal and voluntary support (‘Getting help’).
Training course for facilitators
A training manual/syllabus for a 3-day training course for the REACH-HF intervention facilitators was
developed. Facilitators were defined as professionals with experience in CR or cardiac nursing. The
facilitation role is crucial to the success of the REACH-HF programme. As well as being the main
delivery process, it enables tailoring of the REACH-HF intervention resources to the individual needs
of patients and their caregivers. The course includes the theory and process of facilitation (building
rapport using patient-centred counselling techniques,66 empowerment and support of self-management,
building understanding of the condition61); using behaviour change techniques; techniques for
managing stress and anxiety; contents of the manual; supporting exercise and physical activity using
the intervention materials; and facilitation of the Family and Friends Resource and medical/nursing
issues. The training was linked by three case studies of patients with HF and opportunities to practise
facilitation techniques and to problem-solve potentially difficult situations.
A set of quotations or ‘patient voices’ selected by patients and caregivers in the PPI group from our
prior qualitative work was incorporated throughout the written resources in the form of speech
bubbles to help illustrate key points (Figure 5).
FIGURE 4 The REACH-HF intervention materials.
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REACH-HF exercise programme
Patients were offered a choice of two exercise programmes:
1. A chair-based exercise programme and digital versatile disc (DVD) that had been previously
developed by Professor Patrick Doherty, who is a REACH-HF co-investigator and was principal
investigator at the York trial site. The DVD includes seven levels of aerobic and resistance exercise
with progressively increasing intensity. The exercises are designed to avoid undue breathlessness,
build cardiovascular fitness, improve efficiency of movement and strengthen muscles to facilitate
functional activities associated with daily living. The chair-based exercise programme was integrated
into the REACH-HF intervention and facilitators received training on how to support patients
in using the chair-based exercise DVD. The intellectual property for the chair-based exercise
programme belongs to Professor Doherty who, as part of the REACH-HF and NIHR intellectual
property agreement, licensed the chair-based exercise programme DVD to REACH-HF for the main
trial and subsequent dissemination of REACH-HF.
2. A progressive walking-training programme based on increasing walk duration and intensity over
time to build cardiovascular fitness and lower limb muscle strength.
The starting level (for the DVD) or walking time/distance (for the walking programme) was agreed
(by patient and facilitator) based on results from an ISWT in conjunction with data and metabolic
equivalent (MET) values for each of the known fitness level (METs) for each of the seven chair-based
exercise programme levels. The proposed chair-based exercise level would start patients at around
65–70% of their ISWT MET, which is an expression of physical fitness. Values for ISWT (e.g. metres
walked or speed achieved) were used to guide the walking exercise programme, using mostly distance-
walked targets or speed of walking, where that suited the patient’s ability and goals.
Patients were also given pragmatic instructions on how to work at a moderate intensity. We wanted
to ensure that the initial exercise prescription for patients was in the range of 65–70% of their
maximal fitness derived from the ISWT. In addition, we sought to avoid reliance on the use of heart
rate monitors by helping patients to become familiar with and skilful at using a self-rating scale of
perceived effort (scored 1–10 from ‘nothing’ to ‘exhausted’) and advised patients to work at an effort
level of 4–6. We also encouraged them to monitor their breathing and to work at a level that resulted
in breathing heavier, feeling warmer and having a faster heartbeat. Instructions for warming up and
cooling down were given, and, where possible, the facilitator observed the patient doing some exercise
(using the DVD or walking) to ensure that the patient understood the level of intensity required.
We advised that patients should be a little out of breath but still able to carry on a conversation.
Patients were allowed to ‘mix and match’ between the two programmes if desired and were encouraged
to engage with one of the exercise options every other day, or at least three times per week.
manage it. This includes information about. . .
• what heart failure is and what causes it
• the signs and symptoms of heart failure
• how heart failure is treated
• what you can do about it
Let’s begin by looking at how the heart works
. . .
‘There is a life
beyond heart
failure’
FIGURE 5 Extract from the HF Manual showing a ‘patient voice’ callout.
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Intervention delivery
Based on existing CR practice and clinical guidelines, 12 weeks was considered an appropriate duration
for delivery, with a minimum of three face-to-face contacts with a facilitator (plus telephone contacts)
during this time. The face-to-face contacts were designed to be delivered in the patient’s home. The
number of contacts was not specified exactly to allow tailoring of the delivery to patient needs, and no
maximum number of sessions was stipulated. However, we stated that, in most cases, patients should
receive a minimum of two face-to-face sessions and about six contacts in total over the course of
12 weeks. In practice (see Work package 3: multicentre randomised controlled trial of the REACH-HF
intervention in patients with heart failure with reduced ejection fraction), a mean of four face-to-face
contacts and a mean of 6.5 contacts were delivered in total.
Theoretical basis
As different barriers and enablers (processes of change) were identified for different change targets,
the resulting intervention drew on multiple theoretical perspectives. Despite this, several common
theoretical processes for supporting the targeted changes in behaviour and psychological processes
were identified (Table 3). Key principles included building an understanding of the condition to provide
a rationale for change (Leventhal’s common sense model61); building intrinsic motivation and promoting
autonomy (self-determination theory57); promoting adaptation to living with HF and an active approach
to coping;51,63 and encouraging learning from experience through engagement in self-care activities
(control theory68). The elements were aimed at managing stress and anxiety used psychological intervention
processes based on cognitive–behavioural therapy70 and mindfulness therapy.71,72
TABLE 3 Theory and processes for supporting behaviour change in the REACH-HF intervention
Process (and theoretical basis) Key features and intervention facilitation techniques
Active patient involvement (motivational
interviewing66/self-determination theory57)
The facilitator should encourage the participant to be actively involved
in the consultation. The idea is to maximise the participant’s autonomy
as the main agent of change, developing intrinsic rather than extrinsic
motivation. However, the consultation should be guided. Empathy-building
skills (open questions, affirmation, reflective listening, summaries) and
individual tailoring should be used throughout the consultations. Reflective
listening may be used to direct the conversation or highlight key strengths or
barriers. A collaborative/shared decision-making style is appropriate, and the
facilitator may share their own expertise and ideas. The Ask–Tell–Discuss
technique should be used to exchange information (e.g. to address
misconceptions or offer helpful new information). Overall, the participant
should be increasingly empowered to take control of her/his self-care
behaviour. Interactions should be encouraging, respectful and
non-judgemental. The interaction should also be individually tailored
to the patient’s specific information needs, beliefs, skills, and priorities
Assessing the patient’s current situation
and needs (motivational interviewing,66
individual tailoring67)
The facilitator should use patient-centred communication techniques
(as above), which may include the Ask–Tell–Discuss and open-ended
questions to explore the patient’s current situation. This should include
all of the following:
l Identify and discuss the most important issue currently for the patient,
how well are they managing their fluids, how appropriately are they
using medications
l Is there any obvious immediate clinical need?
l How much stress or anxiety do they have, how much physical activity
are they doing and what other concerns or questions they may have?
continued
DOI: 10.3310/pgfar09010 Programme Grants for Applied Research 2021 Vol. 9 No. 1
Copyright © 2021 Dalal et al. This work was produced by Dalal et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social
Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution,
reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/. For attribution the
title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
23
TABLE 3 Theory and processes for supporting behaviour change in the REACH-HF intervention (continued )
Process (and theoretical basis) Key features and intervention facilitation techniques
Formulating an individualised treatment
plan (self-regulation/control theory,68
individual tailoring67)
The facilitator should use patient-centred communication techniques
(as above) to formulate an appropriate treatment plan based on the
patient’s current situation (as assessed above). The treatment plan will be
staged over time, aiming to work on a few topics initially and introducing
other elements as the programme continues. This should be set up as an
experiment to see how feasible the proposed actions are and whether or
not they help the patient’s situation. An element of guiding to ensure the
inclusion of clinical priorities (e.g. medication issues, exercise), as well
as patient priorities, may be appropriate. The facilitator and participant
should formulate a specific written action plan (using the template in
the Progress Tracker) for exercise-training based on a choice of the two
REACH-HF exercise-training programmes. The patient and caregiver should
be ‘signposted’ to relevant sections of the manual. The facilitator may also
employ some problem-solving techniques at this stage to pre-empt and
address potential problems
Building the patient’s understanding
of HF/their situation (Leventhal’s
common sense model,61 theories of
illness adaptation63)
The facilitator should elicit the patient’s and caregiver’s current
understanding of HF and seek to build their ‘illness model’ in terms of
understanding the identity, causes, consequences, cure/control options
and timeline associated with the condition. This process may take several
weeks and should be reinforced as the programme progresses
Facilitators will signpost the patient and caregiver to relevant sections
of the manual, including the ‘Understanding heart failure’ section and
use patient-centred communication techniques (as above) to elicit and
build understanding. The Ask–Tell–Discuss technique and reflective
listening will be used to exchange information to reinforce elements
of the patient’s understanding that predispose positive self-care
behaviours (e.g. understanding the link between physical fitness and
symptoms of HF). The facilitator should seek to reframe negative attitudes
and exchange information to address misconceptions or address important




relapse prevention,69 theories of
illness adaptation63)
The facilitator should discuss and encourage the use of the ‘Progress
Tracker’ workbook in the HF Manual to keep track of progress and as a
way of recording and addressing any problems completing the activities
and any benefits that might be associated with the planned activities. At
subsequent meetings, the facilitator and participant should review progress
with all planned changes to exercise/physical activity and other self-care
activities. The facilitator should reinforce and reflect on any successes.
The participant and facilitator should discuss any setbacks, encourage
identification and problem-solving of barriers to self-care, and the patient’s
plans should be revised accordingly. Reframing should be used to normalise
setbacks and see them as an opportunity to learn from experience (trial and
error) rather than as failures
Problem-solving should use OARS and information exchange
(Ask–Tell–Discuss) techniques to identify barriers and explore ways to
overcome them. Problem-solving may specifically focus on issues of
connectedness (social influences, involvement of others in supporting
activities) and long-term sustainability or on breaking the problem down
into more manageable chunks
Addressing emotional consequences
of HF (cognitive–behavioural therapy,70
mindfulness,71 theories of illness
adaptation63)
The facilitator should help the patient recognise and address any significant
stress, anxiety, anger or depression that is related to having HF. They
should seek to normalise such feelings and help the patient to access and
facilitate use of the cognitive–behavioural therapy techniques and stress
management techniques within the manual. If depression, anxiety or other
emotional problems are severe, a referral to appropriate clinical services
should be facilitated
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Work package 1: discussion
Summary
Intervention mapping gave a clear structure and process for developing the REACH-HF intervention
and the associated training programme for intervention facilitators. The process took into account
the needs of a range of stakeholders, including patients with HF, their caregivers, HCPs, potential
facilitators and health-care commissioners.
The construction of a causal model as part of the intervention mapping method (see Figure 2) was
useful as a framework to integrate the identified needs and define the intervention’s ‘targets for
change’. However, as reported by other studies that have used intervention mapping to develop
complex health-care interventions,73–75 the overall process was time-consuming and resource intensive.
Successes
To our knowledge, this is the only publication that provides a detailed description of the theoretical
and evidentiary basis, intervention techniques and strategies for an intervention to promote quality
of life in people with HF. The intervention was co-developed with patients, caregivers, clinicians and
academics to optimise it for use with patients with HF in real-world CR settings, and this was a
particular strength of the research. In particular, PPI ensured that the intervention was tailored to
individual needs based on a diverse range of patient backgrounds, knowledge levels and severity of HF.
TABLE 3 Theory and processes for supporting behaviour change in the REACH-HF intervention (continued )
Process (and theoretical basis) Key features and intervention facilitation techniques
Caregiver involvement (if applicable)
(literature on caregiver needs40)
The facilitator should engage the caregiver as much as possible as a
co-facilitator of the intervention. The facilitator should tailor the intervention
to work with the caregiver’s abilities and availability. Person-centred
counselling techniques (OARS) should be used for caregiver assessment
and to exchange information to build the caregiver’s understanding of the
situation and help them recognise and manage their own health needs,
including mental health, physical health and social needs. The facilitator
should facilitate a conversation between the patient and the caregiver to
agree their roles and responsibilities and how these might change if the
patient’s condition declines. Attention should be given to the caregiver’s
needs and concerns about being a caregiver/providing care, as well as those
of the patient
The facilitator should help the caregiver to recognise and address any
significant stress, anxiety, anger or depression related to supporting
someone with HF and facilitate the use of the cognitive–behavioural
therapy techniques and stress management techniques within the manual,
as needed. This includes facilitating a referral for a carer’s assessment if
the caregiver wishes, as well as referral to other relevant care services
as appropriate
The facilitator should help the caregiver to prioritise and look after their
own health and well-being
Bringing the programme to a close
(Leventhal’s common sense model,61
theories of illness adaptation,63
self-regulation/control theory,68
relapse prevention69)
Progress should be consolidated and reinforced. Plans for long-term
sustainability of activities and strategies learned for managing HF should
be discussed. The facilitator will review progress since the start of the
intervention and reinforce what has been learnt. Useful strategies that
were helpful should be identified. Plans to stay well/prevent relapse
should be discussed, as well as ‘cues for action’ and plans to revisit the
manual in the future. The facilitator will discuss plans to sustain any
new activities, identifying any potential problems and coping strategies
to overcome these. The possibility of good and bad days should be
discussed and normalised
OARS, open questions, affirmation, reflective listening, summaries.
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Limitations
The complexity of the intervention development process may affect replicability, and it is unlikely that a
different team of collaborators using the same methods would have produced exactly the same intervention.
Conclusions
We developed a comprehensive, evidence-informed, theoretically driven, self-care and rehabilitation
intervention that is grounded in the needs of patients and caregivers. The intervention was well received
by patients and caregivers and was feasible for and acceptable to the nurses and physiotherapists who
delivered it. The intervention was delivered to an acceptable standard, although some revisions to the
intervention and its associated training course were suggested. After these revisions, the REACH-HF
intervention was ready for evaluation in a full-scale trial.
Work package 2: single-centre, pilot randomised controlled trial
of the REACH-HF intervention in patients with heart failure with
preserved ejection fraction
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is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
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commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/
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Work package 2: overview
We undertook a pilot RCT and a process evaluation in a single centre in Dundee, in which there is
specialist interest in the care of patients with HFpEF, to assess the feasibility of a definitive trial of
the clinical effectiveness of the REACH-HF intervention in addition to usual care in patients with
HFpEF. The trial recruited 50 patients and their caregivers who were identified from outpatient
clinics and a Scottish register/database. Twenty-five participants were randomised to receive a slightly
modified form of the REACH-HF intervention to include information relevant for patients with
HFpEF (see Work package 1: intervention development and feasibility study) in addition to usual medical
management for HF (according to national and local guidelines) and 25 participants were randomly
allocated to receive usual care alone. Potentially favourable impacts of the REACH-HF intervention on
caregiver mental health and measures of burden were observed in this pilot study. The findings support
the feasibility of delivering the facilitated home-based REACH-HF intervention for patients with HFpEF
and their caregivers and the progression to a full multicentre RCT to test its clinical effectiveness
and cost-effectiveness. The protocol and quantitative results have been published (see Appendix 1) and
qualitative results were pre-print published in 2020 and the definitive peer-reviewed paper was
published in 202143 (see Appendix 1).
Work package 2: patient outcomes
Introduction
About 50% of patients with clinical features of HF are estimated to have HFpEF.76 Moreover, the
prevalence of HFpEF is increasing, and both HFpEF and HFrEF pose a substantial burden on patients
in terms of reduced exercise intolerance, poor HRQoL and mortality.77 For the NHS, this is evident
through increased hospital admissions and higher health-care costs.
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Recent systematic reviews and meta-analyses have shown promising evidence for the benefit of
exercise-based CR in HFpEF. The CR programmes undertaken in these trials were predominantly
group-based, supervised and delivered in centre-based settings. There is increasing recognition of the
possibility of alternative delivery models of CR, such as home-based programmes, to overcome the
suboptimal rates of CR uptake seen with HF.
A single-centre pilot RCT (ISRCTN78539530) was conducted in Dundee to assess the feasibility
and acceptability of the novel REACH-HF intervention for patients with HFpEF and their caregivers.
Detailed reports of the rationale and protocol of this pilot RCT and its findings have been published
(see Appendix 1) and a report of the process evaluation has been pre-print published43 (see Appendix 1).
Research aims
The main aim of this pilot study was to assess the feasibility of undertaking a definitive RCT to assess
the clinical effectiveness and cost-effectiveness of the REACH-HF intervention in patients with HFpEF
and their caregivers. Our objectives were to:
l assess the acceptability of the study design and procedures to participants (patients and caregivers)
l assess the feasibility and experience of the delivery of intervention for participants and HCP facilitators
l identify barriers to participation in the intervention and study procedures
l inform a definitive study sample size
l assess methods for the collection of data, including resource use and costs
l assess the fidelity of delivery of the REACH-HF intervention by cardiac nurses.
Methods
A total of 225 patients were approached, of whom 50 were randomised (1 : 1) to the REACH-HF
intervention plus usual care (intervention group) or to usual care alone (control group) (see Report
Supplementary Material 1, Figure B). Participants were randomly allocated in a 1 : 1 ratio to either
intervention or control group arms without stratification or minimisation. Randomisation numbers
were computer-generated and assigned in strict sequence. At the point of randomisation, participants
were assigned the next randomisation number in the sequence. To maintain concealment and minimise
selection bias, randomisation was performed after the baseline visit by a member of Peninsula Clinical
Trials Unit (CTU), independent from investigator teams, using a secure, web-based randomisation system.
As described earlier, the REACH-HF intervention is a home-based comprehensive self-care CR
programme that comprises patient and caregiver manuals with supplementary tools and is delivered
by trained health-care facilitators over a 12-week period. The REACH-HF intervention was originally
designed for patients with HFrEF in terms of coverage of medication and explanations of the condition,
as there was limited evidence to guide the development of the REACH-HF intervention for patients with
HFpEF. Following a review of clinical guidance and consultation with the expert cardiology, primary
care and physiology/CR specialist members of our project management group, the intervention was
adapted for this feasibility study to allow evaluation in patients with HFpEF. Modifications were minor
and were as follows: (1) we excluded information on beta-blockers, angiotensin-converting enzyme
(ACE) inhibitors and angiotensin receptor antagonists, as these drugs have not been shown to be
of prognostic benefit in patients with HFpEF, and (2) we changed text relating to the description of
the condition to include a more comprehensive explanation of what HFpEF is, what causes it and
what treatments are commonly offered (and why). The self-care advice in all other sections of the
REACH-HF intervention was considered to be relevant to all patients with HF and corresponds to
national HF guidelines.5,21 Patient outcomes were collected by blinded assessors at baseline and at 3 and
6 months after randomisation, and included HRQoL (primary) and psychological well-being, exercise
capacity, physical activity and HF-related hospitalisation (secondary). Outcomes were also collected
for caregivers. The parallel process evaluation includes interviews with patients and caregivers
(see Work package 2: process evaluation).
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Analysis
Our sample size was adequate to enable an estimate of attrition, estimates of the standard deviation
(SD) of the primary and secondary outcomes to inform power for a future definitive trial and sufficient
numbers of participants for qualitative interviews. We report the mean and SD (or relevant summary
statistics) for both groups for all patient and caregiver outcomes at each follow-up point and the mean
(and 95% CIs) for between-group differences in outcomes at 6-month follow-up using linear regression
models adjusting for baseline outcome.
Key findings
The study recruited 50 symptomatic patients with HFpEF (LVEF ≥ 45%) (mean age 73.9 years,
54% female) and 21 caregivers. Study retention and intervention uptake were excellent (90% and
92%, respectively) (see Report Supplementary Material 1, Figure B).
At 6 months, data from 45 patients showed a mean between-group difference in favour of the
intervention group for the primary outcome, MLHFQ score, although the CI was wide and included
0 (between-group mean difference −11.5, 95% CI −22.8 to 0.3). A total of 11 patients (four in the
intervention group and seven in the control group) were admitted to hospital over the 6 months of
follow-up, with four of these admissions (all in the control group) being related to HF. In the context of
this study being a single-centre pilot and not fully powered to demonstrate between-group differences
in patients or caregivers, these findings should be considered indicative.
These findings support the feasibility of and rationale for delivering the facilitated, home-based
REACH-HF intervention for patients with HFpEF and their caregivers and progression to a full
multicentre RCT to test its clinical effectiveness and cost-effectiveness (see Report Supplementary
Material 4).
Successes
We recruited to target (Figure 6); the intervention was well received by patients, caregivers and
health-care facilitators, and intervention adherence was good. At follow-up, the primary outcome
(MLHFQ) showed a significant improvement, and a number of other patient outcomes showed a
direction of effect in favour of the intervention group over control, although this pilot trial lacked
power to detect a statistically significant between-group difference.
Limitations
Given that this was a pilot RCT, there were several limitations:
l Originally, this study was going to be run in Birmingham, but the local NHS trust was facing
challenges in agreeing to recruit research staff during a staff recruitment freeze, so the research
team enrolled a centre in Dundee that holds the Scottish database for patients with HF, including
patients with HFpEF. An excellent rate of initial recruitment faltered as the number of patients
from the database who were potential participants diminished, and we had to seek patients from
outpatient medical clinics, which enabled us to recruit to target after extending the recruitment
period by 3 months (see Figure 6).
l As the trial was conducted in a single centre in a population lacking ethnic diversity, the
generalisability of our findings is limited.
l Patient and clinician blinding was not possible in this study because of the nature of the intervention,
although we did show that it was possible to blind outcome assessors to group allocation.
l An issue raised in patient interviews was the method of exercise testing in the trial, as several
patients found that the ISWT exacerbated symptoms such as fatigue and shortness of breath – 27%
were unable to undertake the ISWT at final follow-up.
l The open-label design of the study may have resulted in improvements in patient-reported
outcomes in intervention participants because of placebo effects.
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Recommendations for future research
This pilot study produced compelling evidence for a full multicentre RCT to assess the clinical effectiveness
and cost-effectiveness of the REACH-HF intervention in patients with HFpEF and their caregivers.
Trial registration
This trial is registered as ISRCTN78539530.
Work package 2: process evaluation
Introduction
Process evaluation is becoming an important part of research when assessing complex interventions
such as the REACH-HF intervention (see Work package 1: intervention development and feasibility study).
Currently, evidence is lacking about the experience and needs of patients living with HFpEF and their
caregivers, the factors that influence their self-care decision-making and the provision of support by
caregivers.78 The complexities of living with HF in the real world and the challenges of self-care have
not been adequately addressed in the literature.79
Research aims
The aims of this process evaluation were to:
l assess the intervention fidelity delivered by the facilitators to the patients with HFpEF
l explore the experiences of patients and caregivers who participated in the REACH-HF, single-centre
pilot RCT (see Work package 1: intervention development and feasibility study).
Methods
A mixed-methods process evaluation was completed alongside the single-centre pilot REACH-HFpEF
RCT (see Work package 1: intervention development and feasibility study). The process evaluation
consisted of a quantitative assessment of the fidelity of intervention delivery and a qualitative





































































































FIGURE 6 Work package 2: target vs. actual number of participants randomised for REACH-HFpEF pilot trial.
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Data collection
Data were collected in parallel with the REACH-HFpEF pilot RCT (see Work package 1: intervention
development and feasibility study).
Quantitative data to assess intervention fidelity
Facilitators’ interactions with all participants were audio-recorded and intervention fidelity was assessed
through a 13-item checklist developed by the research team (see Appendix 1) in a purposively selected
subset of six participants (three from each facilitator). Each item of the checklist related to the delivery
of a key component or delivery process of the intervention, as defined by the intervention design
team (see Appendix 1, Work package 1, and Greaves et al.39 for full details of the checklist). Adequate
delivery of the REACH-HF intervention was defined as a score of ≥ 3. A detailed instruction set was
developed and is available in the supplementary file of the published intervention development paper
(see Appendix 1). Intervention exposure was measured in terms of both intervention engagement
(contact hours and number of each type of session attended) and quality of intervention delivery
(intervention fidelity) in this subsample of six patients.
Qualitative data
After the 12 weeks required to complete the REACH-HF intervention, a purposive sample of 15 patients
and seven caregivers were approached and interviewed in participants’ homes (n = 21) or by telephone
(n = 1 caregiver). The interviews explored the experiences of participants living with HFpEF and their
caregivers, the perceived benefits of the various elements of the intervention, maintenance of self-care
behaviours and coping skills.
Analysis
Quantitative data
Descriptive statistics were used to summarise the fidelity of the intervention.
Qualitative data
Individual interviews were completed and transcribed verbatim and a thematic analysis using a
constant comparative method was completed.65 Data familiarisation was achieved by listening to
audio-recordings and repeated reading of the transcripts. Initial codes were produced in a systematic
fashion across all data sets – those with common features were grouped together into emerging
themes before finally being assigned to overarching themes. The participant quotations included under
Key findings illustrate some of the themes.
Key findings
Fidelity of intervention delivery
The fidelity assessment indicated adequate delivery (scores ≥ 3) for most of the key intervention
components by the facilitators. Lower scores (< 3) indicating inadequate delivery were mainly related
to caregiver issues, particularly the need to address caregiver health and well-being, indicating that
there is room for improvement with respect to the involvement of and support provided to caregivers
by the facilitators. The mean score for session closure was also < 3 (see Smith et al.43), indicating
potential for improvement in reinforcing and summarising specifically agreed plans.
Audio-recordings from the six patients included in the fidelity analysis provided a total of 41 interactions,
34 of which were face to face (with a mean duration of 63 minutes). Short telephone contacts were
reported on only seven occasions, lasting an average of 6 minutes.
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Semistructured qualitative interviews
Three overarching themes became apparent (see Report Supplementary Material 1, Table A):
l understanding their condition
l emotional consequences of HF
l response to the intervention and facilitator.
The REACH-HF intervention also enabled positive changes in health-related behaviour, particularly in
relation to exercise and diet, not only among patients but also for some caregivers.
A report on the process evaluation of the pilot study has been pre-print published by Smith et al.43
This is an Open Access article distributed in accordance with the terms of the Creative Commons
Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this
work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/
licenses/by/4.0/. The text includes minor additions and formatting changes to the original text.
Successes
Overall, this process evaluation suggested that the REACH-HF intervention was generally well
delivered and was well received by patients with HFpEF. Qualitative data also captured some excellent
examples of good practice in education, engagement and support of these patients and their caregivers
by the facilitators. The findings highlight a genuine need for support in a population currently excluded
from many HF and CR services.
Limitations
The small number of patients included in the fidelity analysis (n = 6), the characteristics of the
participants (who were predominantly of white ethnic origin) and the single-centre setting limit the
potential generalisability of the findings. Translating complex interpersonal interactions into numerical
scores within the fidelity analysis does not fully illustrate some of the excellent examples of good
practice. Facilitators often demonstrated high levels of skill and competence in providing tailored
educational and psychological support, enabling patients to reframe negative thoughts, engage in
appropriate exercise and participate in self-care. The study also highlighted how involving caregivers
was challenging at times, so more could be done to enhance facilitator training on supporting caregivers.
Recommendations for future research
Given the small numbers in this study, we recommend repeating the process evaluation as part of a
large multicentre RCT of the REACH-HF intervention in patients with HFpEF.
Trial registration
This trial is registered as ISRCTN78539530.
Work package 3: multicentre randomised controlled trial of the
REACH-HF intervention in patients with heart failure with reduced
ejection fraction
Some parts of these sections have been reproduced with permission from Dalal et al.,44 Wingham et al.80
and Frost et al.45 These are Open Access articles distributed in accordance with the Creative Commons
Attribution Non Commercial (CC BY-NC 4.0) license, which permit others to distribute, remix, adapt,
build upon this work non-commercially, and license their derivative works on different terms, provided
the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/. The text includes minor additions and formatting changes to the original text.
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Some parts have also been reproduced with permission from Taylor et al.38 This is an Open Access
article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0)
license, which permits others to distribute, remix, adapt and build upon this work, for commercial use,
provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text
includes minor additions and formatting changes to the original text.
Work package 3: overview
To assess the clinical effectiveness and cost-effectiveness of the REACH-HF intervention in addition
to usual care in people with HFrEF and their caregivers, our RCT recruited 216 people with HFrEF
from four centres in the UK: Birmingham, Cornwall, Gwent and York. Participants were randomly
allocated to the REACH-HF intervention described above plus usual care or to usual care alone.
Patients randomised to the REACH-HF group usually had a home-based consultation with a CR or
HF nurse or physiotherapist (trained in facilitating the REACH-HF intervention), who assessed the
participant’s individual needs and provided instruction in use of the appropriate sections of the HF
Manual. During the 12 weeks after randomisation, the nurse facilitator was on hand to answer specific
questions from individuals with HF or their caregivers during home visits or by e-mail or telephone.
The primary outcome was disease-specific HRQoL measured using the MLHFQ at 12 months. Overall,
the novel REACH-HF home-based facilitated intervention for HFrEF was clinically superior, in terms
of disease-specific HRQoL at 12 months, to usual care alone. Secondary outcomes included death or
admissions with decompensated HF or acute coronary syndrome, N-terminal pro-B-type natriuretic
peptide (NT-proBNP) levels, ISWT, psychological well-being, physical activity level, generic HRQoL,
caregiver outcome, health-care utilisation and adverse events. Papers on the trial protocol, main
trial results and process evaluation and on cost-effectiveness have been published (see Appendix 1).
Full details of the trial-based cost-effectiveness analysis are presented in Appendix 3. A comparison
of psychological well-being, quality of life, self-care activities and burden between caregivers in
the intervention and control groups of the REACH-HF multicentre RCT was also undertaken
(see Appendix 1, Work package 4, and Taylor et al.46). In addition, a trial-based economic analysis
compared the costs associated with health and social care resource use and HRQoL of the REACH-HF
intervention and control groups.46
Work package 3: patient outcomes
Introduction
Chronic HF is a burgeoning global health challenge that affects 1–2% of adults in the Western world.3,6
Globally, the prevalence of HF is increasing,3 with the annual economic burden predicted to grow to
more than US$108B (£82B, conversion as at 27 June 2018: 1 USD = 0.760133 GBP), as the population
ages. Hospital admissions are a key driver of the rising costs,3 with the emphasis of treatment over the
past two decades on pharmacological therapies and devices.
A Cochrane systematic review and meta-analysis of exercise-based CR in patients with HF showed
improvements in HRQoL and a reduction in rehospitalisations. In 2010, national guidance in the UK
recommended centre-based CR (supervised group exercise) for patients with HFrEF,27 with similar
recommendations in Europe and the USA.11,81 However, < 20% of people with HF in Europe and
< 10% in the USA participate in CR, prompting a call to explore newer strategies to improve
participation in CR and explore the clinical effectiveness of alternatives to centre-based CR.
Home-based CR programmes can widen access and have been shown to be as clinically effective
as centre-based CR after MI and coronary revascularisation and with similar costs.82 The high cost
of treating people with HF is well documented,3 but little evidence is available on the cost and
cost-effectiveness of home-based CR in HF.83
We therefore developed a home-based CR programme – ‘the REACH-HF intervention’ – for people
with HF and their caregivers.
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Research aims
The primary aim of this multicentre RCT was to test the hypothesis that addition of the REACH-HF
intervention to usual care would improve disease-specific HRQoL for patients with HFrEF at 12 months’
follow-up compared with usual care alone.
Methods
We targeted men and women aged ≥ 18 years with a confirmed diagnosis of HFrEF on echocardiography
or angiography (LVEF < 45%). Patients were recruited from primary and secondary care settings in four
centres in the UK (Birmingham, Cornwall, Gwent and York), excluding those who had undertaken CR
within 12 months prior to the study and those with a contraindication to exercise testing or exercise
training. Participants were randomly allocated in a 1 : 1 ratio, stratified by investigator site and baseline
plasma NT-proBNP levels (≤ 2000 pg/ml vs. > 2000 pg/ml), using minimisation to facilitate balance
between the groups. Randomisation numbers were computer-generated and assigned in strict sequence
at the point of randomisation. To maintain concealment, the Peninsula CTU used a password-protected,
web-based randomisation system to allocate participants after consent was obtained and baseline
assessment data were entered.
Between January 2015 and February 2016, we approached 1161 patients, 216 of whom were
randomised to the intervention (REACH-HF intervention plus usual care) or the control (usual care alone)
(see Report Supplementary Material 1, Figures D and E). Participants were randomly allocated (see
Report Supplementary Material 1, Figure D) and stratified by investigator site and baseline plasma
NT-proBNP levels.
The REACH-HF intervention was uniquely co-developed with key stakeholders: patients, caregivers and
clinicians (see Work package 1: intervention development and feasibility study). Briefly, the components of
this complex intervention (see Work package 1: intervention development and feasibility study for more
detail) included the HF Manual for patients, a Progress Tracker for the patient, a Family and Friends
Resource for caregivers and facilitation by cardiac nurses or physiotherapists. Development of the
intervention took just over 12 months before it was fully evaluated in our multicentre RCT.
In the trial, participants in both the intervention group and the control group continued with usual
medical management and care of HF according to local and national guidelines. In most places in the
UK, including the four centres participating in our RCT, usual care involved follow-up by the GP with
input from a HF specialist nurse and, in some cases, a cardiologist.
Data collection
The primary outcome was disease-specific HRQoL at 12 months measured using the MLHFQ. Secondary
outcomes were death, hospitalisation, generic quality of life [EuroQol-5 Dimensions, five-level version
(EQ-5D-5L), scale], psychological well-being [Hospital Anxiety and Depression Scale (HADS)], exercise
capacity (ISWT) and physical activity assessed using GeneActiv accelerometer. Additional secondary
measures included the HeartQoL questionnaire, Self-Care of Heart Failure Index (SCHFI) and health-care
utilisation in terms of primary and secondary care contacts, social care contacts and relevant drug use.39
Outcome data were collected from participants during three clinic visits – one each at baseline and at
4 and 12 months – and by postal questionnaire at 6 months. At the baseline clinic visit, after obtaining
written consent, we collected sociodemographic data and information on past medical history from
the participants’ hospital and primary care records, including key comorbidities, NYHA classification,
concomitant cardiac drugs and presence of an implantable cardioverter defibrillator.
Analysis
The sample size was based on an effect size that represented the minimal clinically important difference
in our primary outcome measure, that is 5 points on the MLHFQ (higher scores indicate a poorer
outcome).84 With a type I error of 0.05 and a power of 90%, 85 participants per group were required to
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detect a 5-point difference in the MLHFQ score. With an attrition rate of 20% (in accordance with the
level of attrition seen in previous trials),82 108 participants were required per group.
The primary analyses for all participant outcomes were based on a between-group (intervention vs. control)
intention-to-treat approach, using observed data collected at 12 months. Continuous outcomes were
analysed using linear regression methods. Adjustment was made for baseline scores and randomisation
variables [site, NT-proBNP concentration (≤ 2000/> 2000 pg/ml) and past MI and diagnosis of AF/atrial
flutter (unbalanced at baseline and considered to be predictive of outcome)]. Mortality was reported
descriptively and also analysed using logistic regression (with adjustments as for the linear regression
models, with the exception of adjustment for baseline score); hospital admissions were reported
descriptively, analysed using a negative binomial model and dichotomised according to whether or not
the participant experienced at least one admission to facilitate analysis using logistic regression.
Key findings
The primary analysis included 92 (86%) patients in the REACH-HF group and 93 (85%) in the
control group. Table 4 summarises primary and secondary patient-reported outcomes and secondary
objective outcomes at baseline and follow-up. Compared with control, the REACH-HF intervention
was associated with a reduction in total MLHFQ score (i.e. improved HF-related HRQoL) at 12 months:
between-group difference –5.7 (95% CI –10.6 to –0.7; p = 0.025). At 12 months, there had been eight
deaths (four in each group, 4% of the total). The number of participants with at least one hospital
admission was 19 in the REACH-HF group, compared with 24 participants in the control group (odds
ratio 0.72, 95% CI 0.35 to 1.51; p = 0.386). Overall, there were 33 hospital admissions in the REACH-HF
group (four related to HF) and 35 (10 related to HF) in the control group. The maintenance score on
the SCHFI, a measure of self-care, was in favour of the REACH-HF intervention group at 12 months
(p < 0.001). Within-group improvements from baseline were seen in the REACH-HF group for HADS
anxiety and depression, ISWT and SCHFI (management and confidence) but did not reach statistical
significance compared with the control group at 12 months. No differences were seen in the other
secondary outcomes [i.e. EuroQol-5 Dimensions (EQ-5D), HeartQoL and physical activity]. The mean
cost of the REACH-HF intervention was £418.39 per participant.
Successes
Behaviour theory underpinned the design of all components of the intervention, which was co-developed
with patients, caregivers and clinicians and subjected to the rigours of a multicentre RCT.We recruited to
target on time and achieved 86% retention at 12 months (see Report Supplementary Material 1, Figure D).
The magnitude of the mean between-group difference in our primary outcome measure – total MLHFQ
score – was not only statistically significant but also clinically meaningful (i.e. a reduction of > 5 points)
and consistent with effects found in other exercise-based CR interventions for people with HF. The cost
of the REACH-HF intervention (£418.39 per participant) is below the NHS tariff for CR in England of
£477 per patient.
Limitations
Lack of blinding was a key limitation, as the complex nature of the intervention and the control meant
that we could not mask participants to treatments, introducing the possibility of patient expectation
bias. Another limitation was the 15% missing data for the primary outcome measure at the 12-month
follow-up. Assessment of adherence was also a limitation given the self-directed nature of the home-
based intervention, and we were not able to capture consistent patient-level data on adherence to the
exercise training component of the intervention.
There is an emerging hypothesis that it is the act of exercise training and not the gain in fitness that
improves outcomes for patients. For many patients with HF, there are no or very limited physiological
mechanisms for improved fitness, as cardiac output (heart rate × stroke volume) and difference in
the extent by which oxygen is extracted at the active muscle interface [a-vO2 diff (arteriovenous
oxygen difference)] are severely hindered by HF. Using the EQ-5D, our trial-based analysis showed no
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difference (95% CI) p-value
4 months 6 months 12 months
REACH-HF Control REACH-HF Control REACH-HF Control REACH-HF Control
Primary and secondary patient-reported outcomes
MLHFQ (primary)
Overall 32.8 (23.8) 107 28.3 (22) 109 22.7 (18.4) 96 27.8 (23.2) 100 28.8 (20.5) 90 29.5 (21.8) 94 24.1 (20.9) 92 27.5 (23.2) 93 –5.7 (–10.6 to –0.7) 0.025
Physical 16.5 (11.5) 107 14.7 (11.2) 109 11.7 (9.0) 96 14.5 (11.3) 100 14.7 (10.7) 90 14.9 (11.2) 94 12.2 (10.8) 92 14.5 (11.8) 93 –3.2 (–5.7 to –0.6) 0.016
Emotional 7.7 (7.3) 107 6.8 (6.6) 109 4.8 (5.8) 96 6.4 (6.9) 100 6.2 (6.2) 90 6.8 (6.8) 94 5.1 (5.8) 92 5.5 (6.4) 93 –0.8 (–2.2 to 0.6) 0.273
HADS
Anxiety 5.1 (4.4) 107 5.7 (4.3) 109 4.4 (3.9) 95 5.2 (4.2) 101 4.7 (3.7) 89 5.4 (4.3) 94 4.2 (3.8) 88 4.7 (4.5) 92 0.1 (–0.8 to 1.0) 0.829
Depression 4.4 (3.5) 107 4.6 (3.3) 109 3.6 (2.7) 95 4.5 (3.5) 101 4.6 (3.2) 89 4.7 (3.6) 94 3.6 (3.1) 88 3.9 (3.4) 92 –0.2 (–1.1 to 0.6) 0.563
HeartQoL
Global 1.8 (0.7) 107 1.8 (0.7) 109 2.0 (0.7) 95 1.9 (0.8) 101 1.8 (0.8) 89 1.8 (0.8) 91 1.9 (0.8) 88 1.9 (0.9) 92 0.0 (–0.2 to 0.2) 0.823
Physical 1.7 (0.8) 107 1.7 (0.8) 109 1.9 (0.8) 95 1.7 (0.9) 101 1.6 (0.8) 90 1.7 (0.9) 92 1.8 (0.9) 88 1.7 (0.9) 92 0.0 (–0.2 to 0.2) 0.869
Emotional 2.1 (0.9) 107 2.2 (0.8) 109 2.3 (0.8) 95 2.2 (0.8) 101 2.2 (0.8) 89 2.1 (0.8) 93 2.3 (0.8) 88 2.3 (0.8) 92 0.0 (–0.2 to 0.3) 0.683
EQ-5D-3L 0.739 (0.234) 106 0.723 (0.236) 108 0.758 (0.223) 95 0.753 (0.219) 101 0.708 (0.265) 88 0.733 (0.217) 92 0.752 (0.240) 88 0.739 (0.263) 92 –0.024 (–0.091 to 0.044) 0.487
EQ-5D VAS
(0 to 100)
69 (20) 97 71 (20) 97 73 (17) 90 74 (17) 93 72 (18) 80 70 (19) 85 74 (18) 85 73 (22) 84 1 (–5 to 6) 0.859
SCHFI
Maintenance 55.8 (16.5) 107 54.5 (14.5) 109 68.3 (13.6) 96 55.7 (17.0) 101 65.4 (14.4) 89 54.7 (16.0) 94 63.8 (17.0) 87 55.2 (16.8) 92 8.0 (3.6 to 12.4) < 0.001
Management 43.1 (25.9) 47 40.4 (21) 59 46.8 (24.2) 33 42.0 (21.0) 48 52.1 (18.8) 42 41.9 (21.6) 37 53.8 (23.4) 39 43.4 (20.1) 40 9.4 (–4.0 to 22.8) 0.165


















































































































































































































































































































































































difference (95% CI) p-value
4 months 6 months 12 months
REACH-HF Control REACH-HF Control REACH-HF Control REACH-HF Control
Secondary objective outcomes
ISWT (m) 262.3 (153.4) 99 239.7 (152.4) 103 328.5 (181.3) 66 294.3 (215.5) 75 – – 328.5 (181.3) 66 294.3 (215.5) 75 0.1 (–33.3 to 33.5) 0.995
Number of days/




5.8 (2.3) 99 5.9 (1.9) 103 5.6 (2.4) 78 5.5 (2.6) 84 – – 5.6 (2.4) 78 5.5 (2.6) 84 0.2 (–0.4 to 0.7) 0.601
Average time/day (minutes)
≤ 20 milli-ga 1,104 (102) 99 1106 (114) 103 1107 (110) 88 1092 (116) 93 – – 1092 (124) 78 1103 (118) 84 –7 (–29 to 15) 0.534
21–40 milli-ga 141 (35) 99 136 (35) 103 140 (35) 88 138 (30) 93 – – 142 (39) 78 138 (34) 84 –1 (–9 to 8) 0.880
41–60 milli-ga 80 (25) 99 80 (27) 103 80 (27) 88 82 (26) 93 – – 81 (30) 78 81 (28) 84 0 (–6 to 6) 0.901
61–80 milli-ga 45 (21) 99 46 (21) 103 45 (22) 88 48 (22) 93 – – 48 (23) 78 46 (22) 84 2 (–2 to 5) 0.372
81–100 milli-ga 26 (16) 99 27 (16) 103 26 (16) 88 28 (17) 93 – – – – – –
> 100 milli-ga 42 (34) 99 46 (40) 103 43 (37) 88 51 (46) 93 – – – – – –
EQ-5D-3L, EuroQol-5 Dimensions, three-level version; milli-g: milli-gravity unit; VAS, visual analogue scale.
a 1000 milli-g: = 1 g = 9.81 m/s2, < 40 milli-g is approximately equivalent to sedentary activities such as sitting, lying and ≥ 100 milli-g is approximately equivalent to activities undertaken at a moderate to
vigorous intensity.



































difference in QALY gain between groups at 12 months and we were therefore unable to show that
REACH-HF was cost-effective in the short term according to current willingness to pay (WTP) cost
per QALY thresholds in the UK.31 However, it is important to note that a growing body of evidence is
showing that the EQ-5D lacks sensitivity in the patient population of our trial (i.e. patients with mild to
moderate HF). Extrapolation of our trial findings for long-term outcomes estimated via model-based
cost-effectiveness analysis results showed a high likelihood that the REACH-HF intervention is cost-
effective (see Work package 4: model-based cost-effectiveness analysis). The key characteristics and findings
of this trial are summarised in Report Supplementary Material 1, Figure F.
Recommendations for future research
With the growing availability of evidence-based CR interventions delivered at home, systematic
collection of real-world data utilising vehicles, such as the NACR database in the UK, are needed
to allow the tracking of potential future changes in uptake of and adherence with CR. In addition,
there is a need for further well-conducted RCTs of home-based CR interventions to collect and report
long-term outcomes, including hospital admissions and health-care costs.
Trial registration
This trial is registered as ISRCTN86234930.
Work package 3: caregiver outcomes
Introduction
Caregivers have an important role in supporting chronic disease management, although this often
comes at considerable personal cost and many caregivers are uncertain about how to best provide
this support. Most caregivers have health and well-being problems of their own – either pre-existing
or arising from the burden of their caregiving activities.85 However, there is paucity of evidence on
interventions that support caregivers in their role.78 The needs of caregivers in the management of
HF and their responses have been depicted in two recent qualitative studies.40,86 Caregivers may also
assist patients in appraising and responding to symptoms of HF.87
Research aims
The aims of this evaluation were to:
l compare psychological well-being, quality of life, self-care activities and burden between caregivers
in the intervention and control groups of the REACH-HF multicentre RCT
l explore the views of caregivers on their experience of using the REACH-HF caregiver manual
(Family and Friends Resource) and its influence on their confidence in caring for patients with HF
and themselves.
Methods
Patients aged ≥ 18 years with a confirmed diagnosis of HFrEF (LVEF < 45%) were recruited from four
centres in the UK (Birmingham, Cornwall, Gwent and York) and invited to participate. At study entry,
patients were asked whether or not they had a caregiver, that is a partner, other relative or friend. If
the patient did have a caregiver who was aged ≥ 18 years, the caregiver was invited to participate in
the trial alongside the patient. Participating caregivers provided unpaid support to patients who could
otherwise not manage without such support. Caregivers were allocated to the REACH-HF group or
control group in accordance with the random allocation of their accompanying patient.
Data collection
Face-to-face or telephone interviews were conducted at 4 and 12 months after recruitment to the
trial. The intervention had been completed prior to the first interview. Where possible, all interviews
were conducted with caregivers alone. A topic guide (see Report Supplementary Material 1, Table C)
was reviewed throughout the study so that the questions were informed by relevant emerging topics.
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The data set included facilitator fidelity scores and qualitative notes on the scores, facilitator contact
sheets, baseline questionnaire data, field notes and interview transcripts.
Caregiver outcomes included HADS, HRQoL assessed by EQ-5D-5L questionnaire, Family Caregiver
Quality of Life (FamQol), Caregiver Burden Questionnaire for Heart Failure (CBQ-HF) and Caregiver’s
Contribution to Self-Care of HF Index (CC-SCHFI). Outcome data were collected during three
clinic visits – one each at baseline and at 4 and 12 months – and by postal questionnaire at 6 months.
Sociodemographic data were also collected at the baseline clinic visit. Data were collected by research
nurses who were blinded to the patients’ and caregivers’ group allocations.
Analysis
Caregiver outcomes were analysed and reported using the same methods as for continuous patient
outcomes. Constant comparative techniques were used to compare the individual 4- and 12-month
interviews and all caregiver participants’ interviews.
Key findings
The REACH-HF group included 107 patients and the control group included 109 patients. A total of
97 patients declared having a caregiver, with 53 caregivers allocated to the REACH-HF group and
44 to the control group. At 12 months, data were available for 45 (85%) caregivers in the REACH-HF
group and 37 (84%) in the control group.
Improvements from baseline at 4, 6 and 12 months were seen for a number of outcomes in the
REACH-HF group, including HADS anxiety; CBQ-HF physical, social life and lifestyle; and all SCHFI
dimension scores. However, only SCHFI confidence at 12 months was statistically significant (p < 0.05)
compared with the control. Based on interviews of 17 caregivers, the REACH-HF intervention was
acceptable and was associated with an increase in confidence in their caregiving role.
Successes
Mean between-group differences favoured the REACH-HF intervention for caregiver outcomes of
anxiety, perceived burden and self-care management, although the results were not statistically
significant. The SCHFI confidence score outcome achieved statistical significance at the 12-month
follow-up. Most caregivers who were interviewed following the intervention made changes to how
they supported the person with HF for whom they were caring and gained confidence.
Limitations
As caregivers were not themselves randomised to the intervention and control groups and the study
sample size was powered on the between-group difference in patient outcomes rather than caregiver
outcomes, we did not generally find significant differences in caregiver HRQoL compared with the
control. Non-random allocation of caregivers increased the risk of selection bias between the REACH-HF
and the control groups, which means that our results are subject to confounding. We also found that
facilitators need additional training on how best to involve caregivers in interventions such as REACH-HF.
There is potential to revise the intervention to improve caregiver and facilitator engagement.
Recommendations for future research
The quantitative and qualitative findings for caregivers (see Work package 3: process evaluation)
suggest the need to better engage caregivers in CR and self-care interventions for patients with HF.
Our results suggest that caregivers require skilled and personalised facilitation by HCPs. Facilitators
may need a caregiver assessment tool to help plan care.40 Further high-quality evidence is required
to confirm the benefits of actively involving caregivers in the development and delivery of CR and
self-care interventions for HF and other chronic diseases.
Trial registration
This trial is registered as ISRCTN86234930.
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Work package 3: process evaluation
Introduction
As mentioned earlier (see Work package 2: process evaluation), process evaluation is becoming an
important part of research when assessing complex interventions, such as the REACH-HF intervention
(see Work package 1: intervention development and feasibility study). However, RCTs of CR for HF have
not included process evaluation, so evidence is lacking about the characteristics of CR programmes
that consistently affect the success of self-care interventions across different outcomes, how different
elements of the elements of CR programme interact, and the complexity of living with HF and the
burden of both self-care and adherence to intervention regimens.
Research aims
The aims of this process evaluation were to:
l assess the intervention fidelity and patients’ and caregivers’ experiences (seeWork package 3: caregiver
outcomes) of participation in the REACH-HF multicentre RCT (seeWork package 3: patient outcomes44)
l investigate the change processes that may be responsible for changes in the primary outcome
measure of the RCT – MLHFQ.
Methods
A mixed-methods process evaluation used linked data to build individual case studies with links
between different available data, paying particular attention to fidelity (the consistency of what is
implemented with the planned intervention) and adaptations (alterations made to an intervention in
order to achieve contextual fit) (see Report Supplementary Material 1, Figure G).
Data collection
Data were collected in parallel with the REACH-HFmulticentre trial (seeWork package 3: patient outcomes44).
Quantitative data
A 13-domain fidelity checklist was developed and piloted during the feasibility study and used in the
process evaluation to assess the facilitators’ delivery of the intervention.
Qualitative data
For the 19 patients who constituted our sampling frame (two or three patients per facilitator across
the four recruiting sites), all face-to-face meetings and subsequent telephone contacts with the
facilitator were audio-recorded. Face-to-face or telephone interviews were conducted at 4 and
12 months after recruitment to the trial, allowing changes over time to be explored. The intervention
had been completed prior to the first interview. A topic guide (see Report Supplementary Material 1)
was reviewed throughout the study so that the questions were informed by relevant emerging topics.
The data set included facilitator fidelity scores and qualitative notes of the scores, facilitator contact
sheets, baseline questionnaire data, field notes and interview transcripts.
Analysis
Quantitative data
Descriptive statistics were used to summarise dose and fidelity.
Qualitative data
Individual cases were created for each respondent, including interview transcripts, contact sheets,
audio-recordings of facilitator–patient interactions and associated fidelity scores, summaries of the
intervention sessions, field notes, clinical data such as case report forms, and patient-reported outcome
measures. Interview transcripts were initially analysed using evaluative coding, which assigned a
judgement about the merit or significance of the intervention from the participant’s perspective.
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On the basis of these multimodal and longitudinal data, each case was coded on the basis of intervention
fidelity and tailoring of the intervention. Audio-recordings, sampled on the basis of the fidelity scores
and position in the typology, allowed closer analysis of relevant sections of the intervention sessions.
Key findings
The process evaluation sample was broadly representative of study participants. On average, 7.05
(SD 2.6) facilitated sessions were provided per process evaluation participant, of which 4 (SD 1.8)
were face to face and 2.94 (SD 2.6) were by telephone.
Fidelity of intervention delivery
Audio-recordings of most facilitator contacts were available (n = 110) and assessed by two
investigators (Jennifer Wingham and Colin J Greaves) using the fidelity checklist (Table 5) applied to
the audio-recordings of all of the available (n = 110) facilitator–patient contacts. Fidelity was deemed
adequate (≥ 3) in most domains (see Table 5). However, there was room for improvement, particularly
with respect to the involvement of and support provided to caregivers (items 10–12 in Table 5), for
which the mean scores were well below the acceptable standard (see Table 5). In addition, given that
scores for many items were only marginally above (or just below) the defined standard for adequacy,
this indicates room for improvement across the board. The fact that the range of scores varied widely
also indicates that it is possible to achieve higher scores in every domain (again indicating scope
for improvement).
Successes
Intervention attendance was high, with > 90% of participants receiving the minimum intended dose;
this compares well with six group-based CR programmes, which typically report attendance levels of
about 80% of intended contacts. How well the intervention was perceived by the participant depended
not on the ‘dose’ (i.e. the contact time with the facilitator) but on other factors related to delivery of
the REACH-HF intervention (Table 6). The appropriate ‘dose’ of the REACH-HF intervention was
contingent on fidelity and skilled facilitation rather than the duration or frequency of contact alone.
Importantly, in the case studies that we analysed, the fidelity score at the initial ‘assessment’ session
was indicative of the overall fidelity for an individual participant over the course of the intervention.
TABLE 5 Work package 3: fidelity scores
Characteristic Mean Minimum Maximum n
1. Participant involvement 3.3 1.3 4.9 20
2. Assessment of individual needs 4.1 2.5 5.0 15
3. Tailored treatment plan 2.9 1.8 5.1 20
4. Building understanding of HF 3.3 1.5 5.0 17
5. Support progress monitoring 2.9 1.8 5.0 20
6. Review progress 3.2 2.2 4.8 18
7. Physical activity plan 4.2 3.0 5.5 15
8. Address patient emotion 3.4 1.0 5.0 17
9. Medication issues 3.3 2.0 5.0 17
10. Involve caregiver 1.6 0.0 3.1 16
11. Address caregiver emotion 2.2 0.0 4.0 14
12. Address caregiver well-being 1.1 0.0 3.3 16
13. Closure 3.4 2.0 5.0 14
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Intervention effectiveness was dependent on the facilitator’s style of engagement and the extent to
which the trial materials were matched or adapted to the existing beliefs and goals of participants.
Limitations
Several factors were identified as possible reasons why participants may not have benefited from
the intervention. Behaviour change seemed sustained when the facilitator adapted the intervention
to the needs of the participant. The facilitators’ competence was key to participants’ acquisition of
skills and changes in behaviour. Most participants had multiple comorbidities. Some participants
valued the simplicity of the REACH-HF intervention, specifically the accessibility of the information
provided. Socioeconomic factors influenced the level of engagement with the intervention – sustaining
change seemed easier for participants with favourable financial or social circumstances. The main
REACH-HF RCT (see Work package 3: patient outcomes) and this process evaluation included very few
(< 3%) ethnic minority participants.
The fact that data were not collected during the facilitator training and that interviews with facilitators
were not recorded meant that we had limited insight into the interaction between a practitioner’s
existing professional repertoire and their engagement with and delivery of the REACH-HF intervention.
Recommendations for future research
Future research could explore ways of optimising the ‘workability’ of the REACH-HF intervention and
integration of its components into the facilitators’ clinical practice to ensure that fidelity and adaptation
are maximised in the dynamic and complex context of managing patients with HF. Given the low uptake
of CR among people from minority ethnic backgrounds,88 future research should also attempt to
TABLE 6 Work package 3: process evaluation findings
Finding Participants’ commentsa
One participant, Mary, received one of the lowest
doses of the REACH-HF intervention (293 minutes
over three face-to-face and three telephone-based
intervention sessions), but her fidelity scores were
high (≥ 5) at baseline and remained about 4–5 after
the 12 weeks of the intervention
4 months into the programme, Mary explained how the support
of the facilitator combined with the walking programme had
re-orientated her understanding of HF:
I’ve learnt a lot and I think it is a very good, um manual, I think
it’s excellent and I think, er, given to people – I wished I’d had it
right at the beginning. Because it has changed my attitude . . .
Another participant, Dorothy, received a larger
dose of the intervention (440 minutes over four
face-to-face and two telephone sessions); however,
her fidelity scores remained low (< 2.5) at baseline
and after 12 weeks of REACH-HF. Her lack of
engagement was attributed to her lack of insight,
which was repeatedly reinforced by poor facilitation
of the intervention, resulting in no change in
understanding or behaviour
After 12 months of the REACH-HF programme, Dorothy said:
I can’t seem to get the seriousness of it . . . [exercise] is recreation,
isn’t it? Mainly . . . it keeps, you know, things going . . . I can’t
explain it really now . . . I did have a diary at first ‘cos they said
keep a diary, but even that I don’t tend to . . . no, have got a bit
complacent . . .
To some, the diagnosis came as a relief because
it normalised and explained their symptoms
(e.g. tiredness and breathlessness) making them
feel less anxious
Several patients liked the description of HF in the
HF Manual, along with the facilitator’s explanation,
which aided their understanding of HF, thus better
equipping them to untangle, identify and act on
symptoms of HF
One caregiver stated:
I just feel once he started to understand more about heart
failure, with the [HF] Manual, that, yes, he sort of – I don’t know,
sort of maybe accepted it more . . . I think sometimes he sort
of panics, thinking, oh, you know, should I be feeling this way?
Whereas having the [HF] Manual has, I think, sort of made him
realise, yes, this is normal for me to feel like this and be like this
a All names are pseudonyms.
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understand the specific support needs of people from more diverse ethnic backgrounds and the extent
to which cultural beliefs may moderate or mediate the effectiveness of home-based CR interventions,
such as the REACH-HF intervention.
Trial registration
This trial is registered as ISRCTN86234930.
Work package 3: economic evaluation
Introduction
In addition to information on the effectiveness of interventions, it is important to assess the cost-
effectiveness of interventions to inform health policy decision-making within the context of the NHS in
the UK. This section reports a cost-effectiveness analysis of the REACH-HF intervention versus usual
care, which was carried out alongside the main trial (see Work package 3: patient outcomes).
Research aims
The aim of the trial-based economic analysis was to assess whether or not addition of the REACH-HF
intervention to usual care alone (REACH-HF group) was cost-effective compared with usual care alone
(control group) based on resource use, costs and HRQoL outcomes recorded for participants with
HFrEF over the 12 months of the trial.
Methods
The trial-based economic analysis compared the costs associated with health and social care resource
use and HRQoL of the REACH-HF intervention and control groups. Statistical analyses were used
to estimate between-group differences in estimated costs and QALYs. Bootstrapping was used to
provide estimates of uncertainty. Primary analysis was based on complete cases, with sensitivity
analyses using imputed data, subgroups, caregiver QALYs, and informal care costs and varying the
intervention cost. Full methods for the trial-based analysis are reported in Appendix 3.
Data collection
Data on resource use related to health and social care were collected from REACH-HF trial participants
with HFrEF over the course of the 12 months of the trial and were costed using published estimates
and national data sets.89,90 Data on staff time, training and consumables used in providing the
intervention, collected within the trial, were used to estimate the cost of the REACH-HF intervention.
Data on HRQoL were collected by self-report from trial participants using the EQ-5D questionnaire.
Cost-effectiveness analyses
Cost-effectiveness was reported in terms of the incremental cost-effectiveness ratio [incremental
cost-effectiveness ratio (ICER) cost per QALY] estimated over the 12 months of trial follow-up.
Key findings
The mean estimated total cost for delivery of the REACH-HF intervention was £418.39 per patient
with HFrEF. We found an increase of £345 per patient for health and social care services for the
REACH-HF group compared with the control group over the 12 months of the trial, although the
difference was not statistically significant. No statistically significant difference was seen between
the groups in EQ-5D or QALYs. With an expected additional cost associated with the addition of
the REACH-HF intervention to usual care and no reported health gains, usual care alone dominates.
Full results of the trial-based cost-effectiveness analysis are reported in Appendix 3.
Successes
Retention in the trial was good, with 86% of participants recruited to the trial completing and
providing data for the full 12 months.
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Limitations
The REACH-HF trial did not show a significant short-term improvement in generic HRQoL (EQ-5D)
and it was not found to be cost-effective over the 12 months of the trial, as costs were higher in the
REACH-HF group. Although meta-analyses of randomised trials studies have shown that CR can
reduce all-cause and HF-specific hospital admissions, the main REACH-HF trial was not powered to
detect such a change. This short-term analysis, therefore, was not able to assess whether or not there
would be longer-term benefits to people with HFrEF from receiving the REACH-HF intervention.
Recommendations for future research
Robust, long-term, real-world estimates of the effectiveness of home-based CR for HFrEF in terms of
hospitalisations and deaths are required to further inform the cost-effectiveness of home-based CR in
patients with HF.
Work package 4: model-based cost-effectiveness analysis
Some parts of these sections have been reproduced with permission from Taylor et al.46 This is an
Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial
(CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different terms, provided the original work is
properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
The text includes minor additions and formatting changes to the original text.
Work package 4: overview
To assess the longer-term cost-effectiveness of the REACH-HF intervention, home-based CR and
centre-based CR versus usual care in people with HFrEF, our model-based analyses used an appropriate
model type and analytical framework to capture disease progression using health states that represent
the important event-related activity of HF. An updated Cochrane systematic review of the evidence for
exercise-based CR (both home and centre based) was undertaken as part of our programme-informed
data inputs to the evidence synthesis (see Appendix 1). The detailed costs of the REACH-HF intervention
were obtained through WP3 (see full report in Appendix 3). We estimated the cost-effectiveness of
home-based CR versus usual care, the REACH-HF intervention versus usual care and centre-based CR
versus usual care46 (see Appendices 1 and 3). Using the common comparator of usual medical care, it
was possible to compare (indirectly) the trial-based evidence for centre-based CR and the findings
for the REACH-HF intervention in WP3 to derive the relative effect of centre-based CR versus the
REACH-HF intervention. The cost-effectiveness of centre-based CR versus usual care was considered,
for consistency, using the common decision-analysis framework that we developed (see Work package 4:
model-based cost-effectiveness analysis). Modelling predicts a reduction in hospital admissions, which is
consistent with the literature on trials of home-based CR, and the results indicate the interventions are
likely to be highly cost-effective. The results of the updated Cochrane review of exercise-based CR for
HF1 and the economic modelling have been published (see Appendix 1).
Work package 4: introduction
Among patients with HF, the risk of deterioration leading to hospitalisation is high. Hospitalisation is not
only an indicator of greater morbidity but is associated with an increased risk of death, higher health-care
costs and significant impairments in HRQoL. Systematic reviews and meta-analyses of exercise-based
CR in patients with HF have shown improvements in HRQoL and a reduction in rehospitalisations.1,14,15
Reducing acute events and hospital admissions may have the knock-on effect of slowing disease
progression and reducing mortality, as patients are at increased risk of death during and immediately
after admission. It therefore is important to understand the long-term cost-effectiveness of a home-based
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CR intervention, such as that trialled in the REACH-HF programme, and this can be done using a decision-
analytic economic model. Given the paucity of direct head-to-head RCTs in the HF population identified
by our updated Cochrane review of home- versus centre-based CR (four RCTs in a total of 315 patients,
with only one single-centre study undertaken in a UK setting),91 we decided to restrict our economic
modelling to examine the questions of the long-term cost-effectiveness of:
l REACH-HF versus usual care
l home-based CR versus usual care
l centre-based CR versus usual care.
The data were too limited to directly estimate the longer-term cost-effectiveness of home- versus
centre-based CR.
Work package 4: research aims
The aim of this model-based economic evaluation was to assess cost-effectiveness over the longer
term of the REACH-HF intervention, other home-based CR and centre-based CR versus usual care in
people with HFrEF (see Appendix 1). Additional analyses, including assessment of the cost-effectiveness
of centre-based CR versus usual care, are reported in Appendix 3.
Work package 4: methods
The long-term model-based economic evaluation used a Markov cohort model with a 1-month cycle,
which captured the impact of the intervention on (1) all-cause hospitalisations and (2) HF-related
hospital admissions and related increases in mortality for the lifetime of people with HF. Development
of the model involved a systematic review of the literature on model-based economic evaluations for
HF (see Report Supplementary Material 1 for more details), exploring model structure and data inputs,
building on previously published literature and input from a stakeholder group. The perspective was
of a third-party payer (i.e. the NHS in the UK). Full probabilistic and deterministic sensitivity analyses
were used to test the sensitivity of the results to both uncertainty and changes in model structure and
parameterisation. Detailed methods for the model-based analysis are included in a published paper
(see Appendix 1).46
Work package 4: data collection
The model was parameterised using data on hospital admissions, mortality, costs and HRQoL from
published studies and national data sets. Effectiveness estimates in terms of odds ratios for hospital
admission for HF were drawn from two sources: (1) a systematic review and Cochrane meta-analysis
of randomised trials of the effectiveness of centre- and home-based CR versus usual care (see Appendix 1)
and (2) the REACH-HF trial results (see Work package 3: multicentre randomised controlled trial of the
REACH-HF intervention in patients with heart failure with reduced ejection fraction). Full details of model
parameters are set out in a published paper (see Appendix 1).
Work package 4: cost-effectiveness analyses
The model estimated the lifetime cost-effectiveness of home-based CR (from our meta-analysis) plus
usual care versus usual care alone and the REACH-HF intervention plus usual care versus usual care
alone in terms of the incremental cost per QALY. The key outcomes of the model were costs in GBP
and health outcomes measured in terms of QALYs based on EQ-5D values.
Work package 4: key findings
Although not cost-effective over the 12 months of the trial, over the lifetime of patients with HFrEF
both the REACH-HF intervention and the home-based CR (from our meta-analysis) were potentially
cost-effective, with longer survival, increased HRQoL and slightly increased costs. The model-based
economic evaluation, extrapolating results from the multicentre trial in HFrEF patient over a time
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horizon of 4 years, found that an estimated mean cost per patient of £15,452 (95% CI £14,240 to
£16,780) and a mean QALY gain of 4.47 (95% CI 3.83 to 4.91) for the REACH-HF intervention plus
usual care, compared with a mean cost of £15,051 (95% CI £13,844 to £16,289) and a mean QALY
gain of 4.24 (95% CI 4.05 to 4.43) with usual care alone, resulting in an incremental cost per QALY of
£1721. Probabilistic sensitivity analysis indicated a 78% probability that the REACH-HF intervention
plus usual care is cost-effective versus usual care alone at a threshold of £20,000 per QALY (see Figure 8,
Appendix 3). The full results of the model-based cost-effectiveness analysis are reported in a published
paper (see Appendix 1). The results of the analysis of centre-based CR versus usual care are reported
in Appendix 3.
Work package 4: successes
Consistent with previous research in this area, our modelling work suggests that the reduced incidence
of HF-related admissions seen with home-based CR led to reduced mortality and improved HRQoL.
An average reduction of 2% in HF-related admissions was seen over 12 months, with the difference
in numbers of HF-related admissions falling to 16% after 5 years and 9% at 10 years. Although
evidence of a reduction in HF-related admissions is uncertain (i.e. wide 95% CIs), when this is taken
into account, we predicted that both the addition of the REACH-HF intervention and home-based
CR to usual care were cost-effective in more than 73% of cases compared with usual care alone.
Work package 4: limitations
The main challenge was to assess cost-effectiveness of home-based CR given the limited amount of
current randomised trial evidence for home-based CR and the small number of HF-related admissions.
Using the best available evidence, we used a decision-analytic framework to provide model-based
analyses, applying the reported uncertainty in effectiveness of home-based CR versus usual care in
reducing HF-related hospital admissions. In addition, we did not undertake a network meta-analysis to
estimate indirectly the cost-effectiveness of the REACH-HF intervention versus centre-based programmes.
Work package 4: recommendations for future research
Robust, long-term, real-world estimates of the clinical effectiveness of home-based CR for HF in terms
of hospitalisations and deaths are needed to further inform the cost-effectiveness of home-based CR
in HF. Insensitivity of the EQ-5D in patients with mild HF in other studies has prompted some health
economists to recommend using the Short Form questionnaire-6 Dimensions (SF-6D) in those with
milder disease. Future studies should consider using the SF-6D [from Short Form questionnaire-12
items (SF-12)] alongside the EuroQol-5 Dimensions, three-level version (EQ-5D-3L).
Patient and public involvement in REACH-HF
In the REACH-HF programme, PPI was defined as the involvement of members of the public who had a
diagnosis of chronic HF or were caring for relatives or partners with HF. The term ‘public’ is defined
using guidelines from INVOLVE, where it is understood to include people of different ages, ethnicities,
sexes and disabilities and with different needs and concerns. PPI is an active partnership between the
researchers and the public, which takes the form of consultation and collaboration. The members of the
PPI Advisory Group contributed their own experiences of coping with HF – from the perspective of a
person with HF or a person acting as a caregiver for someone with HF.
Recruitment of the patient and public involvement Advisory Group
Patients with HF and their caregivers were highly involved in our programme of research from
its conception. The first formal meeting of the PPI Advisory Group in March 2011 was chaired
by a representative of the NIHR Collaborations for Leadership in Applied Health Research and
Care South West Peninsula (PenCLAHRC) and included five people with HF, one caregiver and two
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co–investigators/REACH investigators (Jennifer Wingham and Hasnain Dalal). The PPI Advisory Group
met three or four times per year and more frequently during the intervention development phase to
review the various WPs. The group provided detailed comments on aspects, such as the proposed
choice of patient-reported outcome measures. In the summer of 2011, members of the PPI Advisory
Group contributed in particular to the development of the home-based REACH-HF intervention
[helping to select the core intervention targets, identifying barriers to change and ways to facilitate
change, and reviewing the entire content of the intervention as it developed as part of the Programme
Development Grant (RP-DG-0709-10111)]. From the outset, the PPI Advisory Group fed directly
into the Programme Steering Committee (PSC), with the PPI chairperson (Kevin Paul) acting as the
patient representative and included as a co-applicant for the Programme Grant.
Embedding patient and public involvement in the REACH-HF research programme
The PPI Advisory Group reported directly to the Programme Management Group and had a
representative on that committee – the chairperson of the PPI Advisory Group fulfilled this role from
2012. The Programme Management Group meetings had a standard agenda item for PPI activities.
The chairperson reported on PPI activities and kept members of the PPI Advisory Group informed
about discussions and the progress of the REACH-HF programme. The PPI members were keen to have
feedback about how their recommendations were used; for example, they suggested having two types
of exercise programmes (chair based and walking) and they contributed to wording on patient-facing
documents to encourage participants in the control group to continue with the trial.
The lay chairperson, independent of the research team, also reported to the PPI representative on the
PSC (Liz Clark).
Process and impact of patient and public involvement in the REACH-HF programme
Using the methods described in WP1 (see Work package 1: methods), the PPI Advisory Group helped
the REACH-HF research team to develop a new facilitated self-care manual – ‘the REACH-HF
intervention’ – for people with HF and their caregivers to help them manage the condition.39
Over the 6 years to June 2018, the REACH-HF PPI Advisory Group consisted of up to eight active
members – patients and caregivers – who regularly contributed to the development of the research
study through consultation and collaborative approaches. Some members who joined at the start of
the study had to leave the group because of deterioration in their health, with others replacing them
as the study progressed. We developed a whole-systems model in which communication was expected
to flow as a two-way process across all elements of the teams/groups. PPI informed the design of
the intervention and contributed towards the research cycle, including revision of the intervention
following a feasibility study in 2014. The PPI Advisory Group was involved in the dissemination events
in 2018 and have continued to advise on dissemination of the REACH beyond June 2019 at the end of
the NIHR Programme Grant. Some members of the group have become involved in ongoing projects
related to the digitisation of the REACH-HF intervention in 2020–21.
The work of the PPI Advisory Group was presented as an oral poster presentation at the NHS
Research Forum in May 2016.92
Kevin Paul, chairperson of the PPI Advisory Group, described the impact of the REACH-HF project for
him and other members of the group over the course of the project:
From the outset, the management team have been welcoming and willing to take on board comments
from the PPI [Advisory] Group, ensuring that the [HF] Manual is easy to read for the patients and
caregivers. The genuine interest taken in the feedback from the group throughout the project has been
both gratifying and encouraging.
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On 24 November 2017, members of the PPI Advisory Group met with Rod S Taylor and Hasnain Dalal,
the co-chief investigators, as well as Jennifer Wingham (investigator) and Suzanne Nunn (project
administrator). Rod S Taylor and Hasnain Dalal thanked the PPI Advisory Group members for their
contribution and gave a presentation on the REACH-HF study and its key findings. Members of the
group were the first to hear about the main results of both RCTs. They appreciated being involved at
every stage of the REACH-HF project and agreed to continue to help with dissemination of the results.
Members of the PPI Advisory Group joined Rod S Taylor, Hasnain Dalal, Jennifer Wingham and
Suzanne Nunn for a meal after the presentation. Some members of the PPI Advisory Group accepted
an invitation to attend the REACH-HF dissemination event in Falmouth on 6 April 2018. A further
meeting in Truro on 26 June 2018 was convened by Professor Colin J Greaves (investigator) to seek
the views of the PPI Advisory Group on updating the REACH-HF intervention prior to possible
implementation within the NHS.
Conclusions
The REACH-HF research programme focused on developing and evaluating a novel home-based
self-care rehabilitation intervention for patients with HF and their caregivers. Our aim was to create
a clinically effective and cost-effective alternative to centre- or hospital-based CR that could increase
the current low uptake of CR in people with HF.
Our research was conducted across NHS secondary and primary care centres in England, Wales and
Scotland. Over the 5 years of our research programme, we achieved our stated overall aim and
objectives across four WPs.
In the first 15 months of the programme, we successfully co-designed and developed a novel,
home-based, self-care rehabilitation intervention (‘the REACH-HF intervention’), with stakeholders
including patients with HF (see WP1A), their caregivers (see WP1B), clinicians, NHS commissioners and
academics with an interest in CR and HF. This resulting REACH-HF intervention is a comprehensive,
theory-based, user-centred, home-based, self-care support programme for people with HF and their
caregivers comprising three core components (i.e. the REACH-HF Manual, a Participant ‘Progress
Tracker’ booklet and a ‘Family and Friends Resource’ for caregivers) and a training course for
facilitators. This is one of the few studies to describe in detail the theoretical and evidentiary basis,
intervention techniques and strategies for an intervention to promote the quality of life of people
with HF and their caregivers. The main limitation was the complexity of the process, which affects
replicability and requires considerable resources. Despite a transparent audit trail and documentation
of all of the processes involved, it is unlikely that a different team of collaborators using the same
methods would have produced exactly the same intervention. The implementation could have taken
a number of different forms, as ‘judgement calls’, decisions and selection of appropriate methods or
theoretical approaches were required at many stages during the process. Although a panel of experts
ensured that judgement calls involved multiple stakeholders and decisions were based on either
evidence or appropriate expertise, there was often no clear ‘best solution’ and a different group of
experts may have made different decisions. Therefore, intervention development remains as much an
art as a science, depending on the individual expertise, experience, instincts and knowledge of the
team, as well as on team dynamics and collective decision-making. Intervention mapping, along with
strong service user involvement, was a resource-intensive, but rigorous, method that allowed
the development of a comprehensive, evidence-informed, theoretically driven, facilitated self-care
and rehabilitation intervention that is grounded in the needs of patients with HF, caregivers and
service providers.39
The REACH-HF intervention was tested in a feasibility study in patients with HFrEF, in which it was
well accepted by the 23 patients, 12 caregivers and health-care facilitators who took part, with high
attendance and adequate delivery of most aspects of the intervention. Levels of outcome completion
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were generally excellent, and patients/caregivers perceived a relatively low measurement burden.
A number of patient and caregiver outcomes showed evidence of improvement after the REACH-HF
intervention. Analysis of the quality of intervention delivery, based on applying a checklist to recordings
of all the consultations for 18 cases, suggested that the components of the intervention were mostly
delivered as intended and with reasonably high quality. However, there was room for improvement in
terms of addressing caregiver health and emotional health. Potential modifications to the content of the
manual and facilitator training were identified, and, after these revisions, the REACH-HF intervention
was ready for evaluation in a full-scale trial.
The main component of our programme was evaluation of the REACH-HF intervention in a multicentre
RCT (see Work package 3: multicentre randomised controlled trial of the REACH-HF intervention in patients
with heart failure with reduced ejection fraction) in patients with HFrEF from Birmingham, Cornwall,
Gwent and York. We recruited to target (n = 216) and on time, with excellent retention (86%) at the
12-month follow-up. We found a statistically significant and clinically meaningful (> 5 points) mean
between-group difference in the primary outcome measure, MLHFQ score, in favour of the REACH-HF
group at the 12-month follow-up. With the exception of patient self-care (p < 0.001), no significant
difference was seen in other secondary outcomes, including clinical events (p > 0.05), at follow-up
compared with usual care. The maintenance score on the SCHFI was in favour of the REACH-HF
intervention at 12 months (p < 0.001). Within-group improvements from baseline were seen in the
REACH-HF group for HADS anxiety and depression, ISWT and SCHFI (management and confidence),
but these were not statistically significant when compared with the control group at 12 months.
We found no evidence of a significant subgroup treatment interaction on the primary outcome at
12 months by NT-proBNP level, presence of caregiver, recruitment site or duration of HF. The absence
of significant between-group differences in exercise capacity and physical activity and no differences
in most of our secondary outcomes may reflect the fact that the trial was not formally powered on
these outcomes. Furthermore, the mean age of 70 years and multimorbidities of our trial population
may have had a negative impact on the outcomes of exercise capacity and physical activity. In terms of
caregiver outcomes, only the SCHFI confidence score achieved between-group statistical significance
at follow-up. This may reflect that caregivers were not randomised and the study sample size was
powered on the between-group difference in patient outcomes rather than caregiver outcomes.
We calculated that the mean cost of the REACH-HF intervention was £418.39 per participant, which
is less than the current NHS tariff for CR of £477. Our evidence suggests that the novel REACH-HF
home-based facilitated intervention for HFrEF was, thus, clinically superior in terms of disease-specific
HRQoL at 12 months and offers an affordable alternative to traditional centre-based programmes to
address current low CR uptake rates for HF.44
In a cost-effectiveness analysis using data from our multicentre RCT, we used model-based analyses to
capture disease progression using health states that represent important event-related activity of HF.
An updated Cochrane systematic review of the evidence for exercise-based CR in adults with HF, which
was undertaken as part of our programme and includes data from our multicentre RCT, informed data
inputs to the evidence synthesis. Taking a UK National Health and Personal Social Services perspective,
we estimated the incremental cost per QALY gained and assessed uncertainty using probabilistic and
deterministic sensitivity analyses. We estimated the cost-effectiveness of home-based CR versus usual
care, the REACH-HF intervention versus usual care and centre-based CR versus usual care. Using the
results from the main RCT and the EQ-5D, we saw no difference in QALY gain between groups, with usual
care dominant, so the REACH-HF intervention was not cost-effective using this short-term perspective.
The health-economic findings from our main RCT and the lack of responsiveness of the EQ-5D in other
studies support the use of an alternative to the EQ-5D, such as the SF-6D, for future health-economic
evaluations in patients with less severe heart disease. The small number of direct head-to-head RCTs
of centre- versus home-based CR in HF mean that data were too limited to directly estimate the
longer-term cost-effectiveness of home- versus centre-based CR, so we focused on comparisons
of home- and centre-based CR versus usual care (see Work package 4: model-based cost-effectiveness
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analysis and Appendix 3). In the base-case analysis, the REACH-HF intervention was associated with
per patient mean QALY gain of 0.23 and an increased mean cost of £401 compared with usual care,
resulting in a cost per QALY of £1721. Overall, our economic modelling using evidence synthesis and
taking a longer-term view (see Work package 4: model-based cost-effectiveness analysis) suggests that
the REACH-HF intervention was cost-effective compared with usual care. Findings of the REACH-HF
intervention evaluation indicate effectiveness on one set of clinical outcomes but not all, and while the
economic analysis conducted alongside the full RCT did not produce significant differences in EQ-5D
or QALYs, economic modelling of the REACH-HF intervention against usual care suggested greater
cost-effectiveness of the REACH-HF intervention.
In the process evaluation of the main multicentre RCT, intervention attendance was high, with
> 90% of participants receiving the minimum intended dose, which contrasts with group-based CR
programmes for which typical attendance levels are about 80% of intended contacts.45 How well the
REACH-HF intervention was perceived by the participants seemed to depend not on the ‘dose’ of the
intervention (i.e. the contact time with the facilitator), but on other factors related to the delivery of
the intervention. Multimodal and longitudinal qualitative data analysis suggested that behaviour change
might be more likely to be sustained when the facilitator adapts the intervention to a participant’s
needs. The facilitators’ competence also seemed to be a key factor in participants acquiring skills and
changing behaviour. Most caregivers engaged with the intervention and made changes to how they
support the person with HF for whom they were caring and gained in confidence. Lower intervention
fidelity scores were also related to caregiver issues, suggesting that the support provided to caregivers
by facilitators should be improved in a future, revised, intervention. However, based on qualitative data
across WP2, WP3 and the feasibility study, components of the programme patients valued highly or that
seemed to be associated with effectiveness included the Progress Tracker, the facilitators, adaptation
of the intervention to individual needs, addressing emotional consequences (especially for the HFpEF
sample), information in the HF Manual, understanding what to do in an emergency, support for
caregivers (where this was given) and the exercise programme.
We also conducted a single-centre pilot RCT to assess the feasibility and acceptability of the REACH-HF
intervention for patients with HFpEF and their caregivers. The REACH-HF intervention was originally
designed for patients with HFrEF in terms of coverage of medication and explanations of the condition,
as there was limited evidence to guide development of the REACH-HF intervention for patients with
HFpEF. Following a review of clinical guidance and consultation with the expert cardiology, primary
care and physiology/CR specialist members of our project management group, the intervention required
only minor modification for patients with HFpEF. This review and consultation included removing
specific information on certain medications, such as beta-blockers, ACE inhibitors and angiotensin
receptor antagonists, which have not been shown to be of prognostic benefit in patients with HFpEF,
and changing the description of the condition to better cover causes and management of HFpEF. In
contrast to the neutral outcomes of device and drug trials in HFpEF, promising evidence indicates the
potential for exercise-based CR to benefit patients with HFpEF. The revised REACH-HF intervention was
well received by patients, caregivers and health-care facilitators, and adherence to the intervention
was good. At follow-up, a number of patient outcomes, including our primary outcome measure, the
MLHFQ score, showed a direction of effect in favour of the intervention group over control, although
this study was not designed or powered to assess definitively the efficacy or safety of the REACH-HF
intervention in HFpEF. The findings of this pilot study have informed a funding application for a fully
powered, multicentre RCT in patients with HFpEF. Patient interviews from a nested qualitative study
showed that the ISWTwas not feasible as a method of assessing exercise tolerance for some participants,
with more than one in four unable to undertake the exercise test at final follow-up. A fidelity assessment
that was part of the process evaluation suggested that the intervention was generally well delivered by
the facilitators, although lower scores were related to caregiver issues, indicating room for improvement
with respect to the involvement of and support provided to caregivers by facilitators. Semistructured
qualitative interviews gave an insight into the patient’s understanding of HF, the emotional consequences
of HF and the patient’s response to the REACH-HF intervention, including the facilitator.
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In the main multicentre RCT (WP3) the lack of blinding was a key limitation, as the complex nature of
the intervention and control meant that we could not mask participants to treatments, introducing the
possibility of patient expectation bias. Another limitation was the 15% missing data for the primary
outcome measure at the 12-month follow-up. Assessment of adherence was also a limitation given
the self-directed nature of the home-based intervention, and we were not able to capture consistent
patient-level data on adherence to the exercise training component of the intervention. Moreover,
interpretation of our findings should take account of the fact that, compared with the general population
of patients with HF in the UK, our study population had a lower mean age (70 vs. 76 years) and included
a higher proportion of males (78% compared with an almost equal sex balance); in addition, we recruited
only a very small number (n = 7) of people from ethnic minorities.
We successfully completed all components of our programme on time and under budget. We attribute the
smooth running of our programme to several factors.We were able to establish a team of investigators
with a track record of conducting some of the major RCTs of CR in the UK when we were awarded our
NIHR Programme Development Grant in 2010.We had good working relationships within our internal
and external committees and the benefit of active high-quality guidance from our PSC and PPI Advisory
Group. Support from the UKCRC-registered Peninsula CTU helped to ensure that our study centres were
able to recruit to target and on time and achieve high standards of data management and reporting.
Key conclusions
The REACH-HF multicentre trial44 has been acknowledged as ‘one of the first CR studies to systematically
develop a rehabilitation intervention using gold standard methods for developing complex interventions’.93
Other key attributes of the study include co-development of the intervention with patients, caregivers,
clinicians and academics with expertise in health behaviour change, psychology and exercise. The
intervention was evaluated in a fully powered multicentre RCT in patients with HFrEF and a single-
centre pilot RCT in patients with HFpEF. The results of the multicentre RCT showed that the addition
of a home-based rehabilitation and self-care intervention to usual care resulted in a clinically important
improvement in the HRQoL of patients with HFrEF. Our model-based economic evaluation, extrapolating
results from the multicentre trial in patients with HFrEF over a time horizon of 4 years, found that an
estimated mean cost per patient of £15,452 (95% CI £14,240 to £16,780) and a mean QALY gain of 4.47
(95% CI 3.83 to 4.91) for the REACH-HF intervention plus usual care, compared with a mean cost of
£15,051 (95% CI £13,844 to £16,289) and a mean QALY gain of 4.24 (95% CI 4.05 to 4.43) with usual
care alone, resulting in an incremental cost per QALY of £1721. Probabilistic sensitivity analysis
indicated a 78% probability that the REACH-HF intervention plus usual care is cost-effective versus
usual care alone at a threshold of £20,000 per QALY. The mean cost of the REACH-HF intervention was
£418 per participant and within the current NHS tariff for CR of £477 per patient.44
The REACH-HF may be the first alternative to supervised group-based intervention for patients with
HFrEF which has indicated effectiveness in terms of HRQoL and patient self-care. As attendance at
group-based CR for people with HF is poor, ‘the 90% adherence rate achieved in this study is important.
The evidence for an affordable home-based programme as an alternative to other settings is growing
and may have future workforce implications’.94 Our findings provide an important contribution to the
evidence base supporting home-based approaches to delivery of CR in HF, such as the REACH-HF
intervention, which can provide a patient-centred alternative to centre-based CR and could help to
address the current suboptimal uptake of CR for HF in the UK and elsewhere. It also addresses the
recommendations in the most recent NICE clinical guideline for the management of HF (NG106),5,19
which has stated the importance of home-based CR programmes and recommends offering patients with
chronic heart failure an easily accessible personalised programme of exercise-based rehabilitation, which
may be at home, in the hospital or in the community. A 4-minute video demonstrates our intervention
and summarises the findings of our main RCT (https://reachhf.co.uk/; accessed 11 February 2020).
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Recommendations for future research
Specific recommendations for future research include the following:
1. Assess the impact of different models of CR on uptake and adherence (e.g. does introducing
home-based CR increase uptake and adherence by patients with HF compared with traditional
centre-based CR alone?).
2. Assess the impact of CR in people with HFpEF (e.g. is home-based CR clinically effective and
cost-effective in patients with HFpEF?).
3. Assess the impact of digital enhancements to delivery of home-based CR (e.g. are internet-/
app-based CR models clinically effective and cost-effective for patients with HF?).
4. Improve equity in CR delivery (e.g. how do we improve the uptake and delivery of CR in
hard-to-reach groups, including ethnic minorities?).
5. Explore models of CR to address multimorbidity (e.g. how do we best adapt existing CR models to
deliver the health needs of cardiac patients with multimorbidity?).
6. Capture the health utility of therapies for HF {e.g. given the current evidence of the potential
insensitivity of the EQ-5D in patients with HF, especially those with mild disease severity, can we
use instruments to better capture HRQoL utility, such as SF-6D [from the SF-12 or Short Form
questionnaire-36 items (SF-36)]?}.
Discussion
In the UK, < 20% of patients discharged from hospital after a diagnosis of HF are referred for CR.34
The availability of the REACH-HF intervention gives clinicians the opportunity to refer patients to a
potentially clinically effective and cost-effective evidence-based intervention that can be delivered in
their home.
Low referral rates to CR are compounded by poor uptake. In 2017–18, 68,266 patients were admitted
to hospital with a primary diagnosis of HF95 but < 5000 attended at least one session of CR,29 despite
guidance recommending CR for HF from NICE dating back to 2010.5,35 However, recent NACR reports
reflect an increase in the number of patients with HF attending CR,29 suggesting that there may be
more programmes offering dedicated CR to patients with HF than those reported in 2012.96 The
majority of REACH-HF patients were multimorbid, experiencing a number of cardiovascular and
non-cardiovascular comorbidities. Despite the high mean age (≈ 70 years) and presence of multiple
comorbidities, adherence to the REACH-HF programme exceeded 85% in both trials.42,44
The REACH-HF intervention may also offer direct benefits to caregivers. Our qualitative process
evaluation showed that the REACH-HF intervention facilitated communication between the patient
and the caregiver. The inclusion of family/friends was identified as valuable (by patients and caregivers)
in the provision of social support in HF self-care for both patients and caregivers. Patients and caregivers
valued having the Progress Tracker because it enabled them to measure the patient’s progress. Caregivers
who were low in knowledge and confidence at the beginning of the REACH-HF programme reported
increased knowledge and enhanced caregiving skills from REACH-HF to maintain their role and
contribute to the management and maintenance of HF self-care.
Patients valued the simplicity of the REACH-HF programme, and specifically the accessibility of the
information provided. Based on the qualitative data across WP2,WP3 and the feasibility study, the
components of the intervention that patients valued highly and seemed to be associated with effectiveness
included the Progress Tracker, high-quality facilitation, adaptation for the intervention to individual
needs, addressing emotional consequences (especially for the HFpEF sample), the relevance of the
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information in the HF Manual, understanding what to do in an emergency, support for caregivers
(where this was given) and the exercise programme. For patients with HFrEF and their caregivers, the
intervention was considered to be adequately delivered, was well received and could be implemented
more widely. That this could be implemented more widely should be considered in the context of the
small number of drop-outs in the main trial, which was attributed to withdrawal (< 10%) as some
participants did not wish to continue because of their deteriorating health and the modest number
of deaths (4%, n = 8, four in the REACH-HF intervention group and four in the control group). The time
commitment was not reported as a significant issue by patients or caregivers. Although the lack of
significant between-group difference in outcomes other than the total MLHFQ and the SCHFI may
reflect no true difference in these outcomes, it may also reflect the fact that the main trial was not
formally powered to detect differences in secondary outcomes, especially clinical events. Furthermore,
the REACH-HF intervention is comprehensive and multifactorial, with individual patients likely to have
experienced different pathways to improved HRQoL, which may include reduced stress or anxiety;
improved pacing of physical activity, exercise capacity or sleep quality; and better medication management.
Variations in participants’ application of the REACH-HF intervention to their own requirements, as
well as variations in treatment effect, may have precluded the observation of statistically significant
between-group differences in secondary outcomes. In addition, the baseline characteristics of our study
population indicated high levels of comorbidity. The lack of impact on exercise capacity and physical
activity may, therefore, be attributed to the ‘heavy burden of comorbid disease’ that can affect
outcomes in older patients with HF.
Successful development of the REACH-HF Manual/Intervention for people with HF involved the
collaboration of four parties: the University of Exeter, the Heart Manual Department (NHS Lothian),
the Royal Cornwall Hospitals NHS Trust and Professor Patrick Doherty (who developed the chair-
based exercise DVD). A legally executed collaboration agreement regarding the intellectual property
rights of the REACH-HF Manual/Intervention was signed by the four parties, with an equal share in
the intellectual property rights to cover the duration of the study (2013–18). In February 2019, the
four parties signed a memorandum of understanding, in which the parties agreed to explore the
possibility of commercially exploiting the REACH-HF Manual/Intervention.
Implications for practice
Our clinical and economic findings suggest that a home-based CR programme, such as REACH-HF,
may help to improve the HRQoL of patients with HFrEF. Although there was no evidence of impact on
hospital admissions or mortality at 12 months within the RCT, economic modelling showed that the
REACH-HF intervention plus usual care is cost-effective versus usual care alone at a threshold of
£20,000 per QALY.44,46 The clinical characteristics of patient participants were consistent with the
wider population of HF patients in terms of age only; however, most of our participants were male
(78%) and we recruited only a very small number (n = 7) of people from ethnic minorities. In the UK,
usual care involves follow-up by the GP or specialist nurse and, for some patients, a cardiologist. In
addition, we have tested the REACH-HF intervention across a range of geographical sites in UK that
included rural (Cornwall and Gwent) and urban (Birmingham and York) centres with people from
ethnic minorities (Birmingham). However, in applying the results of the REACH-HF programme, it is
important to acknowledge the limitations stated above in terms of sex inequality and ethnicity.45
Given the successful dissemination of our findings and enhanced dissemination through the beacon sites
(funded from an underspend of this Programme Grant), at the time of writing (February 2020), the four
beacon sites set up in 2019 have delivered the REACH-HF intervention to > 100 patients, and outcome
data are being collected from the NACR database as part of ongoing research.97 Furthermore, funding
to set up and evaluate another four beacon sites in Scotland in 2020 has been obtained from Heart
Research UK.98
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We are continuing to disseminate our findings: see Appendices 1 and 2, and Report Supplementary
Material 1 and 7. To gain maximum impact, we are making our findings publicly available in various
formats tailored to the specific audience (Box 3).
The NACR has developed a specific REACH-HF Manual data field as part of the national audit, which
was available to more than 200 CR programmes by the end of 2019. From June 2019, CR programmes
have been able to record REACH-HF as a specific mode of delivery using the NHS Digital/NACR
system, and data are being collected by the national audit team for reporting in the 2020 NACR
report. This has allowed us to track uptakes from 2019 and will be reported in future NACR annual
quality and outcomes reports.
In October 2020, REACH-HF won the BMJ Award for Stroke and Cardiovascular Team of the Year for
our patient involvement and ‘excellent teamwork producing a real-world solution’.99,100
BOX 3 Dissemination
In addition to publication in scientific peer-reviewed journals, we also aim to reach audiences including
clinicians, commissioners, service users, policy-makers, methodologists, research participants, patients,
caregivers, members of the public and academics involved in teaching and research.
We worked with a professional health-care video company to make a brief film involving patients, a
caregiver and the lead researchers to showcase the findings of the REACH-HF RCT to enhance future
dissemination. This video of the intervention and summary of the study results can be viewed at
https://reachhf.co.uk/ (accessed 11 February 2020).
In October 2018, the NIHR Central Commissioning Facility approved our request for enhanced
dissemination by allowing us to use an underspend that we had accrued over the duration of the PGfAR
(2013–18).
l A variation to the contract has allowed us to engage in enhanced dissemination to maximise the
opportunity for the NHS to take up the intervention going forward.
l Specifically, we sought to use the funding to undertake a range of additional dissemination activities that
would increase the value and use of this intervention through the recruitment of four beacon CR centres
within the NHS.
¢ All CR centres in the NHS were invited, through an open competition, to apply to become beacon
sites and engage in enhanced dissemination of the updated REACH-HF intervention from
summer 2019.
¢ In return for free training of three facilitators per beacon site and the provision of 50 free REACH-HF
intervention packs, each site will be expected to recruit 50 patients with HF and their caregivers over a
12-month period.
¢ A dedicated post-doctoral research associate from the University of Exeter will liaise with the NACR
to collect pre- and post-CR outcomes of the patients receiving the REACH-HF intervention so that
we can assess the ‘real-world’ outcomes of the REACH-HF intervention (and compare with what we
have seen in our RCTs).
¢ In addition, beacon sites will allow visits from other interested CR centres and providers to see
first-hand how the REACH-HF intervention is delivered in their location.
¢ A PhD student under the guidance of one of the investigators (Colin J Greaves) is also looking at the
barriers to implementation of a novel intervention such as REACH-HF in the NHS.97
PGfAR, Programme Grants for Applied Research; PhD, Doctor of Philosophy.
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Appendix 1 Links to full text of published
studies and list of other published studies
Work package 1
Greaves CJ, Wingham J, Deighan D, Doherty P, Elliott J, Armitage W, et al. Optimising self-care support for
people with heart failure and their caregivers: development of the Rehabilitation Enablement in Chronic
Heart Failure (REACH-HF) intervention using intervention mapping. Pilot Feasibility Stud 2016;2:37.
Needs assessment questionnaire: supplemental file to the intervention development paper39
https://static-content.springer.com/esm/art%3A10.1186%2Fs40814–016–0075-x/MediaObjects/
40814_2016_75_MOESM1_ESM.pdf (accessed 20 February 2020).
REACH-HF needs assessment summary: supplemental file to the intervention development paper
https://static-content.springer.com/esm/art%3A10.1186%2Fs40814–016–0075-x/MediaObjects/
40814_2016_75_MOESM2_ESM.pdf (accessed 20 February 2020).
Extracts from intervention maps for stress management, medication management and
managing symptoms: supplemental file to the intervention development paper
https://static-content.springer.com/esm/art%3A10.1186%2Fs40814–016–0075-x/MediaObjects/
40814_2016_75_MOESM3_ESM.pdf (accessed 20 February 2020).
The REACH-HF facilitation process: supplemental file to the intervention development paper
https://static-content.springer.com/esm/art%3A10.1186%2Fs40814–016–0075-x/MediaObjects/
40814_2016_75_MOESM4_ESM.pdf (accessed 20 February 2020).
End-of-study feasibility report supplemental file to the intervention development paper
https://static-content.springer.com/esm/art%3A10.1186%2Fs40814–016–0075-x/MediaObjects/
40814_2016_75_MOESM5_ESM.pdf (accessed 20 February 2020).
Note that the outcome data at follow-up were redacted from the published version of this additional
file but are included separately in this report in Report Supplementary Material 1.
Wingham J, Frost J, Britten N, Jolly K, Greaves C, Abraham C, et al. Needs of caregivers in heart failure
management: a qualitative study. Chronic Illn 2015;11:304–19.
Work package 2
Eyre V, Lang CC, Smith K, Jolly K, Davis R, Hayward C, et al. Rehabilitation Enablement in Chronic
Heart Failure – a facilitated self-care rehabilitation intervention in patients with heart failure with
preserved ejection fraction (REACH-HFpEF) and their caregivers: rationale and protocol for a
single-centre pilot randomised controlled trial. BMJ Open 2016;5:e012853.
Lang CC, Smith K, Wingham J, Eyre V, Greaves CJ, Warren FC, et al. A randomised controlled trial of a
facilitated home-based rehabilitation intervention in patients with heart failure with preserved ejection
fraction and their caregivers: the REACH-HFpEF pilot study. BMJ Open 2018;8:e019649.
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ejection fraction and their caregiver’s experiences of home-based rehabilitation (REACH-HFpEF): mixed
methods process evaluation of the REACH-HFpEF single centre pilot randomised controlled trial [published
online ahead of print November 6 2020]. Pilot Feasibility Stud 2020.
Work package 3
Dalal HM, Taylor RS, Jolly K, Davis RC, Doherty P, Miles J, et al. The effects and costs of home-based
rehabilitation for heart failure with reduced ejection fraction: the REACH-HF multicentre randomized
controlled trial. Eur J Prev Cardiol 2019;26:262–72.
Taylor RS, Hayward C, Eyre V, Austin J, Davis R, Doherty P, et al. Clinical effectiveness and cost-
effectiveness of the Rehabilitation Enablement in Chronic Heart Failure (REACH-HF) facilitated
self-care rehabilitation intervention in heart failure patients and caregivers: rationale and protocol
for a multicentre randomised controlled trial. BMJ Open 2015;5:e009994.
Wingham J, Frost J, Britten N, Greaves C, Abraham C, Warren FC, et al. Caregiver outcomes of the
REACH-HF multicentre randomized controlled trial of home-based rehabilitation for heart failure
with reduced ejection fraction. Eur J Cardiovasc Nurs 2019;18:611–20.
Frost J, Wingham J, Britten N, Greaves C, Abraham C, Taylor R, et al. Home-based rehabilitation for
heart failure with reduced ejection fraction: mixed methods process evaluation of the REACH-HF
multicentre randomised controlled trial. BMJ Open 2019;9:e026039.
Work package 4
Long L, Mordi IR, Bridges C, Sagar VA, Davies EJ, Coats AJS, et al. Exercise-based rehabilitation for
adults with heart failure. Cochrane Database Syst Rev 2019;1:CD003331.
Taylor RS, Sadler S, Dalal HM, Warren FC, Jolly K, et al. The cost effectiveness of REACH-HF and
home-based cardiac rehabilitation compared with usual medical care for heart failure with reduced
ejection fraction: a decision model-based analysis. Eur J Prev Cardiol 2019;26:1252–61.
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Greaves C, on behalf of the REACH-HF investigators. The REACH Heart Failure Manual: A Complex
Intervention to Support Rehabilitation and Self-care for People with Heart Failure. Society for Academic
Primary Care (SAPC), Edinburgh, 2014.
Dalal H, on behalf of the REACH-HF investigators. Engaging with Patients, Clinicians and Academics to
Improve the Uptake of Rehabilitation: An Overview of the REACH-HF Programme of Research. Your Heart
Our Passion Conference, Cardiff, 2015.
Taylor R, on behalf of the REACH-HF investigators. The Evidence Base for Exercise Training in Heart
Failure and COPD. NIHR CLAHRC Northwest London meeting, London, 2015.
Austin J, on behalf of the REACH-HF investigators. Engaging with Patients, Clinicians and Academics to
Improve Care: Back to the Future. 6th Aneurin Bevan University Health Board R&D Conference,
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Wingham J, on behalf of the REACH-HF investigators. Supporting Carers in Heart Failure Management:
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Rehab? British Association for Cardiovascular Prevention and Rehabilitation (BACPR) conference,
Manchester, 2015.
Dalal H, on behalf of the REACH-HF investigators. The Rehabilitation Enablement in Chronic Heart Failure
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Appendix 3 Economic analysis
Introduction
The aims of the economic analysis were to estimate the cost-effectiveness in patients with HFrEF of:
l the REACH-HF intervention plus usual care versus usual care alone
l home-based CR plus usual care versus usual care alone.
In this appendix, we present trial-based cost-effectiveness analyses of the REACH-HF intervention
versus usual care undertaken alongside the REACH-HF RCT and based on the trial follow-up period
of 12 months. We estimate the resource use and cost associated with the delivery of the REACH-HF
intervention and compare resource use, costs and outcomes across treatment and control groups to
inform cost-effectiveness analyses.
Model-based cost-effectiveness analyses with primary analyses on home-based CR versus usual care
and secondary analyses reporting cost-effectiveness of REACH-HF intervention versus usual care
are described in a published paper (see Appendix 1).46 These analyses model longer-term costs and
outcomes using a decision-analytic model. In this appendix, we present additional model-based
analyses that were not included in the submitted manuscript, including:
l analysis of both the REACH-HF intervention and the home-based CR versus usual care using
effectiveness in terms of all-cause hospital admissions as opposed to HF-related hospital admissions
l analysis of the cost-effectiveness of centre-based CR (based on both HF-related and
all-cause admissions).
Trial-based cost-effectiveness analysis
Here we present the cost-effectiveness analysis undertaken alongside the REACH-HF RCT in patients
with HFrEF (see Work package 3: multicentre randomised controlled trial of the REACH-HF intervention in
patients with heart failure with reduced ejection fraction and Appendix 1) to estimate the cost-effectiveness
of the REACH-HF intervention plus usual care versus usual care alone over the 12 months of the trial.
Methods
Setting and perspective
The setting is the English health-care system and the perspective is that of the English NHS and
Personal Social Services.
Target population and subgroups
Adult patients with confirmed HFrEF were enrolled (n = 216) and those who completed all elements of
data collection for resource use and HRQoL at all follow-up points, including the last at 12 months, formed
the participant group for the base-case analysis. The trial protocol specified subgroup-level analyses by
trial centre, severity of HF (defined by NT-proBNP levels < 2000 vs. ≥ 2000 pg/ml), time since diagnosis of
HF (< 1 year, 1–2 years or ≥ 2 years) and whether or not the patient had a participating carer.
Intervention cost
The REACH-HF intervention is a nurse-facilitated, home-based CR programme designed to enhance
quality of life and self-care of people with HF and their caregivers. The intervention is described in
full in Work package 1: intervention development and feasibility study. The REACH-HF intervention was
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delivered over 12 weeks. The trial methods, including economic analysis, were set out in the published
trial protocol.38 Resource use associated with delivery of the REACH-HF intervention was informed
by early development research, with the primary item of resource use being the time input of the
HF facilitator who delivered the intervention. Other resource use comprises consumables and some
allowance for training of the HF facilitators. Data on each of these areas of resource use were
collected within trial, with HF facilitator time input collected using a ‘facilitator contact sheet’ (see
Report Supplementary Material 5) capturing contact time with participants and also non-contact time
(e.g. planning and preparation) related to delivery of the intervention.
Unit costs for facilitation staff were based on the grade equivalent to ‘community nurse’ (including
district nursing sister and district nurse) and nurse specialist (community) from Unit Costs of Health and
Social Care for 2016.90 These are based on Agenda for Change band 6, including salary, salary on-costs,
overheads (management costs and non-staff costs including travel/transport) capital overheads and
excluding costs for qualifications.
Training costs per facilitator, specific to delivery of the REACH-HF intervention, were estimated based
on resource use data collected within trial by the trial co-ordinator.
Consumables costs (manuals and DVDs) were based on resource use data collected within trial by the
trial co-ordinator.
Health, social care and other resource use and cost
Data on resource use related to health and social care were collected using a standardised resource
use questionnaire (RUQ) (see Report Supplementary Material 6) at baseline (referring to the previous
6 months), at 4 months (referring to the 4 months since the trial started) and at 12 months (referring
to the 8 months since the last assessment). The RUQ was developed and tested in early development
research on REACH-HF. Data from assessments at 4 and 12 months were combined to calculate
the total resource use during the 12 months of follow-up. Although resource use data for hospital
admissions were collected in the self-reported RUQ, data on hospital admissions were reconciled
against SAE reporting (with SAE reporting being the primary data source). Data on SAEs were used as
the primary source of data on hospital admissions. In addition, the RUQ captured wider societal costs,
including time off work for participants and caregivers, and unpaid caring activities carried out by the
participant’s main caregiver and by other people.
Costs are reported in 2016 GBP. Unit costs per item of resource use (Table 7) were obtained from
published estimates and, where necessary, inflated to 2016 prices using the Healthcare and Community
Health Services index (see Report Supplementary Material 1).90 These unit costs were then applied to the
resource use reported at participant level to estimate the delivery costs associated with the REACH-HF
intervention and the total costs associated with health and social care at baseline and over the 12 months
of follow-up.
Note that the unit cost of a hospital admission represents the expected cost (published cost) of a
typical HF or non-HF hospital admission in patients with HF (see Table 7) rather than the specific cost
of the hospital admission events experienced by patients in the trial, as reported in SAEs. However,
where mean length of stay in the trial was longer than that reported in the NHS reference cost item
for hospital admission (HF related and non-HF), extra costs for additional bed-days were applied. For
non-HF hospital admissions, we used data reported on type of non-HF hospital admission for people
with HF in a large HF RCT and cost data from NHS reference costs103 to estimate a weighted cost for
non-HF hospital admissions (see Table 7 and Report Supplementary Material 1).
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
78
TABLE 7 Unit costs for health, social care and other resource use
Resource use item/category
Unit cost
(2016 GBP) Basis of calculation
Primary care appointment/visit
GP (surgery) 31.0090 9.22-minute (average length) appointment
GP (home) 74.98101 11.4-minute home visit plus travel time
GP (telephone) 22.29101 7.1-minute telephone appointment
Practice nurse (surgery) 11.1190,101 15.5-minute surgery contact at £43/hour
Practice nurse (home) 18.8090,101,102 25-minute home visit at £43/hour + travel cost
Practice nurse (telephone) 4.3090,101 6-minute telephone consultation (nurse advanced) at £43/hour
HF nurse 22.1190 15.5-minute surgery/25-minute home appointment at £44/hour
(AfC band 6) + travel
Physiotherapist 77.5290,102 Community physiotherapist with hourly cost of £47.92
Estimated 83% home and 17% clinic appointments at 60 and
30 minutes, respectively, + travel
Occupational therapist 75.1090,102 Community occupational therapist with hourly cost of £46.42
Estimated 83% home and 17% clinic appointments at 60 and
30 minutes, respectively
Community/district nurse 39.5190,102 Community nurse with hourly cost of £46.14 and 20-minute
appointments + travel
Health visitor 27.22101,102 20-minute visit at (£76/hour of patient-related work + travel)
Secondary care
Hospital admission (HF) 3805.00103 Weighted average cost of a single spell for HRGs (EB03A-D)
Hospital admission (non-HF) 2208.00103,104 Using breakdown of rate of admission by type from EMPHASIS HF
trial and weighted mean cost of a hospital spell for that category
from the national schedule of reference costs 2015/16
Hospital admission (all cause) 2510.95 Weighted all-cause cost based on 18.97% of (followed up)
admissions in REACH-HF being HF-related
A&E attendance 137.82103 Mean cost across all A&E attendances excluding dentistry
Day hospital attendance 319.33103 Based on the weighted average cost of hospital day cases for HF
Outpatient cardiology 135.68103 Unit cost of cardiology outpatient attendance (consultant led)
Outpatient cardiac or HF nurse 102.96103 Unit cost of cardiology outpatient attendance (non-consultant led)
Other outpatient contact 116.54103 Unit cost of a non-cardiology outpatient attendance (consultant and
non-consultant led)
CR classes 477.00105 Based on tariff from national tariff payment system 2017–18 and
2018–19 for rehabilitation post discharge where provider provides
both acute and community care
Social and community care visits
Social worker 79.0090 60-minute appointment at £79/hour of client-related work
Home care/home help 12.0090 30-minute visit at £24/hour (weekday) for face-to-face social
service-provided home care
Voluntary agency 10.0090 30-minute visit at £24/hour (weekday) for face-to-face independent
sector-provided home care
Day care 46.0090 £46 per client session lasting 3.5 hours
continued
DOI: 10.3310/pgfar09010 Programme Grants for Applied Research 2021 Vol. 9 No. 1
Copyright © 2021 Dalal et al. This work was produced by Dalal et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social
Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution,
reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/. For attribution the
title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
79
Medication costs were estimated using data from the RUQ on self-report use (yes/no response) of key
medication types (e.g. beta-blockers, ACE inhibitors and calcium channel blockers) and recommended
dosage and medication costs reported in the British National Formulary (2016–17). We used recommend
dosage or we applied half of the maximum dose where dose uptitration was relevant. Unit costs were
those for generic products, where available; when multiple products were available in a single category
(e.g. ACE inhibitors), we used a weighted cost based on prescribing information available from
OpenPrescribing (2017),109 assuming that prescribing patterns reported were relevant for HF.
Where we have put a monetary value on informal care in sensitivity analyses, we used a replacement
cost approach and assumed that the value of an hour of informal care was the same as the cost of an
hour of care provided by social care/social services (£24 per hour; see Table 7).
TABLE 7 Unit costs for health, social care and other resource use (continued )
Resource use item/category
Unit cost
(2016 GBP) Basis of calculation
Drop-in club 13.0090 1-hour attendance at day care cost of £13/hour




30.24106,107 Drug costs taken from BNF 2017108 assuming recommended dosage,
or where dose up-titration was recommended assuming half the
maximum dose. Generics used where available, and where multiple
products fell within a single average cost was estimated by
weighting based on usage data from OpenPrescribing,109 assuming













Caregiver hours per week 24.0090 Cost per hour of face-to-face home care worker time (weekday
daytime) provided to private purchasers
Non-caregiver hours per week 24.0090 Cost per hour of face-to-face home care worker time (weekday
daytime) provided to private purchasers
Caregiver days off work 122.31110 Mean income for all ages/sexes at £31,800 per annum, assuming
260 working days per year
Non-caregiver days off work 122.31110 Mean income for all ages/sexes at £31,800 per annum, assuming
260 working days per year
Patient days off work 66.35110 Mean participant age was 71 years, mean income in this age group
before tax was £25,000. Assumed 260 working days per year.
Multiplied by 69%, the average %FTE reported by trial participants
A&E, accident and emergency; AfC, Agenda for Change; BNF, British National Formulary; EMPHASIS-HF, Eplerenone
in Mild Patients Hospitalization and Survival Study in Heart Failure; FTE, full-time employment; HRG, Healthcare
Resource Group.
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Health-related quality of life
Data on HRQoL were collected by self-report for both the participants and their caregivers using the
EQ-5D-5L health questionnaire, and health state values were derived using the mapping/crosswalk
values for the UK to provide EQ-5D-3L values from EQ-5D-5L states. This is the method currently
recommended by NICE for assessment of EQ-5D/QALYs in economic evaluation.31 Estimates of QALYs
for the 12 months of the trial were calculated using EQ-5D-5L data at baseline and at 4, 6 and 12 months,
using the area under the curve method.
The primary economic end point was the QALY (derived from EQ-5D-5L) estimated over the 12 months
of follow-up. The primary perspective taken here for analyses is that of the NHS and social care sector
(third-party payer), although data collection on resource use provides an opportunity to consider wider
participant level and societal impacts.
Cost-effectiveness
The trial-based analysis assessed the cost-effectiveness of the REACH-HF intervention plus usual care
compared with usual care alone over the 12 months of the trial. No discounting of future costs or
outcomes was required. Primary analyses were based on intention-to-treat complete-case analyses,
consistent with the trial main statistical analysis plan (see the statistical analysis plan, which is available
here: www.journalslibrary.nihr.ac.uk/programmes/pgfar/rp-pg-1210-12004/#/documentation; accessed
December 2020).
We used statistical analyses to estimate between-group differences in estimated costs and QALYs.
Generalised linear modelling regression models (with appropriate family and link functions) were used
with adjustment for baseline values and prespecified covariates (see the statistical analysis plan, which is
available here: www.journalslibrary.nihr.ac.uk/programmes/pgfar/rp-pg-1210-12004/#/documentation;
accessed December 2020). Given the expected nature of cost data, non-parametric bootstrap methods
were used to estimate CIs. Bootstrapping was used to resample (with replacement) 1000 times (i.e.
simulating 1000 trials) from the empirical trial data, providing estimates of uncertainty around the
modelled estimates of incremental cost, incremental effect and ICER. We produced a cost-effectiveness
acceptability curve, plotting expectation of the REACH-HF intervention being cost-effective compared
with usual care at a range of estimates of WTP per QALY gained. In the UK, using NICE guidance, if the
cost of an intervention is below £20,000 to £30,000 per QALY gained it is considered value for money
for the NHS.
In addition to the primary (complete-case) analysis, the following sensitivity analyses were carried out:
l per protocol [see the statistical analysis plan, URL: www.journalslibrary.nihr.ac.uk/programmes/
pgfar/rp-pg-1210-12004/#/documentation (accessed January 2021)]
l using multiple imputation of missing values for aggregate costs
l by subgroups:
¢ time since HF diagnosis (< 1 year, 1–2 years or ≥ 2 years)
¢ severity of HF (BNP levels < 2000 vs. ≥ 2000 pg/ml)
¢ trial centre
¢ whether or not the patient had a participating carer
l including caregiver QALYs
l considering a wider societal perspective (including informal care and time off work costs)
l including intervention cost variation, based on estimated range of intervention cost.
A multiple imputation by chained equations approach was used, with predictive mean matching owing
to the constrained (non-zero) nature of the cost data.
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In addition to the above sensitivity analyses, we present a ‘post hoc’ sensitivity analysis, in which the
EQ-5D-5L health state values and related QALY estimates are based on use of a ‘mapping’ algorithm
to predict EQ-5D health state values from participant data on the MLHFQ. In this sensitivity analysis,
estimates for the difference in EQ-5D/QALY were not derived from the directly collected/measured
EQ-5D-5L scores (health status) but from the MLHFQ scores in the RCT using an unpublished mapping
algorithm previously developed by Edlin et al. obtained via personal communication (Edlin R, Tsuchiya A,
Brazier J. Mapping the Minnesota Living with Heart Failure Questionnaire to the EQ-5D index; 2002.
Reproduced with permission from Brazier J, personal communication, 2018). This post hoc analysis was
requested by the REACH-HF Trial Steering Committee.
Results
Intervention cost
Facilitator contact sheets were completed and available for 613 contacts in 94 intervention group
participants who received the REACH-HF intervention. Table 8 reports the mean number of contacts




Contacts, mean (SD) [minimum, maximum]
Face-to-face contact 3.96 (1.2) [2, 7] 69.15 (28.4) [8, 170] 35.96 (34.1) [5, 200]
Telephone contact 2.51 (2.37) [0, 9] 18.89 (9.06) [2, 50] 13.68 (12.8) [0, 100]
Total contact 6.52 (2.63) [3, 13]
Total time, mean (SD)
Face-to-face contact 271.45 (93.6)
Telephone contact 47.41 (49.6)
Planning/non-contact time, face to face 141.91 (89.9)
Planning/non-contact time, telephone 34.35 (42.2)
Overall total time input, mean (SD) [minimum,
maximum]a
495.13 (180) [175, 1190]
Costs (£)
aCost per hour90 44.00
Estimated total delivery cost (HF facilitator), mean (SD)a 362.93 (131.96)
Other resource use/costsb
Consumables (1 × HF Manual) 25.00
DVDs (two at £7.50 each) 15.00
Distribution of HF Facilitator training costs
per participantb
15.47
Estimated total delivery cost for the REACH-HF
intervention (mean, estimated 95% CIc)
418.39 (207.14 to 733.28)
a Excluding travel time, as allowance already in unit cost estimate.
b Distributed across the first 100 participants who received the intervention.
c Unit costs: staff grade equivalent to ‘community nurse’ (includes district nursing sister and district nurse) and nurse
specialist (community) from Unit Costs of Health and Social Care 2016;90 based on Agenda for Change band 6 (staff
salary at £32,114 per annum); includes salary, salary on-costs, overheads [management costs and non-staff costs
(including travel/transport)], capital overheads, and excludes costs for qualifications.
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by type (face to face or telephone) and mean duration of contacts and related non-contact activity.
The mean number of contacts was 6.52, and total contact time and non-contact time inputs were
5.3 hours (319 minutes) and 2.9 hours (176 minutes), respectively, with overall time input at 8.25 hours
(495 minutes). Using the unit cost of £44 per hour (based on a salary of £32,114 per annum90), the
estimated mean cost of facilitator input was £363. Training cost per facilitator, specific to delivery
of the REACH-HF intervention, was estimated at £1547 [3 days’ training at £352 per day; cost for
trainers per trainee at £366 (assuming eight trainees per 3-day course) and cost for REACH-HF
facilitator manuals at £50 each plus an estimate of consumables for training sessions]. These were
distributed across the first 100 participants who received the intervention to give mean costs
attributed to each participant of £15.47. The patient’s HF Manual was costed at £40, based on one
hard copy manual at £25 and two DVDs at £7.50 each. This gave a mean estimated total cost for
delivery of the REACH-HF intervention of £418.39 (95% CI £203.64 to £729.78) per participant.
Resource use
Resource use for primary and secondary care and social services is reported in Table 9. Use of
prescribed medications is reported in Table 10. Numbers of all-cause and HF hospital admissions and
length of stay are reported in Table 11. Informal care is summarised in Table 12.
Costs
NHS and Personal Social Services costs are reported by allocation in Table 13. Informal care costs are
reported in Table 14.
Health state values (EuroQol-5 Dimensions, five-level version) and quality-adjusted
life-years
Table 15 summarises the estimated mean health state values and QALY estimates, derived from
participant and caregiver reports for EQ-5D-5L health states (based on EQ-5D-3L values per tariff).
We report data for assessments at baseline and at 4 and 12 months.
Cost-effectiveness: primary analyses
Table 16 summarises the primary statistical analyses undertaken to estimate the mean differences in
costs (by cost category and for total cost) plus differences in participant QALYs between the REACH-HF
intervention and usual care groups. The table reports unadjusted and adjusted analyses, including
adjustment for baseline values and other covariates (trial centre, NT-proBNP group, previous MI
and previous AF).
Excluding the intervention cost for the REACH-HF intervention, we report a difference of £345 in total
costs for health and social care service use, with participants who used the REACH-HF intervention
having a higher cost than usual care, although this was not statistically significant. When including
the REACH-HF intervention cost in the analyses, we see an unadjusted difference in cost between the
REACH-HF intervention and usual care of £516, with this estimated cost difference increasing to £763,
higher cost for REACH-HF intervention participants, after adjustment.
Usual care had a better QALY profile than the REACH-HF intervention (i.e. a mean reduction of –0.024
QALYs in the REACH-HF intervention participants), but this difference was not statistically significant.
The REACH-HF intervention, with a higher expected mean cost and an absence of QALY gains, was
therefore dominated by usual care and did not seem to be a value-for-money investment for the NHS
in the UK in the short term.
When considering uncertainty using the bootstrapped data, Figure 7 illustrates the cost-effectiveness
plane, showing that the incremental cost and QALY data (pairs) from the bootstrapped simulations
are predominantly in the north-west quadrant, indicating additional costs and reduced QALYs.
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TABLE 9 Health and social care resource use by allocation at baseline and over the 12 months of the trial
Resource
Baseline (6 months) Follow-up (12 months)




visits per person n
Mean (SD) [range]
appointments/
visits per person n
Mean (SD) [range]
appointments/





GP (surgery) 106 2.89 (2.67) [0–12] 109 3.43 (3.46) [0–26] 84 3.73 (3.81) [0–18] 88 3.88 (3.53) [0–17]
GP (home) 107 0.09 (0.51) [0–4] 109 0.11 (0.66) [0–6] 84 0.10 (0.43) [0–3] 88 0.03 (0.18) [0–1]
GP (telephone) 107 0.59 (1.12) [0–6] 109 0.89 (1.74) [0–12] 84 0.94 (1.92) [0–11] 88 1.11 (2.05) [0–10]
Practice nurse (surgery) 106 2.70 (4.61) [0–36] 109 3.16 (4.99) [0–30] 83 6.92 (16.54) [0–144] 88 6.02 (9.21) [0–61]
Practice nurse (home) 107 0.01 (0.10) [0–1] 109 0.06 (0.58) [0–6] 83 0.04 (0.24) [0–2] 88 0.08 (0.48) [0–4]
Practice nurse (telephone) 107 0.07 (0.48) [0–4] 109 0.10 (0.59) [0–5] 84 0.27 (1.60) [0–14] 88 0.40 (1.33) [0–9]
HF nurse 107 1.26 (2.39) [0–14] 109 0.89 (1.57) [0–7] 84 1.10 (2.11) [0–12] 88 1.33 (2.91) [0–14]
Physiotherapist 107 0.20 (0.82) [0–6] 109 0.49 (2.51) [0–24] 84 0.39 (1.61) [0–12] 88 0.75 (3.56) [0–24]
Occupational therapist 107 0.01 (0.10) [0–1] 109 0.00 (0.00) [0–0] 84 0.01 (0.11) [0–1] 88 0.00 (0.00) [0–0]
Community/district nurse 107 0.34 (1.39) [0–9] 109 0.30 (2.23) [0–20] 84 0.14 (1.20) [0–11] 88 0.31 (1.88) [0–16]





































Baseline (6 months) Follow-up (12 months)




visits per person n
Mean (SD) [range]
appointments/
visits per person n
Mean (SD) [range]
appointments/





Hospital admission (all cause) 107 0.29 (0.50) [0–2] 109 0.40 (1.14) [0–10] 84 0.31 (0.84) [0–5] 88 0.35 (0.84) [0–6]
A&E attendance 107 0.16 (0.39) [0–2] 109 0.26 (0.55) [0–3] 84 0.19 (0.55) [0–4] 88 0.20 (0.63) [0–4]
Day hospital attendance 107 0.92 (7.54) [0–78] 109 0.28 (0.65) [0–4] 84 0.23 (0.59) [0–4] 88 0.34 (0.95) [0–6]
Outpatient cardiology 107 0.80 (0.87) [0–4] 109 0.88 (0.92) [0–4] 84 1.19 (1.29) [0–5] 88 0.85 (1.31) [0–7]
Outpatient cardiac or HF nurse 107 0.87 (1.35) [0–6] 109 0.68 (1.19) [0–6] 84 0.81 (1.26) [0–6] 88 0.77 (1.98) [0–16]
Other outpatient 107 0.37 (1.13) [0–8] 109 0.61 (1.42) [0–10] 84 0.89 (1.69) [0–9] 88 1.26 (3.66) [0–32]
CR classes NA NA NA NA 84 0.19 (0.40) [0–1] 88 0.03 (0.18) [0–1]
Social and community care visits
Social worker 107 0.03 (0.29) [0–3] 109 0.00 (0.00) [0–0] 84 0.02 (0.15) [0–1] 88 0.01 (0.11) [0–1]
Home care/home help 107 3.38 (24.49) [0–180] 109 3.67 (26.24) [0–208] 84 19.54 (93.37) [0–672] 88 3.86 (27.60) [0–240]
Day care 107 0.22 (2.32) [0–24] 108 0.00 (0.00) [0–0] 84 0.49 (4.36) [0–40] 88 0.00 (0.00) [0–0]
Drop-in club 107 0.07 (0.59) [0–6] 108 0.24 (2.50) [0–26] 84 0.00 (0.00) [0–0] 88 0.18 (1.71) [0–16]
Other-day-care service 107 0.00 (0.00) [0–0] 109 0.00 (0.00) [0–0] 84 0.01 (0.11) [0–1] 88 0.13 (0.91) [0–8]
Other
Voluntary agency 107 0.00 (0.00) [0–0] 109 0.24 (2.49) [0–26] 84 0.02 (0.15) [0–1] 88 0.01 (0.11) [0–1]












































































































































































































































































































































































Figure 8 reports the cost-effectiveness acceptability curve, indicating that the REACH-HF intervention
is expected to be cost-effective versus usual care only in a small number of trials/simulations (< 10%)
regardless of the WTP threshold (per QALY gained) applied.
Cost-effectiveness: sensitivity analyses
Table 17 presents summary statistics for the sensitivity/scenario analyses undertaken to assess the
sensitivity of the primary base-case result to alternative assumptions/scenarios.
In all scenarios, except the MLHFQ–EQ-5D mapping scenario, the REACH-HF intervention remains
dominated by usual care, with no reported QALY gains associated with the REACH-HF intervention.
Where we present analysis with EQ-5D values and QALYs derived from the indirect, participant-level
MLHFQ mapping algorithm, we report a statistically significant difference in mean estimated QALYs of
0.026 (95% CI 0.005 to 0.047), favouring the intervention. When this approach is used alongside the
TABLE 10 Prescription medication use by allocation at baseline and over the 12 months of the trial
Drug
Baseline (6 months) Follow-up (12 months)












107 0.29 (0.46) 109 0.22 (0.42) 84 0.29 (0.44) 88 0.23 (0.41)
ACE inhibitor 107 0.64 (0.48) 109 0.68 (0.47) 84 0.62 (0.47) 88 0.66 (0.45)
MRA 107 0.60 (0.49) 109 0.48 (0.50) 84 0.61 (0.47) 88 0.52 (0.49)
Anticoagulant 107 0.47 (0.50) 109 0.50 (0.50) 84 0.44 (0.48) 88 0.53 (0.49)
Beta-blocker 107 0.84 (0.37) 109 0.83 (0.38) 84 0.85 (0.34) 88 0.81 (0.38)
Digoxin 107 0.19 (0.39) 109 0.13 (0.34) 84 0.16 (0.36) 88 0.16 (0.36)
Ivabradine 107 0.04 (0.19) 109 0.06 (0.25) 84 0.04 (0.19) 88 0.06 (0.22)
Loop diuretic 107 0.65 (0.48) 109 0.62 (0.49) 84 0.62 (0.47) 88 0.59 (0.49)
Nitrate 107 0.11 (0.32) 109 0.14 (0.35) 84 0.10 (0.27) 88 0.12 (0.31)
Thiazide diuretic 107 0.00 (0.00) 109 0.02 (0.13) 84 0.02 (0.10) 88 0.01 (0.11)
MRA, mineralocorticoid (aldosterone) receptor antagonist.
TABLE 11 Hospital admissions at baseline and over the 12 months of the trial, with length of stay and by treatment group
Baselinea (6 months) Follow-upb (12 monthsc)
REACH-HF Usual care Total REACH-HF Usual care Total
Admissions (all cause) 31 44 75 26 31 57
Days per admission 6.5 3.1 4.5 3.2 6.2 4.8
Admissions due to HF NA NA NA 2 9 11
NA, not applicable.
a Self-report data (RUQ).
b Based on SAE protocol and data.
c Note that these data reflect complete-case participants only; excludes data on participants who died/were lost to
follow-up.
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TABLE 12 Resource use for informal care and time of work reported, by treatment group at baseline and over 12 months’ follow-up
Baseline (6 months) Follow-up (12 months)


















Caregiver 106 (37) 4.11 (9.63) [0–50] 108 (30) 6.07 (17.19) [0–98] 83 (35) 6.10 (16.72) [0–114] 87 (23) 6.89 (19.70) [0–99]
Non-caregiver 106 (27) 1.68 (4.58) [0–25] 109 (31) 2.32 (6.33) [0–35] 84 (33) 2.25 (4.72) [0–28] 88 (28) 2.21 (6.41) [0–35]
Days off work
Caregiver 107 (8) 0.85 (5.11) [0–50] 109 (3) 0.06 (0.39) [0–3] 84 (4) 1.19 (10.47) [0–96] 87 (1) 0.02 (0.21) [0–2]
Non-caregiver 107 (7) 0.39 (2.44) [0–21] 109 (4) 0.24 (1.49) [0–14] 84 (4) 0.15 (0.92) [0–8] 88 (2) 0.13 (0.98) [0–9]












































































































































































































































































































































































TABLE 13 Health and social care costs by allocation during the 6 months prior to the trial and the 12 months of the trial
Resource
Baseline (6 months) Follow-up (12 months)
REACH-HF Usual care REACH-HF Usual care
n Mean (SD) cost/person (£) n Mean (SD) cost/person (£) n Mean (SD) cost/person (£) n Mean (SD) cost/person (£)
Primary care appointment/visit
GP (surgery) 106 89.49 (82.67) 109 106.37 (107.25) 84 115.51 (118.10) 88 120.13 (109.31)
GP (home) 107 7.01 (37.89) 109 8.26 (49.30) 84 7.14 (32.13) 88 2.56 (13.68)
GP (telephone) 107 13.13 (25.06) 109 19.84 (38.89) 84 20.97 (42.85) 88 24.83 (45.78)
Practice nurse (surgery) 106 29.97 (51.17) 109 35.06 (55.44) 83 76.82 (183.75) 88 66.90 (102.35)
Practice nurse (home) 107 0.18 (1.82) 109 1.21 (10.94) 83 0.68 (4.59) 88 1.50 (9.11)
Practice nurse (telephone) 107 0.28 (2.07) 109 0.43 (2.55) 84 1.18 (6.88) 88 1.71 (5.70)
HF nurse 107 27.90 (52.82) 109 19.68 (34.75) 84 24.22 (46.77) 88 29.40 (64.39)
Physiotherapist 107 15.21 (63.39) 109 37.69 (194.40) 84 30.45 (125.06) 88 58.14 (275.94)
Occupational therapist 107 0.70 (7.26) 109 0 84 0.89 (8.19) 88 0
Community/district nurse 107 13.29 (54.79) 109 11.96 (87.93) 84 5.64 (47.56) 88 12.12 (74.18)
Health visitor 107 0 109 0 84 0 88 0
Primary care total 105 193.42 (183.89) 109 240.49 (351.91) 83 284.24 (316.82) 88 317.28 (380.86)
Secondary care
Hospital admission (all cause) 107 727 (1244) 109 1014 (2861) 84 777 (2098) 88 885 (2121)
A&E attendance 107 22 (54) 109 35 (76) 84 26 (76) 88 28 (87)
Day hospital attendance 107 292 (2407) 109 88 (208) 84 72 (188) 88 109 (302)
Outpatient cardiology 107 109 (119) 109 119 (125) 84 162 (176) 88 116 (178)
Outpatient cardiac or HF nurse 107 89 (139) 109 70 (122) 84 83 (129) 88 80 (204)
Other outpatient 107 44 (132) 109 71 (166) 84 104 (197) 88 147 (427)
CR classes – – – – 84 85.90 (178.16) 88 15.37 (82.31)





































Baseline (6 months) Follow-up (12 months)
REACH-HF Usual care REACH-HF Usual care
n Mean (SD) cost/person (£) n Mean (SD) cost/person (£) n Mean (SD) cost/person (£) n Mean (SD) cost/person (£)
Social and community care visits
Social worker 107 2.21 (22.91) 109 0 84 1.88 (12.12) 88 0.90 (8.42)
Home care/home help 107 40.60 (293.89) 109 44.04 (314.83) 84 234.43 (1120.40) 88 46.36 (331.23)
Day care 107 10.32 (106.73) 108 0 84 22.45 (200.76) 88 0.00 (0.00)
Drop-in club 107 0.85 (7.63) 108 3.13 (32.52) 84 0 88 2.36 (22.17)
Other day-care service 107 0 109 0 84 0.55 (5.02) 88 5.75 (41.74)
Social care total 107 53.98 (326.86) 108 47.57 (341.43) 84 259.31 (1136.89) 88 55.58 (379.20)
Other
Voluntary agency 107 0 109 0.24 (2.49) [0–26] 84 0.02 (0.15) [0–1] 88 0.01 (0.11) [0–1]
All health and social care visits total 105 1552 (3032) 108 1702 (3023) 83 1860 (2619) 88 1751 (2554)
Medications
Angiotensin II receptor antagonist 107 4.38 (6.89) 109 3.33 (6.29) 84 8.76 (13.35) 88 6.99 (12.54)
ACE inhibitor 107 4.39 (3.34) 109 4.68 (3.24) 84 8.54 (6.51) 88 9.15 (6.22)
Aldosterone receptor antagonist 107 37.72 (31.06) 109 30.08 (31.64) 84 76.57 (58.79) 88 64.97 (61.77)
Anticoagulant 107 3.90 (4.18) 109 4.21 (4.19) 84 7.41 (8.02) 88 8.78 (8.20)
Beta-blocker 107 5.15 (2.25) 109 5.05 (2.33) 84 10.44 (4.22) 88 9.97 (4.71)
Digoxin 107 3.36 (7.05) 109 2.31 (6.05) 84 5.86 (12.97) 88 5.59 (12.99)
Ivabradine 107 9.65 (49.22) 109 16.58 (63.60) 84 18.45 (96.42) 88 29.35 (114.44)
Loop diuretic 107 5.22 (3.81) 109 4.98 (3.88) 84 9.82 (7.45) 88 9.43 (7.77)
Nitrate 107 31.10 (87.92) 109 38.16 (95.98) 84 57.22 (149.06) 88 69.33 (171.23)
Thiazide diuretic 107 0 109 0.18 (1.29) 84 0.30 (1.96) 88 0.22 (2.05)
All medications total 107 104.87 (107.78) 109 109.57 (120.58) 84 203.38 (183.43) 88 213.77 (208.42)
All health and social care total 105 1763 (3048) 108 1917 (3087) 83 2064 (2636) 88 1966 (2585)












































































































































































































































































































































































TABLE 14 Informal care costs at baseline and over 12 months’ follow-up
Baseline (6 months) Follow-up (12 months)

















Caregiver hours per week 106 (37) 98.72 (231.23) 108 (30) 145.78 (412.63) 83 (35) 146.51 (401.37) 87 (23) 165.24 (472.87)
Non-caregiver hours per week 106 (27) 40.30 (109.93) 109 (31) 55.71 (151.89) 84 (33) 54.10 (113.35) 88 (28) 53.00 (153.84)
Total caring hours per week 139 202 201 217
Total caring hours per 6 months 3601 5252 10,465 11,285
Caregiver days off work 107 (8) 104.02 (624.96) 109 (3) 7.85 (47.88) 84 (4) 145.60 (1280.87) 87 (1) 2.81 (26.23)
Non-caregiver days off work 107 (7) 48.01 (298.53) 109 (4) 29.17 (182.25) 84 (4) 18.93 (113.11) 88 (2) 15.29 (119.91)
Total caregiver days off work 152 37 165 18
Patient days off work 107 (13) 310.65 (1459.52) 109 (8) 300.69 (1512.37) 84 (8) 241.69 (1036.65) 88 (4) 271.42 (2141.55)
Patients in FTE (%) 81 84 69 110





































TABLE 15 Health state values and estimated 12-month QALYs per person based on EQ-5D-3L values translated from
EQ-5D-5L using published crosswalk approach
EQ-5D-3L health state value
REACH-HF Usual care
n Mean (SD) [range] n Mean (SD) [range]
Participants
Baselinea 106 0.74 (0.23) [–0.26–1.00] 108 0.72 (0.24) [0.06–1.00]
Month 4 95 0.76 (0.22) [–0.07–1.00] 101 0.75 (0.22) [0.16–1.00]
Month 6 88 0.71 (0.27) [–0.43–1.00] 92 0.73 (0.22) [–0.21–1.00]
Month 12 88 0.75 (0.24) [–0.10–1.00] 92 0.74 (0.26) [–0.31–1.00]
Estimated 12-month QALYsb 81 0.74 (0.22) [–0.04–1.00] 84 0.76 (0.21) [–0.06–1.00]
Caregivers
Baseline 53 0.83 (0.19) [0.30–1.00] 44 0.80 (0.15) [0.55–1.00]
Month 4 46 0.85 (0.17) [0.35–1.00] 36 0.80 (0.20) [0.02–1.00]
Month 6 44 0.83 (0.15) [0.39–1.00] 36 0.78 (0.16) [0.40–1.00]
Month 12 42 0.83 (0.15) [0.42–1.00] 33 0.78 (0.19) [0.09–1.00]
Estimated 12-month QALYsb 41 0.84 (0.14) [0.40–1.00] 30 0.79 (0.16) [0.44–1.00]
a For complete-case participants, mean baseline EQ-5D-3L was 0.75 for both groups.
b Maximum value of 1 (full health) for 12-month QALY, complete cases only.
TABLE 16 Between-group differences in per-person costs and QALYs (treatment compared with control): unadjusted






(intervention – control)n Mean (SD) n Mean (SD)
Primary care (£) 83 284 (317) 88 317 (381) –33 –15.81 (–113.29 to 81.66)
Secondary care (£) 84 1311 (2265) 88 1379 (2390) –69 83.09 (–638.00 to 804.00)
Social and community
care (£)
84 259 (1137) 88 56 (379) 204 201.54 (–716.46 to 1119.54)




83 2064 (2636) 88 1966 (2585) 98 345 (–459 to 1150)
Intervention cost (£) 418.39 0 418
Total cost (£) 2482 1966 516 763
Participant QALYs
(EQ-5D-3L)
0.74 (0.22) 0.76 (0.21) –0.018 –0.024 (–0.059 to 0.010)
ICER (cost per QALY) REACH-HF intervention
‘dominated’ by usual care
(higher cost, no QALY benefit)
GLM, generalised linear modelling.
a Estimated using non-parametric bootstrap.
b Adjusted for baseline value, trial centre, NT-proBNP group, previous MI and previous AF using a GLM approach.
For cost data a log ‘link’ was used due to a strong positive skew in the data, and combined with a gamma ‘family’ to
provide the best-fitting model, based on comparison of deviance and Akaike’s information criterion.
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analysis of costs, with a mean incremental cost of £763, we have an incremental cost per QALY of
£29,346 for the REACH-HF intervention versus usual care. Figures 9 and 10 report the cost-effectiveness
plane and cost-effectiveness acceptability curve for this analysis, where, when using the net benefit
statistic approach, we see the probability that the REACH-HF intervention is cost-effective at WTP
threshold values of £20,000 per QALY and £30,000 per QALY, respectively, at 31.3% and 50.3%.
Discussion
We have reported the trial-based cost-effectiveness analysis of the REACH-HF intervention versus
usual care. We find health and social care costs to be similar over the 12 months of follow-up, with
no significant difference in adjusted analyses, and we find no difference in QALYs; however, we do
expect an additional cost associated with the intervention. The results suggest that the REACH-HF
intervention is dominated by usual care.
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FIGURE 7 Cost-effectiveness plane illustrating the results of 1000 bootstrap resamples of incremental cost and effectiveness
with the REACH-HF intervention compared with usual care. Blue circles reflect bootstrap resample estimates and the orange
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FIGURE 8 Cost-effectiveness acceptability curve showing probability that the REACH-HF intervention is cost-effective
(probability the net benefit statistic > 0) compared with usual care at each WTP threshold.
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TABLE 17 Summary of between-group differences over the 12 months of the trial; absolute mean differences and adjusted differences (for baseline QALY or cost, training centre,
NT-proBNP, previous MI and previous AF) for sensitivity/scenario analyses
Analysis
Mean (SD) values per participant











Social Services costsREACH-HF Usual care REACH-HF Usual care
Complete cases
(base case)
0.74 (0.22) 0.76 (0.21) 2064 (2636) 1966 (2585) –0.024 (–0.059 to 0.010) 345 (–459 to 1150) 418 763 Dominated
Per-protocol participants 0.74 (0.22) 0.76 (0.21) 2135 (2682) 1966 (2585) –0.025 (–0.060 to 0.011) 411 (–423 to 1245) 418 829 Dominated
Multiple imputationa 0.69 (0.23) 0.68 (0.23) 2267 (2591) 2126 (2461) –0.024 (–0.059 to 0.010) 187 (–606 to 981) 418 605 Dominated
Duration (years)
< 1 0.76 (0.23) 0.79 (0.19) 2879 (3465) 2323 (3432) –0.045 (–0.107 to 0.017) 1610 (–1359 to 4579) 418 2028 Dominated
1–2 0.71 (0.18) 0.79 (0.17) 1141 (3769) 1827 (2497) 0.000 (–0.080 to 0.079) 216 (–997 to 1430) 418 634 Dominated
> 2 0.73 (0.23) 0.72 (0.24) 1694 (2751) 1775 (1889) –0.021 (–0.073 to 0.030) –79 (–938 to 780) 418 339 Dominated
Severity
Low NT-proBNP 0.75 (0.22) 0.75 (0.23) 1751 (2736) 2035 (1878) –0.025 (–0.064 to 0.014) 257 (–545 to 1059) 418 675 Dominated
High NT-proBNP 0.68 (0.21) 0.79 (0.13) 3479 (4273) 2315 (2552) –0.033 (–0.130 to 0.065) 841 (–2878 to 4560) 418 1259 Dominated
Centre
1 0.79 (0.14) 0.77 (0.20) 2137 (3333) 3330 (1684) –0.026 (–0.085 to 0.033) 483 (–492 to 1458) 418 901 Dominated
2 0.65 (0.24) 0.71 (0.22) 2124 (1947) 1947 (1512) –0.014 (–0.079 to 0.051) 634 (–328 to 1597) 418 1052 Dominated
3 0.71 (0.25) 0.71 (0.16) 1506 (2215) 2046 (2471) –0.017 (–0.098 to 0.064) –283 (–2588 to 2023) 418 135 Dominated













































































































































































































































































































































































TABLE 17 Summary of between-group differences over the 12 months of the trial; absolute mean differences and adjusted differences (for baseline QALY or cost, training centre,
NT-proBNP, previous MI and previous AF) for sensitivity/scenario analyses (continued )
Analysis
Mean (SD) values per participant











Social Services costsREACH-HF Usual care REACH-HF Usual care
Caregiver
Participating 0.73 (0.24) 0.71 (0.24) 2106 (2417) 2417 (2083) –0.043 (–0.101 to 0.015) 339 (–666 to 1344) 418 757 Dominated
Not participating 0.76 (0.19) 0.78 (0.19) 2011 (2919) 1902 (2839) –0.003 (–0.043 to 0.038) 46 (–1202 to 1293) 418 464 Dominated
Including caregiver QALYs 1.57 (0.29) 1.50 (0.30) 2064 (2636) 1966 (2585) –0.012 (–0.108 to 0.084) 345 (–459 to 1150) 418 763 Dominated
Including informal
care costs
0.74 (0.22) 0.76 (0.21) 12,248 (22,197) 13,260 (26,131) –0.024 (–0.059 to 0.010) 6514 (–2012 to 15,040) 418 6932 Dominated
Including informal care and
time off work costs
0.74 (0.22) 0.76 (0.21) 12,588 (22,213) 13,517 (26,143) –0.024 (–0.059 to 0.010) 4894 (–4096 to 13,884) 418 4894 Dominated
Lower intervention cost 0.74 (0.22) 0.76 (0.21) 2064 (2636) 1966 (2585) –0.024 (–0.059 to 0.010) 345 (–459 to 1150) 204 549 Dominated
Higher intervention cost 0.74 (0.22) 0.76 (0.21) 2064 (2636) 1966 (2585) –0.024 (–0.059 to 0.010) 345 (–459 to 1150) 730 1075 Dominated
MLHFQ mapping to EQ-5Da 0.76 (0.12) 0.76 (0.14) 2064 (2636) 1966 (2585) 0.026 (0.005 to 0.047) 345 (–442 to 1133) 418 763 29,346
GLM, generalised linear modelling.




































A key strength of this analysis is that it is undertaken alongside the REACH-HF RCT and uses
effectiveness data and cost estimates derived from the RCT, which followed up patients over 12 months
from enrolment, with excellent retention (86%). However, despite the trial finding a statistically
significant and clinically meaningful difference in the primary outcome measure of disease-specific
HRQoL using the MLHFQ, the trial did not detect a significant change in EQ-5D, the generic HRQoL
measure currently recommended for use in the assessment of cost-effectiveness of health interventions
in the UK. Therefore, the short-term assessment of cost-effectiveness did not show the REACH-HF
intervention to be cost-effective compared with usual care.
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FIGURE 9 Cost-effectiveness plane showing 1000 bootstrapped resampled estimates of incremental cost and
incremental QALY change, in the scenario where QALYs were derived from mapping between MLHFQ and EQ-5D scores
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FIGURE 10 Cost-effectiveness acceptability curve showing the probability that REACH-HF is cost-effective over a range
of WTP thresholds, in the scenario where QALYs were derived from mapping between MLHFQ and EQ-5D scores using
the algorithm developed by Edlin et al. (personal communication, 2018).
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A limitation of the trial-based cost-effectiveness analysis is that it assesses cost-effectiveness in the
short term using HRQoL (EQ-5D, QALY) data from the RCT, and this may exclude longer-term benefits
such as slowing symptomatic progression, reducing hospital admissions and related mortality impacts.
In the broader literature, the cost-effectiveness of interventions for HF has been commonly assessed
using model-based analyses, considering longer-term (e.g. lifetime) costs and consequences. We
present this form of analysis in Work package 4: model-based cost-effectiveness analysis, with detailed
primary analyses described in a published paper (see Appendix 1)46 and additional analyses below.
Conclusions
The results from our cost-effectiveness analyses undertaken alongside the REACH-HF RCT suggest
that the REACH-HF intervention is not cost-effective versus usual care.
Model-based cost-effectiveness analyses
Introduction
The model-based cost-effectiveness analysis is described in full in a published paper46 (see Appendix 1).
This section sets out additional detail not included in that manuscript, which includes:
l Review of modelling studies in HF – details of the review of cost-effectiveness modelling studies in
HF that informed the development of the model.
l Model-based cost-effectiveness analysis based on all-cause hospital admissions – here, in a form of
sensitivity analysis (structural uncertainty), we examined the effect of changing the mechanism of
intervention effect from impact on HF-related hospital admissions to all-cause hospital admissions.
The HF-specific hospital admissions were used as the base-case analysis, because it was considered
most likely that the intervention would affect HF-related hospital admissions (based on literature
review and stakeholder input) and limiting the effect to these hospital admissions only was a
conservative assumption. However, we also considered scenarios in which a rehabilitation intervention
is shown to be effective on ‘all-cause’ hospital admissions, given that the intervention has a potential
impact on a range of hospital admissions (e.g. other types of cardiac admissions or admissions for
associated symptoms or comorbidities that are worsened by HF).
l Model-based cost-effectiveness analysis of centre-based CR versus usual care – centre-based
rehabilitation, although not available to all patients owing to geographical and transport limitations,
is the main form currently available to patients with HF in the UK but is accessed only by < 10% of
patients with HF. The cost-effectiveness of centre-based CR compared with usual care (which is
assumed to include no CR) was an important context for the cost-effectiveness analysis. This was
assessed based on the impact of the intervention on HF-related hospital admissions as the base
case and all-cause hospital admissions as a sensitivity analysis.
Review of cost-effectiveness modelling studies in heart failure
To inform the modelling approach, a systematic review of the literature on HF economic modelling
was performed. A previous review published in 2011 was identified.111 A systematic search was,
therefore, carried out in MEDLINE, EMBASE, the Cochrane Library, EconLit and CINAHL (Cumulative
Index to Nursing and Allied Health Literature) databases for cost-effectiveness studies of HF covering
the period from 2010 to September 2016. Search terms included those related to HF, as well as costs,
economics, cost-effectiveness or decision modelling. Full search details are reported in Report
Supplementary Material 1.
Studies available in full text and in English were included. Automatic and manual deduplication was
performed, and titles and abstracts were screened for inclusion. Inclusion criteria were studies reporting
on the use of a decision-analytic or mathematical model of costs and consequences associated with HF
treatment or management over time. This included Markov, decision tree and discrete event simulation
models, as well as those based on sets of mathematical equations. Studies were excluded if they did
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not include a model, were not specific to HF (this included studies that reported a model of a related
cardiovascular condition where, for example, HF comprised just one state in a larger model), reported
on only the short-term cost-effectiveness alongside a clinical trial or study, were animal studies or were
specific to HF prevention as opposed to treatment.
Review of literature
Through the searches, 6393 studies were identified. A total of 890 were duplicates and were removed,
and 2010 were removed as they had been published prior to the end date of the previous systematic
review. This left 3493 studies, of which 3350 were removed at the abstract screening stage because
they did not include a health-care evaluation model (n = 2434), were not carried out on those with
HF (n = 815), reported only short-term cost-effectiveness alongside a clinical trial (n = 63), were
animal studies (n = 21) or were about HF prevention and not treatment (n = 17). Sixty-seven
studies were then excluded because they were not available in full text in the English language
(e.g. conference abstracts).
The remaining 76 full-text papers were reviewed and 24 were excluded because they did not meet
inclusion criteria (no model, 14 papers) or were systematic reviews of modelling studies (10 papers),
which left 52 papers. Of these, 50 described a unique economic model or assessment associated
(two were additional reports from existing studies).
The results of the literature search are illustrated in Figure 11.
Identified and screened
(n = 3493)












or in other languages
(n = 67)
Excluded on abstract: did not
meet inclusion criteria
(n = 3350)
FIGURE 11 Results of the literature search.
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Summary of the review of heart failure modelling literature
The review identified a range of studies with varying decision contexts, modelling approaches, model
structures, settings and parameters. In terms of model types, the reviewed models most commonly
used Markov cohort models. Models for pharmaceutical or service-level interventions (as opposed to
those for surgical devices, which tended to include a broader range of states) tended to use one of
three main approaches: using a simple model with two basic disease states, alive (with HF) and dead,
an alive/dead model plus additional states for one or more hospital admission, or modelling disease
progression via NYHA class. Thokala et al.112 included hospital admission (for HF and other causes) and
additionally adjusted mortality for the time from hospital discharge to reflect the increased risk of
death soon after discharge. Some models allowed both for progression in the underlying condition,
based on NYHA grades, and for hospital admission, but this was less common. For example, Kansal
et al.113 reported a Markov cohort model with NYHA progression, as well as additional hospital
admission states for both HF and other-cause hospital admissions for up to three events, allowing
utility to decline with multiple hospital admissions. Two studies used an adaptation of a Markov cohort
approach but modelled specific patient subgroups separately using relevant risk equations allowing
for differences in treatment effect, disease progression, cost or mortality within different subgroups.
Alternative approaches were used by some authors – for example, seven studies reported a discrete
event simulation approach following individual simulated patients based on time-to-event data.
Model-based cost-effectiveness analysis based on all-cause hospital admissions
The primary analyses (see Appendix 1) are based on effectiveness estimates for changes in HF-related
hospital admissions (Table 18). Here, in an additional scenario analysis, we examine the effect of changing
the basis of intervention effectiveness from impact on HF-related hospital admissions to all-cause hospital
admissions.
The cost for all-cause hospital admissions was based on the cost of HF-related hospital admissions
and other-cause hospital admissions, weighted by the proportion of HF-related and other hospital
admissions observed in the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart
Failure (EMPHASIS) trial.104
The results (Table 19) suggest that home-based rehabilitation would dominate usual care, with the
home-based CR resulting in cost savings (–£236 vs. usual care) because of a reduction in hospital
admissions and a similar profile on health outcomes (QALYs), with no difference reported in incremental
QALYs. The results suggest that REACH-HF would dominate usual care if the intervention effect was to
reduce all-cause hospital admissions. The REACH-HF intervention was estimated to be cost saving at a
level of £506 per person, with no difference in incremental QALYs.
Model-based cost-effectiveness analysis of centre-based cardiac rehabilitation versus usual care
The cost-effectiveness of centre-based CR provides important context to the analysis of the cost-
effectiveness of home-based CR in the UK. Effectiveness estimates for centre-based CR on HF-related
hospital admissions were drawn from the recent Cochrane systematic review and meta-analysis (Table 20).1
The results of the cost-effectiveness analysis indicate that centre-based CR is cost-effective versus
usual care, with a mean QALY gain of 0.46, a mean incremental cost of £656, and an incremental cost
TABLE 18 Effectiveness evidence modelled (effect on all-cause hospital admissions)
Intervention
Odds ratio
(vs. usual care) 95% confidence interval Source
Home-based CR 0.79 0.54 to 1.16 Cochrane review and meta-analysis1
REACH-HF intervention 0.72 0.35 to 1.51 REACH-HF trial (see Work package 3:
patient outcomes)
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per QALY of £8828. The mean health gains are much higher than seen for home-based CR versus
usual care (0.20) and REACH-HF versus usual care (0.30), but all interventions are predicted to be
cost-effective versus usual care.
The results of the sensitivity analysis indicate that centre-based CR dominates usual care, with no
change in QALYs but a mean incremental cost reduction of £528 when all-cause hospital admissions
were the intervention effect (Table 21). Similar to home-based CR and the REACH-HF intervention,
when modelled with all-cause hospital admissions (and, therefore, no mortality effect), there were no
QALY gains, but cost savings with centre-based CR were similar to those achieved with the REACH-HF
intervention (£523) and greater than those achieved with home-based CR (£247).
Overall conclusions of the cost-effectiveness analysis
Trial-based cost-effectiveness analyses, using shorter-term outcomes on HRQoL, indicated that the
REACH-HF intervention was not cost-effective when compared with usual care. However, when using
model-based analyses, with evidence synthesis, to estimate longer-term costs and outcomes based
on effectiveness data suggesting a reduction in hospital admissions, the cost-effectiveness analyses
indicate that both the REACH-HF intervention and home-based CR more generally are likely to
be cost-effective when compared with usual care. Sensitivity analyses, against uncertainty in input
parameters (data inputs) and structural uncertainty, suggest that the findings that interventions are
cost-effective when compared with usual care are robust to changes in assumptions used and to
uncertainty in data inputs.
TABLE 20 Effectiveness evidence used in the model
Intervention Odds ratio (vs. usual care) 95% confidence interval Source
Centre-based CR 0.36 for HF admissions 0.18 to 0.73 Cochrane review and meta-analysis1
Centre-based CR 0.60 for all-cause admissions 0.40 to 0.90 Cochrane review and meta-analysis1
TABLE 19 Results of cost-effectiveness analysis comparing home-based CR and REACH-HF intervention to usual care
using the RR of all-cause hospital admissions
Usual care Intervention
Home-based CR based on all-cause hospitalisation rate
Discounted costs (£) 12,082 11,846
Discounted QALYs 4.06 4.06
Incremental costs (£) –236
Incremental QALYs 0.00
Cost/QALY gain (£) Dominating
REACH-HF based on all-cause hospitalisation rate
Discounted costs (£) 12,082 11,576
Discounted QALYs 4.06 4.06
Incremental costs (£) –£506
Incremental QALYs 0.00
Cost/QALY gain (£) Dominating
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TABLE 21 Cost-effectiveness analysis comparing centre-based CR to usual care using HF-specific hospital admissions
and all-cause hospital admissions
Centre-based CR Usual care (mean) Intervention (mean)
Based on HF-specific hospitalisation rate
Discounted costs (£) 15,119 15,418
Discounted QALYs 4.26 4.71
Incremental costs (£) 656
Incremental QALYs 0.46
Cost/QALY gain (£) 8828
Based on all-cause hospitalisation rate
Discounted costs (£) 14,101 13,573
Discounted QALYs 4.06 4.06
Incremental costs (£) –528
Incremental QALYs 0.00
Cost/QALY gain (£) Dominating
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